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Abstract 
Improving  understanding  of  how  inflammatory  responses  by  monocytes  and 
macrophages are regulated may aid in the development of more targeted therapies for 
chronic inflammatory disease. In this thesis the mechanisms by which the cytokine, 
IL-4,  can  suppress  inflammatory  cytokine  production  by  LPS-stimulated  human 
monocytes have been examined. 
 
IL-4 suppressed LPS-induced TNFα transcription, without inhibiting LPS signalling 
through  IκB,  the  mitogen-activated  protein  kinase  (MAPK)  pathways,  or  LPS-
mediated activation of the transcription factor NF-κB. Histone acetylation regulated 
LPS-induced cytokine production but not the suppression of these cytokines by IL-4. 
IL-4 induced three molecules with potential anti-inflammatory properties, suppressor 
of cytokine signalling-1 (SOCS1), peroxisome proliferator-activated receptor gamma 
(PPARγ)  and  triggering  receptors  expressed  on  myeloid  cells-2  (TREM-2),  but 
suppressed LPS-induced TNFα production independently of these molecules. 
 
Targeted gene arrays for Toll-like receptor (TLR) signalling pathways revealed that 
IL-4  down-regulated  mRNA  levels  of  LPS-induced  inflammatory  cytokines  and 
chemokines, without altering other NF-κB-dependent genes or mRNA levels of TLR-
related signalling molecules. Instead, the anti-inflammatory actions of IL-4 may be 
mediated  by  up-regulation  of  an  unknown  signalling  molecule  or  transcriptional 
regulator.  In  LPS-treated  monocytes,  IL-4  up-regulated  mRNA  levels  for  IL-10, 
receptor-interacting serine-threonine kinase 2 (RIPK2), RP105 and c-Maf. However, 
the anti-inflammatory actions of IL-4 did not require IL-10 or the kinase activity of   ii 
RIPK2.  While  the  TLR-homolog,  RP105,  is  likely  to  negatively  regulate  LPS 
responses by monocytes,  IL-4 had no effect on cell surface expression of RP105. 
Additional studies may determine whether c-Maf, a transcription factor which induces 
IL-10, also regulates the suppression inflammatory cytokine production by IL-4. 
 
This  study  identified  novel  candidates  induced  by  IL-4  in  LPS-stimulated  human 
monocytes.  However,  the  molecules  involved  in  the  regulation  by  IL-4  of  LPS-
induced  TNFα  production  were  not  definitively  identified.  Further  studies  may 
identify the mechanisms by which IL-4 is anti-inflammatory. Ultimately, this research 
will contribute towards the development of novel therapies for inflammatory disease. 
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DMEM  Dulbecco’s modified Eagle’s medium 
DNA  deoxyribonucleic acid 
DTT  dithiothreitol 
ECM  extracellular matrix 
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EGF  epidermal growth factor 
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ERK  extracellular signal-regulated kinase 
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GM-CSF  granulocyte macrophage colony-stimulating factor 
GTP  guanosine-5'-tri-phosphate 
h  hours 
HAT  histone acetyl transferase 
HBSS  Hanks balanced salt solution 
HDAC  histone deacetylase 
HEPES  N-2-hydroxyethyl piperazine-N-ethane sulfonic acid 
HLA  human leukocyte antigen 
HRP  horseradish peroxidase 
I4R  insulin IL-4 receptor 
IFN  interferon 
Ig  immunoglobulin 
IGF  insulin-like growth factor 
IKK  IκB kinase   xxi 
IL  interleukin 
IL-1ra  IL-1 receptor antagonist 
IRAK  interleukin-1 receptor associated kinase 
IRF  interferon regulatory factor 
IRS  insulin receptor substrate 
JAK  Janus kinase 
Jmjd3  Jumonji domain containing-3 
JNK  c-Jun N-terminal kinase 
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µCi  microCurie 
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µM  micromolar 
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MAPK  mitogen-activated protein kinase 
M-CSF  macrophage colony-stimulating factor 
MdMac  monocyte-derived macrophages 
MFI  mean fluorescence intensity 
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MHC  major histocompatibility complex 
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miR  micro-RNA 
ml  millilitres   xxii 
mM  millimolar 
MMP  matrix metalloproteinase 
mRNA  messenger ribonucleic acid 
NCoR  nuclear hormone receptor co-repressor 
NF-κB  nuclear factor kappa B 
NO  nitric oxide 
NOD  nucleotide-binding oligomerization domain containing 
NSAID  non-steroidal anti-inflammatory drug 
PBMC  peripheral blood mononuclear cell 
PBS  phosphate buffered saline 
PCR  polymerase chain reactions 
PE  phycoerythrin 
pg  picograms 
PGE2  prostaglandin E2 
pH  potential of hydrogen 
PI3K  phosphoinositide-3-kinase 
PIAS  protein inhibitors of activated STATs 
PKC  protein kinase C 
PMA  phorbol ester myristate 
PPAR  proliferator-activated receptor  
PPRE  peroxisome proliferator response elements 
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RA  rheumatoid arthritis 
rh  recombinant human 
RIPK2  receptor interacting serine-threonine-protein kinase 2   xxiii 
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SEM  standard error of the mean 
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receptor 
 
SOCS  suppressors of cytokine signalling 
SRF  serum response factor 
STAT  signal transducers and activators of transcription 
TAB2  transforming growth factor β activated kinase 1 binding protein 2 
TAK1  transforming growth factor β activated kinas 
TBS  Tris buffered saline 
TGF  transforming growth factor 
Th  T helper 
TIR  toll/ interleukin-1 receptor 
TLR  toll-like receptor 
TNF  tumour necrosis factor 
TPA  tetradecanoyl phorbol acetate   xxiv 
TRAF6  tumour necrosis factor receptor activated factor 6 
TRF  time-resolved fluorescence (assay) 
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TREM-2  triggering receptor expressed on myeloid cells-2 
TSA  trichostatin A 
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UBE2D2  ubiquitin-conjugating enzyme E2D2 
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1.1  Immunity and Inflammation 
The immune system is the body’s defence against foreign or dangerous substances 
that invade it. A normal immune response consists of recognising foreign antigens, 
mobilising forces to defend against it, and attacking it. Cells of the immune system 
are aggregated in lymphoid organs and scattered throughout most tissues of the body. 
They are transported in the two main fluid systems of the body, the blood and the 
lymph.  Key  cells  of  the  immune  system  include  lymphocytes,  monocytes, 
macrophages, dendritic cells (DCs), neutrophils, eosinophils, basophils and mast cells 
(1).  
 
The immune system comprises both the innate and adaptive immune responses (2). 
The innate immune response is a non-specific response which is mobilised upon the 
first sign of infection or foreign antigen, while adaptive immunity is the later acting, 
but  antigen  specific  immune  response,  mediated  by  lymphocytes.  Monocytes  and 
macrophages  form  an  important  part  of  innate  immunity,  by  recognising  and 
phagocytosing foreign substances and releasing cytokines, enzymes and complement 
proteins. After antigen uptake and processing, macrophages and DCs initiate adaptive 
immunity by presenting foreign antigens to antigen-specific B and T lymphocytes. B 
lymphocytes  mediate  humoral  immunity  and  the  production  of  antibodies.  T 
lymphocytes mediate cell mediated immunity which involves the killing of infected 
cells by CD8+ cytolytic T (Tc) cells, and direction of other immune cells by cytokine 
secreting CD4+ T helper (Th) cells.  
 
Immune responses are tightly regulated by cytokines. Their ability to signal to other 
immune cells, and enhance or suppress the production of further cytokines provides   3 
an  important  positive  or  negative  regulatory  mechanism  for  immune  and 
inflammatory  responses.  While  an  inflammatory  response  may  eliminate  foreign 
pathogens, it is often accompanied by local and systemic injury to normal host tissues. 
Normally  such  effects  are  controlled  and  self  limited,  however,  failure  to  control 
immune responses leads to chronic inflammation and autoimmune diseases (3, 4). A 
better understanding  of  the signalling processes which regulate inflammation  may 
lead to new approaches for the treatment of chronic inflammatory diseases. 
 
 
1.2   Monocytes and Macrophages 
The development of monocytes and macrophages begins in the bone marrow where 
they  differentiate  from  bone  marrow  precursors  into  blood  monocytes.  Blood 
monocytes have migratory and chemotactic properties and are generally considered to 
be the immature precursors of macrophages. Human peripheral blood monocytes are a 
heterogeneous population and three distinct subsets of human monocytes have been 
defined  by  their  phenotype  and  cytokine  production  (5).  CD14
+CD16
-  monocytes 
represent 80-90% of blood monocytes. They express high levels of the chemokine 
receptor, CCR2, and low levels of CX3CR1, and produce IL-10 rather than TNFα and 
IL-1 in response to LPS in vitro. In contrast CD16
+ monocytes express high levels of 
CX3CR1 and low levels of CCR2. Of these, CD14
+CD16
+ monocytes are a major 
source of TNFα in response to LPS stimulation and are known as pro-inflammatory. 
In  contrast,  monocytes  that  express  CD16  but  very  low  levels  of  CD14 
(CD14
dimCD16
+) do not produce TNF-α or IL-1 in response to LPS. The function of 
CD14
dimCD16
+ monocytes remains elusive, but they are expanded in the blood of 
septic patients.   4 
When  monocytes  migrate  into  the  tissues  they  undergo  further  differentiation  to 
become varied morphological forms of macrophages (5, 6) (Fig. 1.1) The maturation 
process  from  monocyte  to  macrophage  can  be  achieved  by  a  variety  of  stimuli, 
including macrophage colony-stimulating factor (M-CSF), granulocyte macrophage 
colony-stimulating factor (GM-CSF) and interferons (IFNs). DCs arise from common 
progenitors to monocytes and can be derived from blood monocytes by culturing in 
the presence of GM-CSF and interleukin (IL)-4. Upon differentiation, macrophages 
become  larger  and  more  granular  than  monocytes  (7).  They  also  have  increased 
surface expression of the cell surface molecule CD14, and are more responsive to 
microbial stimuli in terms of inflammatory cytokine production than blood monocytes 
(8).  
 
Macrophages play a central role in the phagocytosis of pathogens and necrotic tissue.  
After  digestion  of  pathogens  they  present  the  foreign  antigens  for  recognition  by 
antigen-specific lymphocytes (9). A steady state population of resident macrophages 
is present in most tissues; however, inflammation results in the infiltration of large 
numbers  of  inflammatory  macrophages  which  are  activated  by  microbial  ligands 
including bacterial lipopolysaccharide (LPS). Activated macrophages are central to 
the  destructive  processes  of  inflammation  through  their  capacity  to  secrete  large 
amounts of pro-inflammatory cytokines, such as tumour necrosis factor-α (TNFα), IL-
1β,  IL-6  and  IL-8,  and  proteases,  which  damage  tissue  (see  Section  1.5).  An 
overzealous  macrophage  response  is  a  key  contributor  in  chronic  inflammatory 
diseases such as rheumatoid arthritis (10). 
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Figure 1.1:  Differentiation of macrophages in vivo. Monocytes differentiate from 
common myeloid progenitors in the bone marrow. Once distributed throughout the 
bloodstream  monocytes  constitutively  enter  all  tissue  compartments  of  the  body. 
Resident  macrophage  populations  distinctly  adapt  to  their  microenvironment  of 
different  organs.  Immune  and  inflammatory  stimuli  result  in  the  recruitment  of 
inflammatory macrophages which are activated by microbial stimuli including LPS. 
Adapted from Gordon, 2003 (6). 
 
1.3   Toll-like Receptor Activation of Monocytes and Macrophages 
Molecular  patterns  associated  with  microbial  pathogens  and  cellular  stress  are 
recognised  by  pattern  recognition  receptors  (11,  12).  These  include  mannose 
receptors,  nucleotide-binding  oligomerization  domain  containing  (NOD)-like 
receptors and toll-like receptors (TLRs). TLRs have evolved to recognise specific 
molecular patterns commonly associated with microbial agents (11). Eleven members 
of  the  TLR  family  have  been  identified  in  humans.  Each  receptor  is  expressed 
differentially among immune cells and recognises distinct microbial stimuli, including 
LPS, bacterial  lipoproteins,  peptidoglycans  and  bacterial DNA. Signalling through 
TLRs  directs  an  inflammatory  response,  which  enables  the  host  to  eliminate  the 
pathogen. However an exaggerated response can have adverse effects on the host, 
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including  inflammation  of  host  tissue,  septic  shock  (12)  and  promotion  of  the 
destructive processes in chronic inflammatory disease (13-15).   
 
The  receptor  for  LPS,  the  principle  component  of  the  outer  membrane  of  Gram-
negative bacteria, is TLR4 (Fig. 1.2). After binding to lipid binding protein (LBP) in 
the plasma, LPS is delivered to the cell surface molecule, CD14, which transfers LPS 
to its transmembrane receptor, TLR4, and its accessory protein MD-2.  Initially, LPS 
activates  the  MyD88-dependent  signalling  pathway  by  recruiting  adaptor  proteins, 
including  MyD88  and  MyD88-adapter  like  (MAL),  to  the  TLR4  receptor.  This 
stimulates  the  activation  of  various  mitogen-activated  protein  kinase  (MAPK) 
pathways  and  the  IκB  kinase  (IKK)  pathway.  These  pathways  activate  several 
transcription  factors  to  potently  stimulate  production  of  the  pro-inflammatory 
cytokines,  TNFα,  IL-1β,  IL-6  and  IL-12,  and  prostaglandin  E2  (PGE2)  (16).  In 
addition, LPS activates a later-acting MyD88-independent pathway by recruiting the 
TIR-domain-containing  adapter-inducing  interferon-β  (TRIF)  to  the  TLR4  (17). 
MyD88-independent  signalling activates interferon regulatory factor-3 (IRF-3) and 
induces  several  IFN-regulated  genes  as  well  as  a  late  NF-κB  response  (17).  The 
signalling pathways  activated by  LPS are discussed in detail in Chapter 4 of this 
thesis.  
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Figure 1.2:  LPS  signalling  through  TLR4  in  monocytes  and  macrophages. 
Adapted from Akira et al. 2001 (12) and Guha and Mackman, 2001 (16). 
 
1.3.1  LPS Activation of Monocytes and Macrophages as a Model for Inflammation 
In  autoimmune  diseases  and  chronic  inflammation,  the  TLR-induced  pro-
inflammatory  cytokines,  TNFα  and  IL-1β,  are  major  drivers  of  inflammation  and 
tissue destruction (18-20). Synovial membrane cells, monocytes and macrophages all 
express functional TLR2 and TLR4 receptors (13) and in rheumatoid arthritis (RA), 
TLR  activation  of  monocytes  and  macrophages  plays  an  important  role  in  the 
initiation of synovial inflammation (15, 18, 21). TLR ligands such as bacterial DNA 
and bacterial cell wall components have been detected in the joints of some patients 
with inflammatory arthritis (14) and recently, it has been discovered RA synovial 
membrane cells release ligands for TLR (13). A better understanding of the processes 
that regulate TLR-agonist driven pro-inflammatory cytokine production by monocytes 
and macrophages may aid the design of new treatments for chronic inflammation. 
   8 
Hence, LPS activation of monocytes and macrophages in vitro is a useful model for 
the study of chronic inflammatory diseases including RA.  
 
1.4  Cytokines and Regulation of the Immune Responses 
Two subpopulations of CD4+ T helper (Th) cells known as Th1 and Th2 cells were 
first described by Mosman et al., 1986 (22) (Fig. 1.3). IL-12 induces Th1 polarisation, 
while IL-4 induces Th2 polarisation. Th1 lymphocytes produce type I cytokines, IL-2, 
IFNγ  and  TNFβ,  which  are  involved  in  the  activation  and  heightening  of  cell-
mediated immunity. In contrast, Th2-lymphocytes produce the Type II cytokines, IL-
4,  IL-5,  IL-9,  IL-10,  and  IL-13,  which  promote  humoral  immunity  and  antibody 
production. Type I cytokines are generally regarded as pro-inflammatory while type II 
cytokines are anti-inflammatory and the relative balance of Th1 vs Th2 activation is 
thought to have a regulatory effect on immune behaviour (23). Several other subsets 
of  T  cells  have  also  been  described  including  Treg,  Th3,  and  Th17  cells.  Tregs 
produce  high  levels  of  IL-10  and  some  transforming  growth  factor-β  (TGF-β)  to 
suppress  immune  responses  (24).  Th3  cells,  which  regulate  mucosal  immunity, 
produce TGF-β and stimulate B cell secretion of immunoglobulin (Ig)A (25). Th17 
cells produce IL-17, a cytokine which triggers potent inflammatory responses and 
promotes recruitment of neutrophils to infected tissues (26).  
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Figure 1.3:   Summary of Th1/Th2 induction 
All Th cells start as naïve non-committed Th0 cells. The innate immune response 
stimulates the production of IL-4 or IL-12. IL-12 induces Th polarisation to a Th1 
phenotype  and  inhibits  the  Th2  phenotype.  Th1  cytokines  heighten  cell  mediated 
immunity and antibody class switching to IgG1 and IgG3. IL-4 induces polarisation to 
a Th2 phenotype and inhibits the Th1 phenotype. Th2 cytokines heighten humoral 
immunity and antibody class switching to IgG2, IgG4 and IgE. Adapted from Spellberg 
et al. 2001 (23). 
 
 
1.5  Pro-inflammatory Cytokines 
Two  of  the  most  important  pro-inflammatory  cytokines  in  the  pathogenesis  of 
inflammatory disease are TNFα and IL-1β. Other pro-inflammatory agents include IL-
6, IFNs, IL-12, IL-17 and prostaglandin E2 (PGE2) (see Table 1.1).  
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1.5.1  TNFα  
TNFα is an inflammatory cytokine produced predominantly by activated monocytes 
and  macrophages  (20)  (Table  1.1).  It  is  potently  induced  by  LPS,  but  numerous 
inflammatory cytokines including IL-1β, IL-3, GM-CSF and IFNγ can also trigger its 
production. TNFα plays a critical role in the mediation of inflammatory synovitis, and 
joint and bone erosion in RA by triggering the release of  inflammatory cytokines 
including IL-1β, IL-6, IL-8, GM-CSF and matrix metalloproteinases (MMPs) from 
monocytes, macrophages, neutrophils, fibroblasts and chondrocytes (27, 28). TNFα 
also promotes the expression of adhesion molecules by fibroblasts and endothelial 
cells,  increasing  the  transport  of  leukocytes  into  inflammatory  sites  (29,  30). 
Therapies  which  target  TNFα,  including  monoclonal  antibodies  to  TNFα,  are 
currently used clinically to treat inflammatory diseases such as rheumatoid arthritis 
(see Section 1.8.3). 
 
1.5.2  Regulation of LPS-induced TNFα Production by Monocytes 
In  monocytes  and  macrophages,  LPS  rapidly  induces  TNFα  gene  transcription 
following  the  activation  of  several  transcription  factors,  including  Nuclear  Factor 
Kappa B (NF-κB), Activating Protein 1 (AP-1), Activating Transcription Factor 2 
(ATF2)  and  Specificity  Protein  1  (SP-1)  (31,  32).  TNFα  transcription  may  be 
enhanced by the activation of several transcriptional coactivators, including cAMP 
Response  Element  Binding  (CREB)  and  p300,  or  repressed  by  transcriptional 
corepressors such as Nuclear Hormone Receptor Co-Repressor (NCoR) and Silencing 
Mediator for Retinoic acid receptor and Thyroid hormone receptor (SMRT) (33). LPS 
also  triggers  epigenetic  changes  to  the  TNFα  promoter,  including  histone 
modifications, which regulate the accessibility of transcription factors and cofactors to   11 
the TNFα promoter (34) (see Chapter 5). In addition, TNFα production is regulated 
post-transcriptionally  by  AU-rich  elements  (ARE)  in  the  3’  untranslated  region 
(3’UTR)  of  TNFα  transcripts  which  mediate  mRNA  stability  and  efficiency  of 
translation (35). 
 
1.5.2  Other Pro-inflammatory Agents  
Like TNFα, IL-1β induces the synthesis of pro-inflammatory mediators and promotes 
joint and tissue damage in RA by stimulating the release of matrix metalloproteinases 
(MMPs) from fibroblasts and chondrocytes (20, 36). A naturally occurring antagonist 
known as IL-1 receptor antagonist (IL-1ra), which binds to the IL-1 receptor with 
high  affinity  without  triggering  a  signal,  is  believed  to  modulate  the  potentially 
deleterious effects of IL-1β in inflammation (37). The cytokines IL-6, IL-12 and IL-
17 are also potent inducers of inflammation and autoimmunity (Table 1.1). Interferons 
(IFNs) are regulatory cytokines which amplify the expression of pro-inflammatory 
cytokines in monocytes, including TNFα, IL-1β, IL-5 and IL-12 (38, 39), and cross-
regulate the actions of the anti-inflammatory cytokines, IL-4 (40) and IL-10 (41). 
Prostaglandin E2 (PGE2) is a lipid compound derived from fatty acids by the enzyme 
cyclooxygenase, and promotes inflammatory reactions and has been associated with 
oedema and erosion of cartilage and bone in RA (42). 
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Table 1.1:  Pro-inflammatory mediators. 
Cytokine  Produced by  Target cells  Immune functions  Refs. 
 
 
TNFα 
 
Activated 
monocytes 
and 
macrophages 
Monocytes, 
macrophages, 
neutrophils, 
fibroblasts, 
chondrocytes, 
endothelium 
 release of 
inflammatory cytokines 
 
 leukocyte infiltration 
 
MMP release, joint and 
bone erosion in RA 
 
 
(27-30) 
 
 
IL-1 β 
 
Activated 
monocytes 
and 
macrophages 
 
Monocytes, 
macrophages 
fibroblasts, 
T cells, 
endothelium 
 release of 
inflammatory cytokines 
 
 leukocyte infiltration 
 
MMP release, joint and 
bone erosion in RA 
 
 
(20, 
29, 36) 
 
 
IL-6 
 
Monocytes, 
macrophage  
T cells,  
 
T and B cells 
neutrophils, 
osteoclasts 
 
 inflammation and 
autoimmunity 
 
Activates osteoclasts to 
absorb bone during RA 
 
 
 
 
(43, 44) 
 
IL-12 
 
Monocytes, 
macrophages, 
DCs 
 
 
T cells 
NK cells 
 
 Th1 driven 
inflammation and 
autoimmunity 
 
(45) 
 
 
IL-17 
 
 
Th17 cells 
Neutrophils, 
T and B cells, 
monocytes, 
macrophages, 
epithelium 
 
 release of 
inflammatory cytokines 
 
Attracts neutrophils 
 
 
(26) 
 
Type I IFNs 
(IFNα,  
IFN β) 
 
 
Monocytes 
and 
macrophages 
 
 
Monocytes, 
macrophages, 
T cells 
 
Amplifies 
inflammatory cytokine 
expression 
 
Cross-regulates the 
actions of anti-
inflammatory cytokines 
 
 
 
(38-41) 
 
Type II IFNs 
(IFNγ) 
 
 
T cells, 
NK cells, 
macrophages 
 
 
PGE2 
 
Monocytes, 
macrophages, 
DCs, 
fibroblasts, 
osteoclasts 
 
Monocytes, 
macrophages, 
DCs, 
T cells 
 
Mediates inflammatory 
responses, fever and 
oedema 
 
Triggers cartilage and 
bone erosion in RA 
 
 
 
(42) 
 
 
1.6  Anti-inflammatory Cytokines 
Anti-inflammatory cytokines such as IL-4, IL-13 and IL-10, inhibit the production of 
inflammatory cytokines and dampen the inflammatory response. IL-4 has pleiotropic 
effects on the immune system. It drives Th2 polarisation and antagonises the effects   13 
of  Th1  cytokines  (46,  47)  while  controlling  immunoglobulin  class  switching  by 
human B cells (48). IL-4, together with GM-CSF, stimulates the differentiation of 
monocytes to DCs (7). In monocytes and macrophages, IL-4 inhibits the production of 
the pro-inflammatory mediators, IL-1β, TNFα, PGE2 and IL-6, while inducing the 
production of IL-1ra (49-51). The anti-inflammatory properties of IL-4 in monocytes 
and macrophages are discussed in detail in Section 1.10. IL-13 is also produced by 
Th2 cells and shares much of IL-4’s biological activity on monocytes, macrophages 
and B cells. However, unlike IL-4, it does not induce the expansion of Th2 cells. The 
overlapping activities of IL-4 and IL-13 reflect the existence of a common receptor 
component, IL-4Rα (52, 53). IL-10 is a cytokine which functions in the limitation and 
termination of inflammatory responses. IL-10 inhibits development of cytotoxic Tc 
cells while promoting Th cell and Treg development. Similarly to IL-4, IL-10 inhibits 
LPS-induced  IL-1β,  TNFα,  PGE2  and  IL-6  production  by  monocytes  and 
macrophages, while inducing the production of IL-1ra (54, 55).  
 
Table 1.2:  Anti-inflammatory cytokines.  
Cytokine  Produced by  Target cells  Immune functions  Refs. 
 
 
 
 
IL-4 
 
 
 
Th2 cells, 
basophils, 
masts cells 
 
 
 
Monocytes, 
macrophages,  
T and B cells, 
DCs 
 
 
 release of 
inflammatory cytokines 
 
Th2 differentiation 
 
Immunoglobin class 
switching by B cells 
 
DC differentiation 
 
 
 
 
 
(46-51) 
 
 
 
IL-13 
 
 
Th2 cells, 
mast cells 
 
 
 
Monocytes, 
macrophages, 
B cells 
 
 
 release of 
inflammatory cytokines 
 
Immunoglobin class 
switching by B cells 
 
 
 
 
(52, 53) 
 
 
 
IL-10 
 
 
Monocytes, 
macrophages, 
T cells 
 
Monocytes, 
macrophages, 
DCs, 
neutrophils, 
T and B cells 
 
 
 release of 
inflammatory cytokines 
 
Regulates T cell 
differentiation 
 
 
(54, 55)   14 
1.7  Chronic Inflammatory Disease 
The immune system must be carefully balanced between clearing foreign antigens 
(immunity) and inflammation of host tissues. Pro-inflammatory cytokines initiate and 
maintain inflammation while anti-inflammatory cytokines dampen the inflammatory 
response. Normally, immune responses are tightly controlled and resolve as soon as 
the foreign antigen is cleared. However, an imbalance in the response or persistence 
of inflammation can result in chronic inflammatory and autoimmune diseases (18, 
20). A better understanding of signalling processes that occur during these diseases 
may result in improved and more targeted therapies  
 
1.8  Rheumatoid Arthritis 
Rheumatoid  arthritis  (RA)  is  a  chronic  inflammatory  disease  that  affects 
approximately 2% of the population and mainly involves the small joints of the hands 
and feet. It is an autoimmune disease caused by self-reactive antibodies which trigger 
the body’s immune system to attack the joint tissues. The auto-antibodies, rheumatoid 
factor (RF) and anti-citrullinated protein antibodies  (ACPAs), are observed in  the 
blood  of  about  70-80%  of  patients  and  their  presence  predicts  a  more  aggressive 
destructive course of the disease (21, 56). 
 
1.8.1  Pathogenesis of Rheumatoid Arthritis 
The antigen/s which initiate and/or perpetuate RA are yet to be confirmed, though 
collagen,  proteoglycans,  chondrocyte  antigens,  heat  shock  proteins  and  exogenous 
(viral  and  bacterial)  antigens  have  been  proposed  as  candidate  antigens  (57-60). 
Genetics also plays a key role in susceptibility to RA, and a strong link has been 
found between RA and human leukocyte antigen (HLA)-DRB1 molecules. Variability   15 
in  these  genes  may  influence  the  ability  of  cells  to  bind  and  present  specific 
arthritogenic  peptides  (61).  Cytokine  polymorphisms  may  also  be  important  in 
determining loss of tolerance and auto-reactivity to newly exposed articular antigens 
(62). 
 
 
 
 
 
 
 
Figure 1.4:  Comparison of the histology of a normal joint (A) and an arthritic 
joint (B) in a murine model of bovine serum albumin (BSA)-induced arthritis. 
Note pannus formation (PN), bone erosion (BE) and inflammatory exudate (E). P= 
patella, F= femur. Adapted from Egan et al, 2003 (63). 
 
Activation of innate immunity plays  a key role in  the initiation of early  synovial 
inflammation in RA. TLR agonists including proteoglycans and bacterial DNA, which 
are  found  in  the  joints  of  RA  patients,  activate  synovial  dendritic  cells  and 
macrophages (13, 64). Activated DCs migrate to the lymph nodes and prime T cells 
towards a Th1 phenotype which  then home to the inflamed synovial  tissue along 
chemotactic gradients. Activated T cells express adhesion molecules and cytokines 
which trigger continued influx of immune cells into the joint (64, 65). CD4+ T cells, 
B cells and macrophages infiltrate into the synovium, and sometimes organise into 
discrete lymphoid aggregates with germinal centres (21). 
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The RA joint is characterised by a predominance of macrophage-derived cytokines, 
including  IL-1β,  IL-6,  IL-15,  IL-18,  TNFα,  TGF-β  and  GM-CSF  (64,  65). 
Inflammatory cytokine release by macrophages is triggered by both TLR ligands and 
the Th1 cytokines, IFNγ and IL-12, produced by activated T cells. TNFα and IL-1β 
stimulate  synoviocytes  to  produce  degradative  enzymes  such  as  matrix 
metalloproteins,  serine  proteases  and  aggrecanases,  which  digest  the  extracellular 
matrix and begin to degrade cartilage and bone. Hyperplasia of the synovium occurs 
because of a marked increase in macrophage-like and fibroblast-like synoviocytes. 
Inflammation of the synovium progresses to form an aggressive front of tissue called 
pannus which invades and destroys local articular structures leading to the erosion of 
the bone and cartilage at the margin of the joints (Fig. 1.4). With further progression 
of  disease,  the  joint  becomes  unstable  and  begins  to  deform  (21).  The  cytokine 
networks involved in rheumatoid arthritis are summarised in Fig. 1.5. 
 
1.8.2  Current Treatments for Rheumatoid Arthritis 
Therapeutic approaches to RA, and other chronic inflammatory diseases, commonly 
target  inflammatory  cytokine  production,  in  particular  TNFα  and  IL-1β. 
Pharmacological  control  of  inflammation  often  involves  combinations  of  disease-
modifying  anti-rheumatic  drugs  (DMARDs)  with  non-steroidal  anti-inflammatory 
drugs (NSAIDs). Alternative treatments include the use of biological therapies such as 
TNFα and IL-1β inhibitors, B cell depletion therapy and the administration of anti-
inflammatory cytokines (66-68). 
 
NSAIDs  are  anti-inflammatory  drugs  that  principally  act  by  interfering  with 
prostaglandin  production  by  inhibiting  cyclooxygenase  (COX)-1  and  -2,  enzymes   17 
which  convert  arachidonic  acid  into  the  precursors  of  prostaglandins  (69).  Many 
NSAIDs are not selective and inhibit all types of COX enzymes and therefore carry 
the side effect of increased risk of peptic ulceration. Selectivity for COX-2 can halve 
the risk of peptic ulceration but does not seem to affect many of the other side effects 
of NSAIDs, most notably renal failure (70).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5:  Cytokine  networks  in  rheumatoid  arthritis.  Antigen-activated  T 
cells release IFNγ and IL-17. These cytokines, and TLR ligands, trigger the release of 
inflammatory mediators from macrophages and synovial fluid fibroblasts. TNFα and 
IL-1β, stimulate synoviocytes to release matrix metalloproteins (MMPs), resulting in 
erosions  and  joint  damage.  Activated  T  cells  also  stimulate  B  cells  to  secrete 
immunoglobulins, including rheumatoid factor, resulting in the formation of immune 
complexes, which contribute to inflammation and joint erosion. Anti-inflammatory 
cytokines,  such  as  IL-4  and  IL-10,  cooperatively  inhibit  the  production  of 
inflammatory cytokines. Adapted from Christodoulou and Choy 2006 (65) 
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DMARDs are a category of otherwise unrelated medications defined by their use in 
RA to reduce inflammation and slow progression of joint damage. Commonly used 
DMARDs  include  methotrexate,  azothioprine,  sulphasazaline,  gold  injections  and 
gold tablets. They are often used in combination with NSAIDs, particularly when 
NSAIDs alone do not effectively control RA. While DMARDs tend to be slow acting 
drugs and may take months to evoke a response, they target disease progression as 
well as symptoms. Therefore, DMARDs tend to have a greater effect on arthritis than 
NSAIDs. However, they are also associated with side effects including nausea, rashes 
and mouth ulcers (67, 68).  
 
Corticosteroids  (glucocorticoids)  are  still  widely  used  to  treat  most  autoimmune 
diseases. In patients with chronic RA, they are often administered either continuously 
as background therapy or at high doses during disease flairs. Corticosteroids bind to 
nuclear DNA-binding receptors to  prevent  transcription of inflammatory  genes. A 
disadvantage of corticosteroids is that their long term use can result in serious side 
effects including adrenal suppression, weight gain, high blood pressure and diabetes 
(67, 71).  
 
1.8.3  Biological Therapies in the Treatment of Rheumatoid Arthritis 
While NSAIDs, DMARDs and corticosteroids provide some symptomatic relief, their 
overall  impact  on  disease  outcome  is  only  modest  and  they  have  numerous  side 
effects (66-68).  An alternative is the use of biological therapies such as TNFα and IL-
1β  inhibitors  (see  Table  1.3).  Not  only  do  these  therapies  effectively  control 
inflammatory  processes,  many  are  also  effective  in  stopping  the  course  of  RA. 
Another advantage of these therapies is that they target molecules with expression   19 
restricted to immune and inflammatory cells and therefore it is hoped they will have 
fewer systemic side effects (66). Biological therapies include the use of monoclonal 
antibodies to prevent binding of the inflammatory cytokines, including TNFα and IL-
1β, to their cell surface receptors. Another approach is to deplete autoreactive B and T 
lymphocytes using  monoclonal antibodies to  B or T cell  specific surface markers 
(Table 1.3). While these biological therapies have had excellent success in improving 
tissue inflammation and halting disease course, they have some side effects, including 
the potential for adverse drug reactions  and  an increased risk of sepsis  and other 
serious infections (67, 72).  
 
Table 1.3:  Biological therapies currently in use for the treatment of chronic 
autoimmune and inflammatory conditions. Adapted from Dinarello, 2010 (67). 
 
Drugs  Function  Diseases treated  References 
 
Anti-TNFα MoAb 
(infliximab, adulimumab) 
Protein inhibitors of TNFα 
(etanercept) 
 
 
Reducing 
TNFα 
activities 
 
RA, 
Crohn’s disease, 
psoriasis 
 
 
(72-75) 
 
IL-1 receptor antagonist 
(anakinra) 
Anti-IL-1R MoAb  
(AMG 108) 
Anti-IL-1 MoAb 
(canakinumab) 
 
 
 
Reducing 
 IL-1β 
activities 
 
 
RA and other 
autoinflammatory 
diseases 
 
 
 
(76-78) 
 
Anti-IL-6 receptor 
(toculizumab) 
 
Reducing  
IL-6  
activities 
 
 
 
RA 
 
 
(79) 
 
Anti-IL-12/23 
(ustekinumab) 
Anti-IL-17 MoAb 
(AIN457 / LY24398) 
 
 
Neutralisation 
of IL-12, IL-
23 and IL-17 
 
RA, 
Crohn’s disease, 
psoriasis 
 
 
(80, 81) 
 
Anti-CD20 
(rituximab, crelizumab, 
ofatumumab) 
Anti-CD22 (epratuzumab) 
 
 
 
Targeting B 
cells 
 
RA  
type 1 diabetes, 
multiple sclerosis, 
systemic lupus, 
 
 
(82, 83) 
 
Anti-CD3 (teplizumab) 
 Anti-IL-2 receptor MoAb 
(daclizumab) 
 
Targeting T 
cells 
 
Type 1 diabetes,  
multiple sclerosis, 
transplant rejection, 
 
 
 
(84, 85)   20 
Anti-inflammatory cytokines, such as IL-10 and IL-4, are an alternative approach to 
inhibiting  the  activity  of  pro-inflammatory  cytokines.  IL-10  has  been  effective  in 
reducing inflammation, cellular infiltrates and joint destruction in animal models of 
arthritis (86, 87). However, while administration of recombinant human IL-10 is safe 
and well tolerated, IL-10 has had only marginal clinical efficacy for the treatment of 
RA (88) and Crohn’s disease (89). It is hoped that use of IL-4 or an IL-4 receptor 
agonist, or perhaps targeting of signalling intermediates induced by IL-4, may have 
more  success.  The  following  sections  of  this  thesis  will  review  the  signalling 
pathways initiated by IL-4, the mechanisms by which IL-4 is anti-inflammatory and 
its potential in the treatment of RA and chronic inflammation. 
 
1.9  Signalling Through the Interleukin-4 Receptor 
The IL-4 receptor consists of two chains, an IL-4Rα chain, and a gamma common 
chain (γc), also known as the IL-2Rγ chain, which was first identified as a component 
of the IL-2 receptor (Figure 1.6). Both of these chains are required for the activation 
of signalling pathways after binding of IL-4 (90). The IL-4Rα chain also functions as 
a component of the IL-13 receptor, which uses the IL-13Rα1 chain in place of γc. 
This receptor can also bind IL-4 and is known as the ‘Type II’ IL-4 receptor (53). 
Both receptors are expressed on monocytes. 
 
Physiologic signalling of IL-4 depends on heterodimerisation of IL-4Rα with the γc 
chain. The IL-4Rα and γc chains do not have endogenous kinase activity and require 
the receptor associated kinases, Janus kinases (JAKs). Three members of the JAK 
family have been demonstrated to be activated by IL-4, namely JAK1, JAK2 and 
JAK3. JAK1 associates with the IL-4Rα while JAK3 associates with γc (Fig.1.6).   21 
JAK2 associates with IL-4Rα in certain cell lines. Activation of JAKs leads to the 
rapid  tyrosine  phosphorylation  of  the  IL-4Rα  chain  itself.  These  phosphorylated 
tyrosine  residues  provide  the  docking  sites  for  Src-Homology  2  (SH2)  or 
phosphotyrosine binding (PTB) domains of downstream signalling proteins (90).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6:  The IL-4 receptor. The IL-4 receptor complex is composed of the IL-
4Rα  and  γc  receptor  subunits  which  associate  with  the  JAK1  and  JAK3  kinases, 
respectively.  The  IL-4Rα  chain  contains  five  tyrosine  residues,  which  once 
phosphorylated  are  docking  sites  for  SH2  containing  proteins  including  STATs. 
Adapted from Nelms et al. 1999 (90). 
 
1.9.1  IL-4 Activation of STAT6 Signalling 
IL-4-induced  gene  expression  is  mediated  by  activation  of  STATs  (Signal 
Transducers  and  Activators  of  Transcription)  through  the  JAK-STAT  pathway. 
STAT6  is  the  primary  STAT  activated  in  response  to  IL-4  and  is  critical  in  the 
activation or enhanced expression of many IL-4-responsive genes. STAT6 binds to 
distinct phosphorylated tyrosine residues of the cytoplasmic tail of IL-4Rα via its SH2 
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domain. Upon binding to the IL-4 receptor, STAT6 is phosphorylated by JAKs. Once 
phosphorylated,  the  STAT6  molecule  disengages  from  the  receptor  and  forms  a 
homodimer with another STAT6 molecule via interaction between one SH2 domain 
and the phosphorylated residue of the second STAT6 molecule. Dimerised STAT6 
complexes translocate to the nucleus where they bind to specific DNA motifs in the 
promoters of responsive genes (Fig. 1.7). STAT6 preferentially binds to palindromic 
DNA motifs with the sequence TTC(N)4GAA (90).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7:  The  STAT6  activation  pathway.  IL-4  binds  to  the  IL-4  receptor 
resulting in its phosphorylation. STAT6 binds to phosphotyrosine residues in the IL-
4Rα  cytoplasmic  tail,  becomes  phosphorylated,  disengages  from  the  receptor, 
dimerises and translocates to the nucleus where it regulates transcription of STAT6-
dependent genes. Adapted from Nelms et al. 1999 (90).  
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1.9.2  IL-4 Activation of IRS-1/2 Signalling 
In addition to activating STAT6, IL-4 initiates signalling through the insulin  IL-4 
receptor  (I4R)  motif  of  the  IL-4Rα,  a  sequence  which  is  shared  with  the  insulin 
receptor. Signalling through I4R by IL-4 activates several signalling pathways critical 
for  cellular  proliferation  (Fig.  1.8).  For  instance,  recruitment  of  insulin  receptor 
substrate  (IRS)-1/2  molecules  to  the  I4R  motif  of  the  IL-4  receptor  activates 
phosphoinositide-3-kinase (PI3K) signalling (Fig. 1.8A). This pathway results in the 
activation of downstream kinases, including protein kinase C (PKC) and Akt kinase, 
which mediate the enhancement of haematopoietic cell survival by IL-4 (90, 91). In 
addition, PI3K signalling may play an important role in restricting pro-inflammatory 
responses by TLR-stimulated macrophages (92) and regulating the phagocytic activity 
of alternatively activated macrophages (93). 
 
1.9.3  IL-4 Activation of Ras/MAPK Signalling 
In certain cell types, IL-4 activates the Ras/MAPK pathway (Fig. 1.8B). This pathway 
is initiated by recruitment of Grb2/Sos, by either IRS-1/2 (Fig. 1.8A) or via the I4R 
motif  recruitment  of  the  adaptor  protein  Shc  (Fig.  1.8B).  Grb2/Sos  activates  the 
guanosine-5'-tri-phosphate  (GTP)ase,  Ras,  which  activates  MAPK  signalling 
pathways.  IL-4  activation  of  MAPK  signalling  plays  an  important  role  in  the 
regulation of cell growth and differentiation (90). It has also been implicated in the 
potentiation  of  pro-inflammatory  cytokine  secretion  by  alternatively  activated 
macrophages (93) (see Chapter 4). 
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Figure 1.8:  Activation of signalling pathways through the I4R motif of the IL-
4Rα. A. The PI-3-kinase pathway can be activated through the interaction of IRS-1/2 
molecules with the phosphorylated I4R motif. Once phosphorylated IRS-1/2 recruits 
the  p85  and  p110  subunits  of  PI-3-kinase,  which  catalyse  the  production  of 
phosphoinositides, and activate downstream effectors such as Akt kinase and protein 
kinase C (PKC). B. The Ras/MAPK pathway is activated following recruitment of the 
adaptor Grb2 by either IRS-1/2 or other proteins recruited to the I4R motif such as 
Shc.  Grb2  is  constitutively  associated  with  the  protein,  Sos,  which  catalyses  the 
exchange of GDP in inactive Ras for GTP, activating Ras and downstream MAPK 
pathways. Adapted from Nelms et al. 1999 (90). 
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1.9.4  Regulation of IL-4 Signalling 
Regulation  of  IL-4  signalling  occurs  via  the  induction  and  recruitment  of  various 
negative  regulators  of  cytokine  signalling,  including  the  Suppressors  Of  Cytokine 
Signalling  (SOCS)  proteins,  Protein  Inhibitors  of  Activated  STATs  (PIAS),  SH2-
containing Phosphatases (SHP) and SH2-containing Inositol 5’ Phosphatases (SHIP). 
The role of these negative regulators in mediating IL-4 signalling, and their potential 
to cross-regulate additional pathways, including TLR signalling, is described in detail 
in Chapter 6. 
 
1.10 Anti-inflammatory Actions of IL-4 in Monocytes and Macrophages 
IL-4 was first identified as an anti-inflammatory cytokine in 1989 when it was shown 
to  block  in  vitro  production  of  LPS-induced  TNFα,  IL-1β  and  PGE2  by  LPS 
stimulated human monocytes (49). Since then the list of anti-inflammatory properties 
of IL-4 in monocytes has grown, with IL-4 also inducing the production of IL-1ra 
(50) and the decoy type II IL-1 receptor (94). In addition, IL-4 has protective effects 
against  cartilage  and  bone  erosion  in  ex  vivo  models  of  RA.  For  instance,  in 
rheumatoid synoviocytes and synovium cultures, IL-4 reduces cellular proliferation 
and significantly reduces spontaneous production of pro-inflammatory cytokines (51, 
95).  IL-4  inhibits  the  production  and  release  of  metalloproteinases  in  both 
macrophage and cartilage cultures (96, 97). In an ex-vivo model of bone resorption, 
IL-4  reduced  IL-6  and  leukaemia  inhibitor  factor  (LIF)  production  and  inhibited 
osteoclast activity and survival, thereby blocking resorption of bone (98). It is now 
recognised that IL-4 is an alternative activator of macrophages. 
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1.10.1  Alternative Activation of Macrophages by IL-4 
The traditional or ‘classical’ view of immune activation of macrophages involves a 
priming signal from IFNγ followed by encounter with an antigen such as bacterial 
LPS. Exposure to the Th2 cytokines, IL-4 and IL-13, results in an alternative pathway 
of  macrophage  activation.  These  macrophages  have  distinct  and  often  opposing 
functions in immune responses to classically activated macrophages (99-102) (Fig. 
1.9). Mirroring the Th1 and Th2 nomenclature used to describe the two different types 
of effector T-lymphocytes, classically activated macrophages are often described as 
‘M1’  cells  while  alternatively  activated  macrophages  are  designated  ‘M2’. 
Macrophages activated with IL-10 and glucocorticoids or immune complexes share 
many of the features of alternatively activated macrophages and are often designated 
as distinct subsets of M2 macrophages, M2b and M2c respectively (101, 102). 
 
 Classical  activation  results  in  a  dramatic  change  in  the  cellular  morphology  of 
macrophages,  increased  surface  expression  of  major  histocompatibility  complex 
(MHC)  class  II  and  CD86,  and  enhanced  antigen-presenting  capacity.  Classically 
activated  macrophages  dramatically  increase  their  secretion  of  chemokines, 
inflammatory  cytokines  such  as  TNFα,  IL-1β  and  IL-6,  and  proteolytic  enzymes 
which degrade the extracellular matrix (ECM) compartments. While the release of 
these molecules is important in conveying resistance to intracellular pathogens, when 
uncontrolled they can elicit chronic inflammation and tissue injury (99-102) 
 
In  contrast,  M2  macrophages  are  characterised  by  decreased  pro-inflammatory 
cytokine secretion and increased secretion of anti-inflammatory mediators, including 
IL-1ra, IL-10 and TGF-β.  M2 macrophages have enhanced expression of mannose   27 
receptor and MHC class II antigen. They are involved in the killing and encapsulation 
of  parasites,  but  also  the  promotion  of  Th2  driven  diseases  such  as  asthma  and 
allergies (6, 103). In contrast to classically activated (M1) macrophages which tend to 
promote tissue damage, M2 macrophages promote tissue repair and wound healing by 
preventing  cellular  apoptosis,  increasing  secretion  of  ECM  components,  ECM 
crosslinking  enzymes  and  fibronectin,  and  enhancing  angiogenesis  via  increased 
expression of angiogenic factors (6).  
 
 
 
 
 
 
 
 
 
 
Figure 1.9:   Key  properties  and  functions  of  classically  activated  (M1)  and 
alternatively activated (M2) macrophages. Adapted from Mantovani, 2006 (102). 
 
The balance between classical (M1) and alternative (M2) activation states has been 
implicated as an important factor in the pathogenesis of inflammation (104, 105). 
While M1 macrophages act as pro-inflammatory effectors that ensure elimination of 
the  causative  pathogen  or  foreign  antigen,  M2  macrophages  may  be  important  in 
down regulating the pro-inflammatory response promoted by M1 macrophages. M2 
macrophages populations appear during the resolution of acute inflammation (106) 
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and  wound  healing  (107).  The  detection  of  M2  macrophages  in  inflammatory 
conditions such as rheumatoid arthritis is a likely indication that the immune system is 
attempting  to  counterbalance  classical  inflammatory  reactions  via  alternative 
activation states (10). 
 
Macrophages exhibit plasticity in their phenotype and function and recently it was 
discovered  that  a  single  macrophage  taking  part  in  inflammation  can  switch  its 
phenotype so it can then participate in the resolution of inflammation (108). This has 
lead to the view that macrophages may switch from being classically to alternatively 
activated upon a specific signal such as IL-4. This may allow tissue macrophages to 
resolve  inflammation  quickly  without  the  need  for  new  monocyte/  macrophage 
recruitment (105, 108). Further clarification of the pathways involved in macrophage 
activation, in particular the signals involved in switching to an alternative pathway by 
IL-4 may lead to improved therapeutic approaches for targeting tissue inflammation 
and chronic inflammatory disease.  
 
1.11  Potential of IL-4 in the Treatment of Rheumatoid Arthritis 
Synovial fluid samples from RA joints contain very low amounts of IL-4 and other 
Th2  cytokines  and  unstimulated  synovial  membranes  are  unable  to  produce  IL-4 
(109).  In  contrast,  CD4+  Th1  cells  and  inflammatory  macrophages  and  their 
cytokines, TNFα and IL-1β, predominate in the RA joint (110). It is possible that the 
lack of IL-4-producing CD4+ Th2 cells may contribute to pathogenesis of the disease, 
by allowing an uncontrolled macrophage inflammatory response. This, in addition to 
the  numerous  anti-inflammatory  actions  of  IL-4  demonstrated  on  monocytes  and 
macrophages  in  vitro  and  in  vivo  has  lead  to  the  suggestion  that  therapeutic   29 
administration  of  IL-4,  drugs  that  induce  IL-4,  or  targeting  of  IL-4  signalling 
intermediates, may be a useful strategy for the treatment of RA.  
 
1.11.1 Use of IL-4 in Animal Models 
IL-4  has  been  successful  in  the  treatment  of  a  number  of  animal  models  of 
inflammatory disease, particularly when IL-4 is targeted to the affected joints and 
tissues. For example, continuous administration of exogenous IL-4 using an osmotic 
pump in murine collagen induced arthritis (CIA) led to a thousand-fold decrease in 
TNFα secretion, significantly delayed the onset of arthritis and suppressed clinical 
symptoms (111). In another study of murine CIA, a single intra-articular injection of 
IL-4-expressing adenovirus given prior to disease onset reduced the production of the 
pro-inflammatory cytokines, IL-1β and TNFα, and the inflammatory mediator, nitric 
oxide  (NO).  Furthermore,  IL-4  reduced  the  activity  of  matrix  metalloproteinase, 
resulting in reduced cartilage destruction (Fig. 1.10) (112). In rat models of adjuvant-
induced arthritis, IL-4-adenoviral gene therapy successfully increased IL-4 levels in 
the inflamed joint resulting in significantly reduced joint swelling, vascularisation and 
bone destruction (113-115). 
 
 
 
 
 
 
 
   30 
 
 
 
 
 
 
Figure 1.10:  Protective  effect  of  local  treatment  of  IL-4  in  murine  collagen-
induced  arthritis.  A.  Arthritic  joint  of  mouse  7  days  after  administration  of  an 
adenoviral control vector. B. Arthritic joint of mouse 7 days after administration of an 
adenoviral vector overexpressing IL-4. Note in (B) the almost complete prevention of 
chondrocyte death and cartilage damage (shown by arrows) and enhanced cellular 
infiltrate. Taken from Lubberts et al. 1999 (112). 
 
 
1.11.2 Potential Inflammatory Actions of IL-4 
While IL-4 has been successful in the treatment of chronic inflammation in a number 
of murine and rat models (112-115), a few studies have reported conflicting results. 
For example, while IL-4-deficient mice developed less acute CIA, they were more 
likely to develop chronic relapsing disease (116). Similarly, systemic injections with 
IL-4  enhanced  inflammatory  cytokine  production  and  exacerbated  disease  in  rat 
autoimmune uveoretinitis (117) and a murine model of colitis (118). A successful 
response to IL-4 may depend on the timing of addition of IL-4 relative to disease 
onset.  For  example,  administration  of  an  anti-IL-4  antibody  for  6  days  post-
immunisation exacerbated murine CIA. However, when treatment with the antibody 
was shortened to 2 days post-immunisation, it reduced disease, suggesting IL-4 may 
play a role in triggering RA (119).  
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Indeed, while Th1 cytokines have previously been implicated in the disease processes 
of RA, the presence of Th2 cytokines, including IL-4, in the early rheumatoid lesion 
may  favour  progression  to  persistent  RA.  One  study  found  patients  with  early 
inflammatory arthritis who subsequently developed RA had a distinct but transient 
early  synovial  fluid  cytokine  profile,  characterised  by  a  marked  absence  of  Th1 
cytokines and a predominance of the Th2 cytokines, IL-4 and IL-13 (120). This early 
transient Th2 profile did not exist in early arthritis patients who did not develop RA 
and only when the disease progressed to the established stage, were cytokines skewed 
in favour of a Th1 response. In conclusion, it appears both the timing of IL-4 addition 
relative  to  disease  onset,  and  whether  or  not  IL-4  is  targeted  into  the  area  of 
inflammation, are important factors determining IL-4’s potential effectiveness as a 
therapy. This highlights the need for further in vitro studies to determine the exact 
mechanisms of action of IL-4. 
 
1.11.3 Use of IL-4 in Human Studies 
Therapies which target IL-4’s actions have potential in the treatment of a number of 
human diseases. For instance, IL-4 drives asthma and allergies via its effects on Th2 
cells. Hence pitrakinra, a drug which blocks the actions of IL-4 and IL-13 on these 
cells, is a promising therapy currently under development for the treatment of asthma 
and other Th2 diseases (121). Conversely, due to the anti-inflammatory actions of IL-
4 in macrophages, the administration of IL-4, or drugs that induce IL-4, may be useful 
for the treatment of chronic inflammatory diseases involving excessive macrophage 
inflammatory  response,  inclduing  RA.  Recombinant  human  IL-4  (rhIL-4), 
administered by both the subcutaneous and intravenous routes, was first trialled in the 
early 90s for the treatment of haematological malignancies (122-125). Subsequently,   32 
rhIL-4 has been trialled for the treatment of inflammatory disease but with variable 
success. For example, in a Phase I six week trial on RA patients, systemic injections 
of rhIL-4 three times a week was well tolerated but had no significant clinical benefit 
compared to the placebo (126). However, in a pilot study on patients with psoriasis, 
daily subcutaneous  injections  of  rhIL-4 skewed  cytokines  to  an anti-inflammatory 
Th2 pattern and markedly improved psoriasis in 19 of 20 study patients (127). 
 
In  the  above  clinical  trials,  some  concerns  were  raised  about  the  systemic 
administration of IL-4. While injections of IL-4 were generally well tolerated, side 
effects  such  as  fever,  flu-like  symptoms  and  reduced  lymphocyte  counts  resulted 
because of the pleiotropic effects of IL-4 on immune cells (123-125). Secondly, the 
local concentrations of cytokines reached in the affected tissues following systemic 
administration may be too low to have an optimal effect, while increasing systemic 
doses may cause toxicity (128). Thus, a more effective treatment regimen with IL-4 
will require specific targeting of IL-4 to affected joints and tissues.  
 
Gene therapy may allow IL-4 to be delivered into targeted organs or tissues. The RA 
joint is a good candidate for gene therapy because it is an enclosed space and can be 
targeted by direct injection. Several studies have demonstrated it is possible to safely 
and effectively transfer genes with anti-inflammatory properties, including IL-4, into 
the joints of mice and rats (129, 130). A second possibility is that drugs which act to 
increase concentrations of IL-4 in tissues may be a useful strategy in the treatment of 
inflammation.  For  example,  the  anti-inflammatory  actions  of  atorvastatin  in  brain 
inflammation (131) and simvastatin in autoimmune disease (132) are proposed to be 
mediated by IL-4. Finally, more specific therapies could be developed by targeting the   33 
pathways used and the molecules induced by IL-4 to mediate its anti-inflammatory 
actions.  I  propose  that  the  inflammatory  signalling  cascades  of  monocytes  and 
macrophages  are  distinct  to  those  activated  in  lymphocytes,  hence  the  interacting 
pathways of cell activation and suppression of inflammatory cytokine production by 
IL-4  are  likely  to  be  monocyte-  and  macrophage-specific.  Therefore,  targeting  of 
these pathways may avoid side effects resulting from the pleiotropic effects of IL-4 on 
other immune cells such as lymphocytes. However, initially the molecules induced by 
IL-4 and the components of inflammatory signalling cascades targeted by IL-4 need 
to be identified. Therefore, the following sections will summarise what is currently 
known about the mechanisms by which IL-4 exerts its anti-inflammatory actions in 
human monocytes and macrophages.  
 
1.12  Mechanisms of the Anti-inflammatory Effects of IL-4 
The anti-inflammatory action of IL-4 may be mediated by both STAT6-dependent 
and  -independent  mechanisms,  and  in  the  presence  and  absence  of  new  protein 
synthesis. It is also unclear whether IL-4 acts at the level of transcription or post-
transcriptionally  by  affecting  mRNA  stability  or  translation  of  pro-inflammatory 
cytokines.    It  is  logical  that  the  suppression  of  LPS-induced  pro-inflammatory 
cytokine production by IL-4 is mediated by interacting with, and inhibiting, parts of 
the TLR signalling cascade. However, reports conflict whether IL-4 acts by directly 
affecting  NF-κB  activation  or  binding  activity,  or  acts  further  upstream  of 
transcription factors at the level of TLR signalling components or adaptor proteins 
(see Chapter 4). This lack of understanding is compounded by the fact that IL-4 has 
different effects in murine and human cells, monocytes and macrophages and in other 
cell types including cell lines, lymphocytes and fibroblasts.   34 
1.12.1  Role of STAT6 in Mediating the Anti-inflammatory Effects of IL-4 
Studies in mice lacking functional STAT6 suggest that STAT6 plays an essential role 
in many of the biological functions of IL-4 (133-135). Likewise, STAT6 mediates 
many of the anti-inflammatory actions of IL-4 in monocytes, including induction of 
the IL-1ra gene (136) and is important for the suppression of inflammatory cytokine 
production by IL-4 (137-139) 
 
STAT6-dependent Mechanisms  
STAT6  is  capable  of  directly  suppressing  the  transcription  of  pro-inflammatory 
cytokines  in  the  absence  of  new  protein  synthesis  (137-140).  For  example,  IL-4-
activated STAT6 directly suppresses IFNγ-induced inflammatory gene transcription 
by competing with IFNγ-induced STAT1 for STAT-1 binding sites (137, 138) and for 
limiting quantities of transcriptional co-activators (138, 139). In transfected HEK293 
cells, IL-4-induced STAT6 inhibits NF-κB dependent transcription by sequestration 
of the transcriptional co-activator, CREB-binding protein (CBP) (139). In addition, 
IL-4-induced STAT6 inhibits expression of the E-selectin gene by competing with 
NF-κB for binding to overlapping STAT6 and NF-κB binding sites in the E-selectin 
promoter (140). STAT6 competition with NF-κB may not be unique to the E-selectin 
gene and may be a novel mechanism for IL-4 mediated inhibition of LPS-induced 
inflammatory gene expression. 
 
It  is also  possible that  STAT6 mediates the anti-inflammatory  actions  of  IL-4 by 
inducing synthesis of new protein/s. Studies with the protein inhibitor, cycloheximide, 
demonstrated  that  suppression  of  the  LPS-induced  inflammatory  cytokines,  TNFα 
(141), IL-1β (142) and IL-8 (143), by IL-4 in monocytes were dependent on new   35 
protein synthesis. Identification of the protein/s involved may allow us to identify the 
mechanisms by which IL-4 regulates the production of inflammatory mediators.  
 
STAT6-independent Mechanisms 
IL-4  activates  several  STAT6-independent  pathways  in  monocytes  (90)  and  it  is 
possible that some of the actions of IL-4 do not require STAT6. In a study of STAT6-
null murine bone marrow-derived macrophages (BMM), STAT6 was required for IL-
4 mediated inhibition of TNFα and IL-12 in LPS-treated cells, but not in cells treated 
with the more physiologically relevant combination of LPS with IFNγ (144). It is 
possible  that  this  STAT6-independent  suppression  of  IFNγ-induced  production  of 
TNFα and IL-12 occurred through STAT3 because stimulation of both wild-type and 
STAT6-null  BMM-derived  macrophages  with  IL-4  lead  to  a  modest  increase  in 
tyrosine phosphorylation of STAT3.  
 
1.12.2  Transcriptional Regulation by IL-4 
Several studies on human monocytes have found that IL-4 suppresses LPS-induced 
production of pro-inflammatory cytokines at the level of transcription (142, 145-147). 
However, reports conflict whether IL-4 targets NF-κB or another transcription factor 
involved  in  inflammatory  gene  expression  (see  Table  1.4).  In  addition,  is  unclear 
whether post-transcriptional mechanisms may also be involved. 
 
1.12.3  Post-transcriptional Regulation by IL-4 
IL-4 may also inhibit inflammatory cytokine production post-transcriptionally, either 
by affecting mRNA stability or translation of pro-inflammatory cytokine mRNA. For 
example, in a study on human monocytes, IL-4 suppression of IL-1β mRNA occurred   36 
both transcriptionally, and post-transcriptionally by reducing mRNA stability (142). 
In another study on human peripheral blood mononuclear cells (PBMCs), IL-4 had no 
effect on NF-κB DNA-binding activity or transcription of TNFα, IL-6, IL-1β and IL-
8. Rather, IL-4 acted by enhancing mRNA degradation of these cytokines (148) 
 
The  mechanism  by  which  IL-4  suppresses  LPS-induced  inflammatory  cytokine 
production by murine macrophages may differ to that of human cells (Table 1.4). In 
macrophage cell lines, IL-4 suppressed the production of TNFα protein and inhibited 
NF-κB DNA binding activity and NF-κB-dependent transcription. However, IL-4 had 
no effect on LPS-induced TNFα mRNA levels, suggesting the suppression of TNFα 
by IL-4 in murine macrophages had little to do with the suppression of NF-κB and 
instead occurred post-transcriptionally (149). In another study, IL-4 suppressed LPS-
induced TNFα production in murine macrophages by repressing translation of TNFα 
mRNA (150). This required the presence of the 3’ AU-rich sequence of TNFα mRNA 
which plays a central role in the translational control of the TNFα gene and suggested 
that IL-4 may be down regulating LPS signalling intermediates that mediate TNFα 
translational  activity  such  as  p38.  In  conclusion,  the  mechanisms  by  which  IL-4 
suppresses inflammatory cytokine production may differ depending on the stimulus, 
the cytokine in question and whether the study is on human cells, murine cells or cell 
lines (Table 1.4). 
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Table 1.4:  Mechanisms  of  the  anti-inflammatory  actions  of  IL-4  in human 
and murine monocytes and macrophages. 
 
Cell Type 
 
Stimulus 
 
Cytokine  
Transcription 
factors 
targeted 
 
Proposed 
Mechanism 
 
Reference 
 
Human 
monocytes 
 
LPS or 
IL-1β  
 
IL-6 
 
NF-κB 
 
Transcriptional 
Donnelly et 
al. 1993 
(145) 
 
Human 
monocytes 
 
LPS 
 
IL-6 
 
AP-1,  
NF-IL-6 
 
Transcriptional 
Dokter et 
al. 1993 
(147) 
Human 
monocyte 
cell line 
 
PMA 
+ LPS 
 
IL-6 
 
NF-κB 
 
Transcriptional 
Takeshita 
et al. 1996 
(146) 
 
Human 
monocytes 
 
LPS 
 
IL-1β   
 
- 
Transcriptional 
and mRNA 
stability 
Donnelly et 
al. 1991 
(142) 
 
Human 
PBMCs 
 
 
LPS 
TNFα, 
IL-6,  
IL-1β, 
IL-8 
 
 
None 
 
mRNA 
stability 
 
Wang et al. 
1995 (148) 
Murine 
macrophage 
cell line 
 
LPS 
 
TNFα 
 
NF-κB 
 
Translational 
Clarke et 
al. 1998 
(149) 
Murine 
macrophage 
cell line 
 
LPS 
 
TNFα 
 
- 
 
Translational 
Mijatovic 
et al. 1997 
(150) 
 
 
1.12.4  Differences in IL-4 Signalling Between Monocytes and Macrophages 
The anti-inflammatory actions of IL-4 on freshly isolated blood monocytes differ to 
those on monocyte-derived macrophages (MdMacs) and synovial fluid macrophages 
(Table  1.5).  When  compared  to  blood  monocytes  from  the  same  patients,  the 
responses to IL-4 by macrophages isolated from the joints of patients with RA are 
selective, namely that in synovial fluid macrophages IL-4 suppresses LPS-induced IL-
1β  and  IL-12,  but  not  IL-10  and  TNFα  production  (151).  Similar  effects  were 
observed in monocytes that have been cultured for seven days in the presence of M-
CSF (MdMacs), namely that IL-4 suppresses LPS-induced IL-1β and IL-12, but not 
TNFα or IL-10 (152).    38 
These different responses to IL-4 may be due to changes in the IL-4 receptor and 
signalling  processes  that  occur  during  monocytes  differentiation.  As  monocytes 
differentiate in vitro into MdMacs, mRNA levels for the γc chain decline over time so 
that  by  seven  days,  MdMacs  express  significantly  reduced  levels  of  functionally 
active γc protein (152). This decline correlates with the reduced ability of IL-4 to 
suppress LPS-induced TNFα and IL-10 production. Cross-linking studies with 
125I-IL-
4 reveal that for monocytes, the binding of IL-4 to the receptor components, IL-4Rα  
and  γc,  is  approximately  1:1,  while  in  MdMacs  the  ratio  of  IL-4Rα:  γc  is 
approximately  3:1.  This  suggests  that  in  MdMacs  the  IL-4  receptor  may  form  a 
different receptor conformation than the one comprising 1:1 IL-4Rα and γc (153).  
 
Possibly as a consequence, IL-4 induces a more rapid and transient phosphorylation 
of the IL-4Rα chain and lower phosphorylation of STAT6 in MdMacs relative to 
monocytes (152). Further, IL-4 stimulates the phosphorylation of STAT3 in MdMacs 
but  not  in  monocytes  (Unpublished  data,  P.  Hart  and  C.  Bonder,  personal 
communication). It is possible that IL-4-mediated regulation of LPS-induced TNFα 
and IL-1β occurs via separate mechanisms. Regulation of TNFα may be dependent on 
STAT6 while IL-4 regulation of IL-1β may also occur via STAT3. This could explain 
why IL-4 fails to suppress LPS-induced TNFα but retains the ability to suppress LPS-
induced IL-1β in MdMacs. This is supported by the observation there are two STAT3 
binding sites in the IL-1β promoter (154). 
 
These changes in IL-4 signalling and expression of the IL-4 receptor components are 
likely to be induced by an endogenous monocyte product which increases over time 
with  culture.  The  Type  I  IFNs,  including  IFNα,  are  constitutively  produced  by   39 
macrophages at low levels (155) and mRNA levels for IFNα gradually increase in 
monocytes over time in culture (156). In human monocytes, treated with exogenous 
IFNα, expression of the IL-4 receptor γc chain, and the ability of IL-4 to activate 
STAT6  were  reduced.  Furthermore,  IL-4-suppression  of  LPS-induced  TNFα 
production was impaired in IFNα-treated monocytes and the addition of an IFNα-
neutralising antibody significantly reversed the suppression of γc and restored IL-4-
suppression of LPS-induced TNFα production (156). This suggests that differential 
expression of γc, and varied responses to IL-4 by MdMac relative to monocytes, may 
be due to increasing levels of IFNα secreted over time in culture. IFNα detected in 
synovial fluids from inflamed joints could explain the inability of IL-4 to suppress 
TNFα production by synovial fluid macrophages (156). 
 
 
Table 1.5:  Differences  in  IL-4  signalling  and  suppression  of  LPS-induced 
cytokines by monocytes, monocyte derived macrophages (MdMacs) and synovial 
fluid macrophages (SF). 
 
 
 
Monocytes 
 
MdMac 
 
SF 
Suppression of cytokines by IL-4 
LPS-induced TNFα  
LPS-induced IL-10 
LPS-induced IL-1β  
LPS-induced IL-12 
 
 
 
 
 
 
- 
- 
 
 
 
- 
- 
 
 
IL-4 receptor signalling 
γc expression 
Phosphorylation of IL-4Rα 
STAT6 phosphorylation 
STAT3 phosphorylation 
 
 
 
 
- 
 
 
Rapid, transient 
 
 
 
nd
a 
nd 
nd 
nd 
 
IFNα secretion 
 
 
 
 
 
 
and, not done 
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1.13  Summary and Aims of this Thesis 
Understanding  how  inflammatory  responses  by  monocytes  and  macrophages  are 
regulated by IL-4 may aid in the development of more targeted therapies for chronic 
inflammatory disease. However, currently the mechanisms by which IL-4 suppresses 
LPS-induced  pro-inflammatory  cytokine  production  are  poorly  understood.  It  is 
unclear  whether  IL-4  acts  directly  via  STAT6  or  through  STAT6-independent 
pathways.  While  several  studies  suggest  the  actions  of  IL-4  require  new  protein 
synthesis, the proteins involved have not been identified. Exactly how, and where, IL-
4 interacts with TLR signal transduction pathways is yet to be determined and it is 
unclear whether IL-4 suppresses pro-inflammatory cytokine production at the level of 
transcription or post-transcriptionally by affecting stability or translation of mRNAs. 
Further, there are fundamental differences in IL-4 signalling between monocytes and 
macrophages as well as in cell lines, primary human cells and murine cells. There is 
therefore a need for more detailed studies in human primary cells to determine the 
exact regulatory properties of IL-4. 
 
The three main objectives of this thesis were: 
(1) To determine the different mechanisms by which IL-4 suppresses inflammatory 
cytokine  production  by  human  monocytes  in  two  different  differentiation  states, 
namely freshly isolated monocytes and monocytes cultured overnight in M-CSF. 
(2) To identify TLR-related signalling components and transcription factors that IL-4 
inhibits,  or  interacts  with,  to  suppress  LPS-induced  pro-inflammatory  cytokine 
production by these cells of different differentiation states.  
(3) To identify the IL-4-induced proteins responsible for the suppression of pro-
inflammatory cytokine production by IL-4.  41 
 
 
 
 
 
Chapter Two 
Materials and Methods 
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2.1  Ethics Approval 
All studies were performed in accordance with National Health and Medical Research 
Council (Australia) guidelines. Ethics approval for experiments on human cells was 
obtained from the Princess Margaret Hospital Human Ethics Committee, Subiaco, 
Project  Number  1492/EP.  Ethics  approval  for  experiments  on  murine  cells  was 
obtained from the Animal Ethics Committee at the Walter and Eliza Hall Institute of 
Medical Research. 
 
2.2  Isolation and Culture of Human Cells 
2.2.1  Isolation of Human Peripheral Blood Mononuclear Cells (PBMCs)  
Blood (50 ml) was collected from volunteers into a tube containing heparin (10 IU/ ml 
blood). The blood was diluted 1:2 in 0.9% NaCl solution and carefully layered on top 
of Lymphoprep (Nyegaard, Oslo, Norway). To separate blood into the various cellular 
constituents according to their density, tubes were centrifuged for 20 min at 1600 rpm 
and 24°C. PBMCs (lymphocytes and monocytes) were harvested from the buffy layer 
(the uppermost cellular layer) into new tubes. The tubes were filled with serum-free 
RPMI  1640  culture  medium  (Invitrogen  Life  Technologies,  Mount  Waverley, 
Australia) supplemented with 2 mM glutamine, 50 μM 2-mercaptoethanol, 5 μg/ml 
gentamycin and 2 mM MOPS (complete RPMI) and centrifuged for 10 min at 1500 
rpm and 18°C. Supernatants were discarded and cells were resuspended in complete 
RPMI and centrifuged for 7 min at 1200 rpm and 18°C. The resulting pellet was 
resuspended  in  complete  RPMI  and  cell  yield  was  determined  using  a 
haemocytometer.  Typically  1-1.5  x  10
6  PBMCs  were  obtained  per  ml  of  blood. 
Mononuclear enrichment was determined by morphological characterisation of Diff-
Quik (Lab Aids, Narrabeen, Australia) stained cytocentrifugal smears, with PBMCs   43 
generally comprising of approximately 30% monocytes and 70% lymphocytes (Fig. 
2.1A). 
 
2.2.2  Isolation of Human Monocytes 
Monocytes were purified from buffy coats from human blood, kindly provided by the 
Australian Red Cross Blood Service (Perth, Australia). The buffy coats were diluted 
1:4 in 0.9% NaCl, layered on top of Lymphoprep (Nyegaard), then centrifuged for 30 
min at 1600 rpm and 24°C. PBMCs were harvested from the buffy layer into new 
tubes, which were filled with Hanks Balanced Salt Solution (HBSS) (Thermo Trace, 
Melbourne,  Australia)  or  saline  solution  (Baxter  Healthcare,  Old  Toongabble, 
Australia), then centrifuged for 10 min at 1500 rpm and 18°C. Supernatants were 
discarded and cells were resuspended in HBSS or saline solution and centrifuged for 7 
min at 1200 rpm and 18°C.  PBMCs were resuspended in HBSS or saline solution and 
further enriched to monocytes using countercurrent centrifugal elutriation using the 
Beckman J2-21M/E centrifuge and JE-6B  elutriator rotor (Beckman Coulter,  Palo 
Alto, CA). This system works on the principle of separation of cells according to size 
and density. A counter-flow force was balanced with a centrifugal force (2000 rpm) 
so  that  particles  larger  than  a  specific  size  were  concentrated  in  the  rotor,  while 
smaller particles were washed out. To increase the size of cells that were washed out, 
the pump speed (flow rate) was gradually increased. Smaller cells, including platelets 
and lymphocytes, were washed out at lower pump speeds. Monocytes were washed 
out  at  the  maximum  pump  speed  (~24  ml/min).  Once  elutriated,  monocytes  were 
washed  to  remove  HBSS/  saline  solution  and  resuspended  in  complete  RPMI 
medium.  Post  elutriation,  cell  yield  was  determined  using  a  haemocytometer. 
Monocyte  enrichment  was  determined  by  morphological  characterisation  of  Diff-  44 
Quick-stained cytocentrifugal smears. Typically this method enriched monocytes to a 
purity  of  >85%,  with  contaminating  cells  primarily  lymphocytes  (<15%)  and 
neutrophils (<1%) (Fig. 2.1B). 
 
2.2.3  Isolation of Synovial Fluid Cells 
Synovial fluid  was  drained as part  of  clinical  practice from patients  with  chronic 
arthritis.  All  patients  were  classified  as  having  chronic  inflammatory  arthritis, 
predominantly rheumatoid arthritis (RA) but including some patients with psoriatic 
arthritis.  Aspirates  were  diluted  1:4  in  0.9%  NaCl  and  layered  over  Lymphoprep 
gradients (Nyegaard). After centrifugation at 1600 rpm for 20 min at 24°C, cells at the 
interface were removed and washed twice with complete RPMI before resuspension 
in  the  same  medium.  Mononuclear  enrichment  was  determined  by  morphological 
characterisation of Diff-Quik stained cytocentrifugal smears. Typically synovial fluid 
mononuclear  cells  comprised  of  approximately  50%  monocytes/macrophages  and 
50%  lymphocytes  (Fig.  2.1C).  Due  to  the  small  number  of  cells  obtained  from 
synovial fluid samples, synovial fluid cells were principally used for extraction of 
RNA and subsequent PCRs, rather than being cultured with additional stimuli. 
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Figure 2.1:   Cellular composition of isolated human cells. Cells were centrifuged 
onto glass slides, stained with Diff-Quik, and examined by light microscopy (100 x 
magnification). PBMCs (A) consisted of approximately 70% lymphocytes (‘L’, small, 
round cells with dense nuclei) and 30% monocytes (‘M’, larger cells with kidney- or 
horseshoe-shaped  nuclei).  Arrows  indicate  anuclear  blood  cells  and  platelets. 
Elutriated  monocytes  (B)  were  predominantly  monocytes  (>  85%),  with 
contaminating  cells  primarily  lymphocytes.  C.    Synovial  fluid  mononuclear  cells 
comprised  of  approximately  50%  lymphocytes  and  50%  monocytes/  macrophages 
(‘Mø’, larger cells with rounder nucleus). 
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2.2.4  Culture of Human Monocytes and PBMCs 
Monocytes were used either immediately after isolation (freshly isolated monocytes) 
or  cultured  overnight  in  Teflon  Pots  (Savillex,  Minnetonka,  MN)  with  25  ng/ml 
recombinant human M-CSF (PeproTech, Rehovot, Israel) before addition of stimuli. 
Cell suspensions were diluted to 2 x 10
6 cells/ ml (PBMCs) or 1 x  10
6 cells/ ml 
(freshly isolated monocytes and overnight cultured monocytes) in complete RPMI 
medium  supplemented  with  10%  FCS  (Thermotrace,  Melbourne,  Australia).  For 
assays of cytokine production, 500 µl of monocyte or PBMC cell suspensions were 
dispensed into flat bottomed 48 well plates (Falcon Plastics, Oxnard, CA). For RNA 
extractions, protein extractions and flow cytometry, 1 ml of monocytes or PBMC cell 
suspensions  were  dispensed  into  cell-non-adherent  Minisorp  70X11  Nunc-
Immunotubes  (Nunc,  Roskilde,  Denmark).  PBMCs  and  monocytes  were  then 
incubated with their respective stimuli at 37°C in a 5% CO2 incubator in a humidified 
atmosphere.  
 
2.3  Isolation and Culture of Murine Cells 
2.3.1  Generation and maintenance of Socs1
-/-Ifnγ
-/-, Ifnγ
-/- and IL10
-/- mice 
Mice with a homozygous deletion of both the Socs1 and Ifnγ genes (Socs1
-/-Ifn
-/-) 
were generated as described previously (157) and were maintained on a C57BL/6 
background. C57BL/6 mice with a homozygous deletion of the Ifnγ gene (Ifn
-/-), and 
C57BL/6 mice with a homozygous deletion of the IL10 gene (IL10
-/-) were obtained 
from The Jackson Laboratory (Bar Harbor, MN). C57BL/6, Socs1
-/-Ifnγ
-/-and Ifnγ
-/- 
mice  were  bred  at  the  animal  facilities  of  The  Walter  and  Eliza  Hall Institute  of 
Medical Research, Parkville, Australia, while  IL10
-/- mice were supplied as a kind   47 
gift by Dr Mark Febbraio and Greg Kowalski (Baker IDI Heart & Diabetes Institute, 
Melbourne, Australia).  
 
2.3.2  Isolation and Culture of Murine Bone-Marrow Derived Macrophages  
Murine  bone  marrow-derived  macrophages  (BMM)  were  derived  from  C57BL/6, 
Socs1
-/-Ifnγ
-/-,  Ifnγ
-/- and IL10
-/- mice by culture of whole bone marrow for seven days 
in  Dulbecco’s  modified  Eagle’s  medium  (DMEM)  supplemented  with  100  U/ml 
penicillin, 0.1 mg/ml streptomycin, 10% FCS and 20% L-cell conditioned medium as 
a source of M-CSF. Independent cultures were generated from three mice of each 
genotype. Cells (10
6 in 1 ml) were re-plated in DMEM culture medium supplemented 
with 10% FCS and 20% L-cell conditioned medium in 12-well plates and incubated 
overnight before addition of stimuli. 
 
2.4  Assessment of Functional Responses to IL-4 
Unless  otherwise  indicated,  the  following  reagents  were  added  to  give  the  final 
concentrations:  LPS from  Escherichia  coli  0111:B4 (500 ng/ml; Sigma, St  Louis, 
MO),  recombinant  human  (rh)  IL-4  (10  ng/ml;  Bender  MedSystems,  Burlingame, 
CA),  recombinant  human  IL-10  (10  ng/ml;  ProSpec-Tany  TechnoGene,  Rehovot, 
Israel),  IFNγ  (10  ng/ml;  ProSpec-Tany  TechnoGene).  For  experiments  on  murine 
BMM,  LPS  (10  ng/ml)  and  recombinant  murine  IL-4  (10  ng/ml;  R&D  systems, 
Minneapolis, MN) were used. Unless otherwise indicated, IL-4 was added to cultures 
at the same time as LPS. Triplicate cultures were used for each test variable. For 
assessment  of  cytokine  content  by  time-resolved  fluorescence  (TRF)  assays, 
supernatants  were  harvested  from  cell-adherent  wells,  centrifuged  to  remove  any 
remaining cells in suspension, and stored at -20°C. Monocytes from non adherent   48 
cultures were pelleted by centrifugation. Pellets were used for mRNA extraction, or 
assayed for the expression of proteins using Western blotting and flow cytometry or 
transcription factor binding using electrophoretic mobility shift assays (EMSAs). 
 
Table 2.1:  List of inhibitors used to assess functional responses to IL-4. 
 
 
Pathway/ 
molecule 
inhibited 
 
 
Inhibitor 
 
Source 
 
Concentration 
 
Timing of 
addition 
 
p38 MAPK 
 
SB203580 
 
Sigma 
 
1 µM 
1h before 
LPS/IL-4 
 
 
ERK MAPK 
 
PD98059 
 
Sigma 
 
5 µM 
1h before 
LPS/IL-4 
 
 
Proteasomal 
degradation 
 
MG-132 
 
Sigma 
 
10 µM 
Same time 
as LPS/IL-4 
 
 
 
 
Histone 
deacetylase 
(HDAC) 
enxymes 
 
TSA
a 
(broad 
spectrum 
inhibitor) 
 
 
Sigma 
 
 
50 nM 
 
1h before 
LPS/IL-4 
 
 
MS-275 
(Class I 
specific  
inhibitor) 
 
 
Sigma 
 
 
50 nM 
 
1h before 
LPS/IL-4 
 
 
 
 
PPARγ 
 
 
GW9662 
(antagonist) 
 
Sigma 
 
1-20 µM 
1h before 
LPS/IL-4 
 
 
GW1929 
(agonist) 
 
Sigma 
 
1-10 µM 
 
1h before 
LPS/IL-4 
 
 
 
 
 
IL-10 
 
Anti-IL-10 
monoclonal 
antibody 
(MAB2171) 
 
 
R&D systems 
 
 
 
10 µg/ml 
 
Same time 
as LPS/IL-4 
 
 
IgG control 
antibody 
(MAB004) 
 
R&D systems 
 
 
10 µg/ml 
 
Same time 
as LPS/IL-4 
 
 
 
RIPK2 
kinase 
activity 
 
SB203580 
 
Sigma 
 
1 µM 
 
1h before 
LPS/IL-4 
 
 
PP2 
 
Calbiochem, 
San Diego, CA 
 
1 µM 
 
1h before 
LPS/IL-4 
 
aTrichostatin A 
 
   49 
2.4.1  1nhibition in vitro of LPS- and IL-4-mediated Pathways 
To  determine  the  pathways  mediating  the  suppression  of  LPS-induced  TNFα 
production  by  IL-4,  specific  inhibitors  of  these  pathways  were  added  to  human 
monocyte cultures. These included inhibitors of the MAPK pathways, proteasomal 
degradation, histone deacetylase (HDAC) enzymes and Receptor Interacting serine-
threonine-Protein  Kinase  2  (RIPK2).  A  peroxisome  proliferator-activated  receptor 
gamma (PPARγ) antagonist and an anti-IL-10 neutralising antibody were also added. 
The  sources  of  these  inhibitors,  the  concentrations  used,  and  the  timing  of  their 
addition relative to addition of LPS and IL-4 are listed in Table 2.1. 
 
2.5  Detection  of  Human  and  Murine  Cytokines  in  Tissue  Culture 
Supernatants 
Human TNFα, IL-10 and IL-1β and murine TNFα and IL-10 levels were assayed in 
culture supernatants (from 5x 10
5 cells per 500 μl) using a time resolved fluorescence 
(TRF) assay. Table 2.2 summarises the capture and detection antibodies used and the 
sensitivity of each assay. Briefly, 100 µl of anti-human TNF, IL-10 or IL-1β,  or anti-
mouse TNF  capture antibodies, diluted 1/500 in 0.1 M sodium carbonate buffer (100 
mM NaHCO3, 33.6 mM Na2CO3, pH 9.5) were added to 96 well Nunc Maxisorp 
plates (Roskilde, Denmark) and incubated overnight at 4°C.  The anti-mouse IL-10 
capture antibody was diluted in 0.2 M sodium phosphate buffer (83 mM Na2HPO4, 
134 mM NaH2PO4, pH 6.5). Between each incubation step, plates were washed with 
TRF  wash  buffer  (8%  NaCl,  1.16%  Na2HPO4,  0.2%  KH2PO4,  0.2%KCl,  0.05% 
Tween-20 (Finechem,  Auburn, Australia), pH 7.0). After washing, the wells  were 
incubated with 200 µl blocking buffer (8% NaCl, 1.16% Na2HPO4, 0.2% KH2PO4, 
0.2%KCl, 10% FCS, pH 7.0) for 2 h at room temperature (RT) with shaking. Serial   50 
dilutions of recombinant human TNFα, IL-10 or IL-1β and recombinant mouse TNFα 
or IL-10 were used as standards and incubated, along with 100 µl test samples, for 2 h 
at RT with shaking. Biotinylated anti-human IL-10, TNF and IL-1β or biotinylated 
anti-mouse TNF  and  IL-10 detection antibodies, diluted 1/500  in  blocking buffer, 
were added to their corresponding wells (100 µl/ well) and incubated for 1 h at RT 
with shaking. 100 μl per well of Europium-labelled Streptavidin (Wallac Oy, Turku, 
Finland), diluted 1/1000 in DELFIA assay buffer (Wallac Oy) was added to plates and 
incubated for 30 min at RT with shaking. Finally, plates were incubated in the dark 
with Enhancement Solution (100 μl/ well, Perkin Elmer, Glen Waverley, Australia) 
for 15 min at RT. Time resolved fluorescence was measured at 615 nm on a Wallac 
Victor 2 counter (Wallac Oy). 
 
Table 2.2:  List of antibodies sets used for TRF assays 
 
Cytokine  Set  Source  Sensitivity 
 
Human 
TNFα 
 
Human TNF  
ELISA Set 
 
BD OPtEIA, BD Biosciences 
(San Diego, CA) 
 
>10 pg/ml 
 
Human IL-
1β  
 
Human IL-1β  
ELISA Set 
 
 
BD OPtEIA, BD Biosciences 
 
> 15 pg/ml 
 
Human IL-
10 
 
Human IL-10 
Antibody Pairs 
 
 
BD Pharmingen, BD 
Biosciences 
 
> 10 pg/ml 
 
Murine 
TNFα 
 
Murine TNF  
ELISA Set 
 
 
BD OPtEIA, BD Biosciences 
 
> 15 pg/ml 
 
Murine IL-
10 
 
Murine IL-10  
ELISA Set 
 
 
BD OPtEIA, BD Biosciences 
 
> 15 pg/ml 
 
2.5.1  Detection of Prostaglandin E2 in Supernatants 
Prostaglandin E2 (PGE2) levels were assayed in human monocyte culture supernatants 
using a monoclonal PGE2 competitive EIA kit (Catalogue Number 514010, Cayman 
Chemical  Company,  Ann  Arbor  MI)  as  per  the  manufacturer’s  instructions.  
Supernatants  from  cells  stimulated  with  LPS  ±  IL-4  were  diluted  1/50  in  culture   51 
medium (RPMI + 10% FCS) before being assayed. Each dilution of supernatants (50 
μl) was added to wells of the pre-coated plate in duplicate with serial dilutions of the 
PGE2  standard  in  RPMI  +  10%  FCS.  PGE2  tracer  (50  μl)  and  PGE2  monoclonal 
antibody (50 μl) were added to wells and the plate was covered with plastic film and 
incubated for 18 h at 4°C. After incubation the plate was washed five times with EIA 
wash buffer and 200 μl of Ellman’s reagent was added to each well. The plate was 
covered and incubated in the dark for 40 mins, then read at an absorbance of 405 nm 
using  a  Wallac  Victor  2  counter.  PGE2  concentrations  were  calculated  from  the 
absorbance readings using Assay Zap 2.51 (Biosoft, Cambridge, UK). 
 
2.6  Detection of Gene Expression Using Real-time PCR  
2.6.1  RNA Extractions 
Human monocytes (10
6 in 1 ml) were cultured in medium or treated with IL-4 (10 
ng/ml), LPS (500 ng/ml), and LPS with IL-4 for up to 24 h. Non-adherant monocytes 
were pelleted by centrifugation at 1200 rpm for 7 mins at 18°C. For PCRs in Chapters 
3,  6  and  7,  total  RNA  was  isolated  using  TRIzol  reagent  (Invitrogen  Life 
Technologies). Pellets were lysed in TRIzol reagent (1 ml/ 10
6 cells), and stored at -
80°C. TRIzol samples were then thawed and incubated for a further 5 min at room 
temperature. Chloroform (0.2 ml/ tube) was added to each sample and tubes were 
shaken vigorously for 15 sec. The resulting mixtures were incubated for 3 min at 
room temperature, and then centrifuged at 12,000 x g for 15 min at 4°C, to separate 
the mixture into three distinct phases. Approximately 0.6 ml of the upper aqueous 
phase, containing the RNA, was  carefully removed into a fresh  tube.  Isopropanol 
(100%) (0.5 ml/ tube) was added and samples were incubated at room temperature for 
10 min to precipitate RNA. Samples were then centrifuged at 12,000 x g for 15 min at   52 
4°C. The resulting RNA pellet was washed in 1 ml of 75% ethanol, vortexed and 
centrifuged for 5 min at 7,500 x g at 4°C. Ethanol was removed and the RNA pellets 
were air dried for up to 10 min, then dissolved in 50 μl of RNase-free water. 
 
For  IL-10,  c-Maf,  RIPK2  and  RP105  PCRs  (Chapters  8  and  9),  total  RNA  was 
isolated using the RNeasy Plus Mini-Kit (Qiagen), according to the manufacturer’s 
instructions. Briefly, pellets were lysed in the supplied lysis buffer containing 1% 2-β-
mercaptoethanol (350 μl/ 10
6 cells) and stored at -80°C. Samples were thawed and 
spun through gDNA Eliminator spin columns to remove genomic DNA. Total RNA 
was then purified using RNeasy Mini spin columns, then eluted from the column in 
40 μl RNase free water. Purified RNA was immediately placed on ice and a portion of 
each sample was taken for spectrophotometric analysis using the Nanodrop ND-1000 
spectrophotometer  (BioLab,  Mulgrave,  Australia).  The  yield  and  concentration  of 
RNA  samples  was  calculated  from  the  absorbance  at  260  nm,  while  the  ratio  of 
absorbance values at 260 nm and 280 nm were calculated to ascertain the purity of the 
samples. RNA was either used immediately for cDNA synthesis or for longer term 
storage, samples were snap frozen in liquid nitrogen and stored at -80°C. 
 
2.6.2  Reverse Transcription of RNA 
RNA  extracted  using  TRIzol  reagent  was  reverse  transcribed  to  cDNA  using  the 
Omniscript RT Kit (Qiagen, Doncaster, Vic, Australia). Briefly, RNA template (14.1 
µl per 20 µl reactions) was incubated with 4 U omniscript II reverse transcriptase, 0.5 
mM  dNTPS  and  1x  RT  buffer  (Qiagen)  with  1  µM  oligo-dT  primers  (Promega, 
Alexandria, Australia) and 10 U RNase Inhibitor (Perkin Elmer) for 1 h at 37°C and 5 
min at  93°C. RNA extracted using the RNeasy Plus Mini-Kits (Qiagen) was reversed 
transcribed to cDNA using the QuantiTect kit (Qiagen). RNA templates (0.2 µg) were   53 
incubated with 1x gDNA Wipeout Buffer in 14 µl reactions for 2 min at 42°C to 
eliminate genomic DNA and immediately placed on ice. The RNA template was then 
made up to 20 µl with Quantiscript Reverse Transcriptase, RT Primer Mix, and 1x 
Quantiscript RT Buffer and incubated for 15 min at 42°C and 3 min at 95°C. cDNA 
was diluted 1:5 and stored at -20°C until ready to be used for real-time PCRs. 
 
2.6.3  Real-time PCR 
Gene-specific primers were designed using Primer Express Software v2.0 (Applied 
Biosystems,  Mulgrave,  Australia)    or  Primer-BLAST  Software  accessed  online 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast)  to recognise the following human 
transcripts- TNFα, IL-10, both spice variants of c-Maf, RIPK2, RP105, SOCS1, CIS, 
SOCS3, SOCS4, SOCS5, PIAS1, PIAS3, SHP1, SHP2, SHIP, PPARγ and TREM-2 
(Table  2.3).  Specificity  of  primers  was  confirmed  using  NCBI  Blast  Searches 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and where possible, primers were designed to 
span  introns.  Real  time  PCR  was  performed  in  optical  384-well  reactions  plates 
(Applied  Biosystems)  using  the  QuantiTect  or  QuantiFast  SYBR  green  PCR  kit 
(Qiagen)  and  ABI-PRISM  7900HT  (Applied  Biosystems).  PCR  conditions  for  all 
primers are summarised in Table 2.4. Melting curve analysis was used to assess the 
specificity of the PCR, with one clean peak indicating one PCR product of a uniform 
size.  Copy  numbers  were  determined  using  a  standard  curve  created  from  serial 
dilutions of the PCR product, then normalised to expression of the housekeeping gene 
ubiquitin-conjugating enzyme E2D2 (UBE2D2). Data are represented as either the 
ratio of PCR product relative to UBE2D2 expression (Chapters 3, 6 and 7) or the fold 
change in mRNA levels relative to expression in freshly isolated, untreated monocytes 
(Chapters 8 and 9).   54 
Table 2.3:  List of primers used for real-time PCR. 
  
PCR  
product 
Product Size  Forward and reverse primers 
 
TNFα 
 
72 bp 
Intron spanning 
 
 F: 5’-GGCAGTCAGATCATCTTC TCGA-3’ 
 R: 5’-TCAGCTTGAGGGTTTGCTACAA-3’ 
 
 
IL-10 
 
178 bp 
Intron spanning 
 
 F: 5’-CATCAAGGCGCATGTGAACT-3’ 
 R: 5’-GATGTCAAACTCACTCATGGCTTT-3’ 
 
 
c-Maf 
 
124 bp 
Non-intron spanning 
 
 F: 5’-TGCAGCAAGTCGACCACCTCAA-3’ 
 R: 5’-TTGTCGCTGCTCGAGCCGTTTT-3’ 
 
 
RIPK2 
 
188 bp 
Intron spanning 
 
 F: 5’-TCAAGGGCCAGTATCAAGCACGA-3’ 
 R: 5’-ATCATACGTGCTCGGTGAGGT-3’ 
 
 
RP105 
 
176 bp 
Intron spanning 
 
 F: 5’-CACAATAGAACCTTCAGCAGACT-3’C 
 R: 5’-AGTGACTTGGGCCCATTAAGCGA-3’ 
 
 
SOCS1 
 
104 bp 
Non-Intron spanning 
 
 F: 5’-TCCTCCTCTTCCTCCTCCTC-3’ 
 R: 5’-GAACGGAATGTGCGGAAGT-3’ 
 
 
CIS 
 
200 bp 
Non-intron spanning 
 
 F: 5’-TGTGCATAGCCAAGACCTTCT-3’ 
 R: 5’-CGGCATACTCAATGCGTACA-3’ 
 
 
SOCS3 
 
189 bp 
Non-intron spanning 
 
 F: 5’-CCCCAGAAGAGCCTATTACATCTACT-3’ 
 R: 5’-GCATCGTACTGGTCCAGGAACT-3’ 
 
 
SOCS4 
 
77 bp 
Non-intron spanning 
 
 F: 5’-TGACATTACTGGGCTCCTAGAA-3’ 
 R: 5’-AAGGGAGTGGATAGAAGTGGTTCA-3’ 
 
 
SOCS5 
 
100 bp 
Non-intron spanning 
 
 F: 5’-GGGAAACCTGAAGGCACGTT-3’ 
 R: 5’-ATTCGGGCATGCAGGGATCT-3’ 
 
 
PIAS1 
 
200 bp 
Non-intron spanning 
 
 F: 5’-TCGGGCCCTTACATGTTCTC-3’ 
 R: 5’-CAAGTGCCATCCTCCTTAAATTG-3’ 
 
 
PIAS3 
 
204 bp 
Non-intron spanning 
 
 F: 5’-CGATGCTGCCCTTTATCTACAGA-3’ 
 R: 5’-AACCTCAGATGCCTCCTTCTTG-3’ 
 
 
SHP1 
 
200 bp 
Non-intron spanning 
 
 F: 5’-GCCCTGATGAGAACGCTAAGA-3’ 
 R: 5’-TCACAGAGTAGGGCCCATAAGC-3’ 
 
 
SHP2 
 
200 bp 
Non-intron spanning 
 
 F: 5’-GCCTGCAAAACACGGTGAA-3’ 
 R: 5’-CTCTTAGCGTATAGTCATGAGCGG-3’ 
 
 
SHIP 
 
209 bp 
Non-intron spanning 
 
 F: 5’-GCTGCTTGGAGAGTT TTGTCAA-3’ 
 R: 5’-CTAACCGAAGGGCAATGCA-3’ 
  
 
PPARγ 
 
122 bp 
Intron spanning 
 
 F: 5’-TCCGTGGATCTCTCCGTAATG-3’ 
 R: 5’-ATCTGTTCTTGTGAATGGAAT-3’ 
 
 
TREM2 
 
105 bp 
Intron spanning 
 
 F: 5’-GGTCAGCACGCACAACTTG-3’ 
 R: 5’-CGCAGCGTAATGGTGAGAGT-3’ 
 
 
UBE2D2 
 
104 bp 
Intron spanning 
 
 F: 5’-ATGGCAGCATTTGTCTTGATATTCTAC-3’ 
 R: 5’-TGGATTGGGATCACACAACAGA-3’ 
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Table 2.4:  Real-time PCR conditions. 
All primers 
(except SOCS1) 
QuantiTect SyBr Green 
All primers 
(except SOCS1) 
QuantiFast SyBr Green 
 
SOCS1 primers 
 
QuantiTect SyBr Green 
20 µl reactions: 
 
4 µl cDNA 
10 µl 2x supermix 
0.3 µM F-primer 
0.3 µM R-primer 
10 µl reactions: 
 
2 µl cDNA 
5 µl 2x supermix 
0.3 µM F-primer 
0.3 µM R-primer 
20 µl reactions: 
 
4 µl cDNA 
10 µl 2x supermix 
0.3 µM F-primer 
0.3 µM R-primer 
 
95°C for 15 min 
 
95°C for 15 sec         40 
60°C for 1 min       cycles 
 
 
95°C for 5 min 
 
95°C for 10 sec         40 
60°C for 30 sec        cycles 
 
 
 
95°C for 15 min 
 
95°C for 15 sec         45 
60°C for 30 sec      cycles 
72°C for 30 sec 
 
 
 
2.7  PCR Array Analysis of TLR Related Gene Expression in LPS- and IL-4-
treated Human Monocytes 
Total RNA was isolated from 5 x 10
6 human monocytes cultured for 1, 2 and 3 h with 
LPS (500 ng/ml) ± rhIL-4 (10 ng/ml) using the RNAeasy plus minikit (Qiagen). RNA 
was quantified using a Nanodrop ND-1000 spectrophotometer and 1 µg of total RNA 
was reverse-transcribed to cDNA using the RT
2 First Strand kit as per manufacturer’s 
instructions (SABiosciences, Frederick, MD). PCR arrays were performed by adding 
25 µl of RT
2 SYBR Green/ ROX q-PCR master mix containing the cDNA (diluted 
1/6) to a 96-well Human TLR-signaling pathway RT
2 Profiler PCR plate (PAHS-018, 
SABiosciences).  Amplification  was  performed  on  the  ABI  7000  (Applied 
Biosystems) in accordance with the manufacturer’s guidelines. For data analysis, four 
housekeeping  genes,  hypoxanthine  phosphoribosyltransferase  1,  ribosomal  protein 
L13a, glyceraldehyde-3-phosphate dehydrogenase, and β actin, as present on the PCR 
array, were used for normalisation. The cycle threshold (CT) was determined for each 
sample  and  normalised  to  the  average  CT  of  the  four  housekeeping  genes. 
Comparative CT method was used to calculate relative gene expression. Data were   56 
represented as either fold changes induced by IL-4 in LPS-treated monocytes relative 
to expression in monocytes treated with LPS only, or fold changes induced by LPS 
and IL-4 relative to expression in freshly isolated, untreated monocytes. Genes were 
defined  in  LPS  treated  cells  as  being  up-  or  down-regulated  by  IL-4  over  three 
experiments if their was a greater than 2-fold change from LPS-treated cells and the 
mean expression was significantly different (p<0.05) as determined using a paired t 
test.  
 
2.8  Western Blotting 
For detection of phosphorylated and total levels of IκB, p38, ERK and JNK MAPK, 
and STAT6, human monocytes (10
6 in 1 ml) were treated with LPS (500 ng/ml) ± IL-
4 (10 ng/ml) for up to 2 h. For detection of SOCS1, human monocytes (10
6 in 1 ml) 
were treated with LPS (500 ng/ml), IL-4 (10 ng/ml) or IFNγ (10 ng/ml) for up to 4 h. 
Triplicate  non-adherent  monocyte  cultures  were  washed  in  ice-cold  phosphate 
buffered saline (PBS) (8% NaCl, 1.16% Na2HPO4, 0.2% KH2PO4, 0.2%KCl, pH 7.4), 
pooled and centrifuged at 1200 rpm, 4°C to pellet cells. Pellets were lysed in protein 
lysis buffer  (10 mM  Tris,  50 mM  NaCl,  5 mM  ethylene diamine tetraacetic acid 
(EDTA), 1% Triton X-100, pH 7.6) supplemented with 5 mM sodium fluoride, 10 
mM sodium molybdate, 1 mM sodium pyrophosphate, 2 mM sodium orthovanadate 
and 1x protease inhibitors (complete mini, protease inhibitor cocktail tablets; Roche, 
Penzberg,  Germany).  Total  protein  content  of  lysates  was  quantified  using  the 
Bradford protein assay method (Coomassie Plus Protein Assay, Pierce Biotechnology, 
Rockford, IL). Approximately 7.5 μg (or 30 μg for detection of SOCS1) of protein 
lysates, was resolved per lane of a sodium dodecyl sulfate (SDS)-PAGE gel. Control 
pre-stained molecular weight markers (Biorad, Hercules, CA) were included in each   57 
gel  to  determine  the  molecular  weight  of  the  proteins.  Western  blot  analysis  was 
performed  by  transferring  separated  proteins  onto  nitrocellulose  membrane  (Pall 
Corporation, Pensacola, FL) in Tris-glycine buffer (192 mM glycine, 25 mM Tris) 
containing 20% methanol. Membranes were blocked for at least 1 h in 5% skim milk 
in Tris buffered saline (TBS) (10 mM Tris, 150 mM NaCl, pH 7.6)/ 0.05% Tween-20 
(Finechem), followed by overnight incubation at 4°C with primary antibodies (see 
Table 2.5). Primary antibodies were diluted in 5% skim milk or 5% BSA (Sigma), in 
TBS/ 0.05% Tween-20, according to the manufacturer’s guidelines. Following four 
sequential 5 min washes in TBS/ 0.05% Tween 20, membranes were incubated with 
horseradish  peroxidase  (HRP)-conjugated  goat  anti-rabbit  (Rockland 
Immunochemicals,  Gilbertsville,  PA)  or  goat-anti-mouse  (Pierce)  secondary 
antibodies  diluted  in  5%  skim  milk  in  TBS/  0.05%  Tween-20.  Membranes  were 
washed extensively in TBS/ 0.05% Tween 20 and bound secondary antibody  was 
detected using BM chemiluminescence Western blotting kit (Roche) and visualised 
using  CL-XPosure  film  (Pierce).  For  subsequent  detection  of  protein  bands  of  a 
similar size on the same membrane, previously bound antibodies were stripped by 
incubating for 30 min, 50°C with stripping buffer (100mM 2-β-mercaptoethanol, 2% 
SDS,  62.5  mM  Tris,  pH  6.8)  before  reprobing  with  the  new  primary  antibody.  
Exposed films were scanned and quantitative analysis of protein levels was carried 
out  using  Gel  Doc  Software  (Biorad).  p38,  ERK  and  JNK  phosphorylation  were 
normalised to the amount of total p38, ERK and JNK protein.  Quantitative analysis 
of all other proteins  were normalised to  the amount  of loading controls,  α-  or β-
tubulin. 
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Table 2.5:  List of antibodies used for Western blotting. 
 
Target 
Protein 
Antibody  Source  2° Antibody 
 
P-IκB 
 
Phospho-IkappaB-α 
(Ser32) 
 
Cell Signaling 
Technology 
(Danvers, MA) 
 
 
Goat anti-rabbit 
 
IκB 
 
IκB-α (C21) 
 
Santa Cruz 
Biotechnology 
(Santa Cruz, CA) 
 
 
Goat anti-rabbit 
 
P-p38 
 
Phospho-p38 MAP 
Kinase (Thr180/Tyr182) 
 
Cell Signaling 
Technology    
 
Goat anti-rabbit 
 
p38 
 
P38 (C-20) 
 
Santa Cruz 
Biotechnology 
 
 
Goat anti-rabbit 
 
P-ERK1/2 
 
Phospho-p44/42 Map 
Kinase (Thr202/Tyr204) 
 
Cell Signaling 
Technology 
 
 
Goat anti-rabbit 
 
ERK1/2 
 
p44/42 Map Kinase 
 
Cell Signaling 
Technology 
 
 
Goat anti-rabbit 
 
P-JNK 
 
Phospho-SAPK/JNK 
(Thr183/Tyr185) 
 
Cell Signaling 
Technology 
 
 
Goat anti-rabbit 
 
JNK 
 
SAP/JNK 
 
Cell Signaling 
Technology 
 
 
Goat anti-rabbit 
 
P-STAT6 
 
Phospho-Stat6 (Tyr641) 
 
Cell Signaling 
Technology  
 
 
Goat anti-rabbit 
 
SOCS1 
 
anti-SOCS1, clone 4H1 
 
Millipore (North 
Ryde, Australia) 
 
 
Goat-anti-mouse 
 
α-tubulin 
 
anti-α-tubulin clone  
B-5-1-2 
 
 
Sigma 
 
Goat-anti-mouse 
 
β-tubulin 
 
Anti-β-tubulin 
 
Abcam 
(Cambridge, MA) 
 
 
 
Goat anti-rabbit 
 
2.9  Nuclear Extraction, NF-κB and STAT6 EMSAs  
Nuclear extracts were prepared from monocytes treated with LPS ± IL-4. Briefly, 
following stimulation with LPS and IL-4 for 30, 60, 90 and 120 min, 1 ml of ice-cold 
RPMI was added to each tube and cells were harvested by centrifugation at 1200 rpm 
for  7  min  at  4°C.  Cells  were  washed  in  ice-cold  PBS  and  subsequently  lysed  in 
protein  lysis  buffer  (10  mM  N-2-hydroxyethyl  piperazine-N-ethane  sulfonic  acid   59 
(HEPES).KOH, pH 7.9, 10 mM KCl, 1.5 mM MgCl2) supplemented with 1x protease 
inhibitor  (complete  mini,  protease  inhibitor  cocktail  tablets;  Roche),  0.5  mM 
dithiothreitol (DTT) and 2 mM sodium orthovanadate. Lysates were incubated on ice 
for 20 min before 0.6 % NP-40 was  added with vortexing to mix. Samples were 
centrifuged at 12,500 rpm for 30 sec at 4°C. The cytoplasmic fraction (supernatant) 
was transferred to a new microfuge tube while nuclear extraction buffer (420 mM 
NaCl, 20 mM HEPES.KOH, pH 7.9, 1.5 mM MgCl2, 0.2 mM EDTA, 25% glycerol 
supplemented  with  1x  protease  inhibitor,  0.5  mM  DTT  and  2  mM  sodium 
orthovanadate) was  added to  the pellet.  Following 20 min incubation on ice with 
intermittent  agitation, the nuclear fraction was  collected by  centrifugation (12,500 
rpm, 5 min at 4°C) and quantified using the Bradford protein assay method. NF-κB 
(sc-2505  and  sc-2511)  and  STAT6  (sc-2567  and  sc-2668)  consensus  and  mutant 
oligonucleotides were obtained from Santa Cruz Biotechnology. Oligonucleotides (5 
pmol) were end-labelled with 50 µCi (γ-
32P)-ATP (Perkin-Elmer) by incubating for 
10 min at 37°C with 10-20 U T4 Polynucleotide Kinase (Promega). Approximately 1 
μg of nuclear extract was incubated in binding buffer (10 mM TrisCl, pH 7.5, 100 
mM  NaCl,  1mM  EDTA,  5%  glycerol,  0.1%  NP40,  5mM  DTT  with  Poly  dIdC 
(Sigma) for 10 min on ice to allow non-specific binding. 20 fmols 
32P-labelled NF-κB 
or STAT6 probe was then added, and incubated on ice for a further 20 min. Proteins 
were resolved on a non-denaturing 5% polyacrylamide/ 0.5x Tris borate-EDTA gel at 
180 V for up to 2 h. Specificity of NF-κB and STAT6 DNA binding was determined 
by pre-incubating the nuclear lysates with a 50 fold excess of either unlabelled probe 
or an unlabelled mutant probe. Gels  were dried onto  3MM  Whatman filter paper 
(Whatman International, Maidstone, England) and complexes visualised using Super 
RX X-ray film (Fuji Film).    60 
2.10  Flow Cytometric Analysis of CD14, TLR4 and RP105 Surface Expression 
and Intracellular RP105 
2.10.1  Antibodies 
The following anti-human monoclonal  antibodies were obtained from  eBioscience 
(San  Diego,  CA):  Fluorescein  isothiocyanate  (FITC)-anti-CD14;  Allophycocyanin 
(APC)-anti-TLR4;  Phycoerythrin  (PE)-anti-CD180  (RP105),  functional  grade  anti-
CD180 (RP105).  PE-Mouse IgG1 and APC-Mouse IgG2a κ Isotype Controls were 
also  from  eBiosciences.  All  cells  were  phenotyped  using  a  washing  solution  of 
glucose  potassium  sodium    buffer  (GKN)  (127  mM  NaCl,  5.5  mM  KCl,  25mM 
Na2HPO4,  5.5  mM  NaH2PO4.2H2O,  11  nM  glucose,  containing  0.2%  w/v  bovine 
serum albumin (BSA; GKN-BSA). All antibody incubations and cell washes were 
performed at 4°C. 
 
2.10.2  Cell Surface Staining 
For staining of surface markers, PBMCs were cultured for 1, 3, 5 and 24 h with 
medium alone or with IL-4 (10 ng/ml), LPS (500 ng/ml) or LPS + IL-4. Cells were 
washed  and  pre-incubated  with  anti-CD16/CD32  Fc  receptor  antibody  (BD 
Biosciences) for 5 min to prevent nonspecific antibody binding before incubation for 
30 min with 0.5 µg anti-CD14, anti-TLR4 or anti-RP105 antibodies or appropriate 
isotype  controls.  Cells  were  washed  in  1 ml  GKN-BSA  with  1 μg/ml  propidium 
iodide (Sigma), to stain for non-viable cells, then resuspended in GKN-BSA, and 
immediately acquired on a LSRII flow cytometer (BD Biosciences). 
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2.10.3  Intracellular Staining of RP105 
A Cytofix/ Cytoperm Plus Fixation/ Permeabilization Kit (BD Biosciences) was used 
to determine intracellular RP105 expression in PBMCs cultured for 5 and 24 h with 
LPS ± IL-4. Briefly, PBMCs were first stained for surface CD14 (see Section 2.10.2), 
and then resuspended in Fixation and Permeabilization Solution for 20 min to allow 
transit of any subsequent antibodies into the cells. Cells were washed and resuspended 
in  Perm/Wash  solution  and  incubated  for  30  min  with  the  PE-conjugated  RP105 
antibody or appropriate isotype control. Any extracellular binding of PE-anti-RP105 
was previously blocked by adding non-conjugated anti-RP105 antibody to cells with 
the anti-CD14 antibody before permeabilization. After being washed and resuspended 
in GKN-BSA, cells were immediately acquired on a LSRII flow cytometer. 
 
2.10.4  Flow cytometric analysis 
Analysis  of  antibody  binding  was  performed  on  PBMCs  using  FlowJo  software 
(Treestar, version 8.7.3, Ashland, OR).  The monocyte population was defined as the 
larger  cells  by  forward  and  side  scatter  (Fig.  2.1A),  and  confirmed  to  be 
approximately 70% enriched with CD14 expression (see Fig. 2.1B). The amount of 
surface CD14, TLR4 and RP105, and intracellular RP105, per cell was assessed as 
mean fluorescence intensity (MFI)  using FlowJo software.  Analysis of TLR4 and 
RP105  surface  expression  was  determined  on  both  the  monocyte  population  as  a 
whole (shown in Fig. 2.1A) and in monocytes defined by CD14 positivity (shown in 
Fig. 2.1B). All samples from the same experiment were analysed at the same time 
using identical settings and parameters.  
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Figure 2.2:   Gating of monocytes in the PBMC population. A. Monocytes were 
defined as larger cells by forward and side scatter. Cells outside the gate are proposed 
to  be  mainly  lymphocytes,  debris  and  dead  cells.  B.  Representative  histogram  of 
freshly isolated cells showing that approximately 70% of cells in the monocyte gate 
were CD14-positive. Cells outside of the gate were predominately CD14-negative. 
 
 
2.11  Statistical Analysis  
Unless otherwise indicated, all values have been expressed as mean ± SEM for cells 
obtained from individual donors, using mean values of triplicates for cells from each 
donor.  Significance  of  results  has  been  determined  using  one-way  ANOVA  and 
Tukey’s  post-test  or  a  paired  Students  t  test.  The  statistical  program  used  was 
GraphPad  Prism  5.03  where  a  p-value  of  <0.05  was  considered  significant.  For 
analysis of PCR data, an up- or down-regulation of a particular gene transcript was 
considered to be significant by a paired t test with p-value of <0.05, where it was 
regulated by more than 2-fold. 
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Chapter Three 
 
Different Mechanisms Involved in the 
Suppression of Inflammatory Cytokine 
Production by IL-4 in Monocytes after 
Overnight Culture  
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3.1  Introduction 
A better understanding of IL-4 signalling in human monocytes may allow the design 
of more effective anti-inflammatory therapies, perhaps by targeting IL-4 signalling 
intermediates. However, several differences in IL-4 signalling occur between murine 
and human cells (142-150), and as monocytes differentiate into macrophages (151-
153). Little is known about the LPS-signalling components that IL-4 interacts with 
and it is not clear whether the suppression of pro-inflammatory cytokine production 
by IL-4 occurs by transcriptional or post-transcriptional mechanisms. Thus, there is a 
need  for  more  detailed  studies  in  human  primary  cells  to  determine  the  exact 
mechanisms by which IL-4 is anti-inflammatory. 
 
STAT6  mediates  several  of  the  anti-inflammatory  actions  of  IL-4  in  human 
monocytes (136-139). Some of the actions of IL-4, such as the suppression of IFNγ-
induced STAT1-dependent transcription, are mediated directly through STAT6 in the 
absence  of  new  protein  synthesis  (137-139).  However,  the  suppression  of  LPS-
induced TNFα (141), IL-1β (142) and IL-8 (143) production by IL-4 in monocytes is 
dependent on synthesis of a new protein, possibly induced by STAT6. 
  
Reports  conflict  whether  the  anti-inflammatory  actions  of  IL-4  are  mediated 
transcriptionally or by affecting mRNA stability or translation of pro-inflammatory 
cytokines. Several studies on human monocytes suggest that IL-4 suppresses LPS-
induced production of pro-inflammatory cytokines at the level of transcription (142, 
145-147), possibly by inhibiting the transcription factors involved in inflammatory 
gene expression, namely NF-κB (145, 146), NF-IL-6 (147) and AP-1 (147). However, 
IL-4 may also reduce pro-inflammatory cytokine production by human monocytes by   65 
reducing  mRNA  stability  (142,  148).  In  murine  macrophage  cell  lines,  IL-4 
suppresses  LPS-induced  TNFα  production  post-transcriptionally,  most  likely  by 
repressing translation of TNFα mRNA (149, 150). 
 
Responses to IL-4 also differ between freshly isolated blood monocytes and in vitro 
monocyte-derived macrophages. In human monocytes cultured for seven days in M-
CSF (MdMacs), IL-4 loses the ability to suppress a subset of LPS-induced cytokines, 
namely TNFα and IL-10, but maintains the ability to suppress LPS-induced IL-1β and 
IL-12  (152).  Similarly,  in  synovial  fluid  macrophages  from  patients  with 
inflammatory arthritis, IL-4 suppresses IL-1β and IL-12 production, but not TNFα 
and IL-10 production (151). In macrophages, the IL-4 receptor may form a different 
conformation  than  the  one  comprising  1:1  IL-4R  and  γc  (153).  As  monocytes 
differentiate in vitro into MdMacs, mRNA levels for the gamma-c (γc) chain of the 
IL-4  receptor  decline  over  time  and  IL-4  induces  a  more  rapid  and  transient 
phosphorylation of the IL-4Rα chain and reduced phosphorylation of STAT6 (152). 
These  changes  in  IL-4  signalling  and  expression  of  IL-4  receptor  components  in 
MdMacs  may  be  induced  in  vitro  by  the  increased  secretion  of  the  endogenous 
monocyte product, IFNα (156).  
 
In conclusion, the mechanisms by which IL-4 suppresses LPS-induced production of 
pro-inflammatory cytokines vary, depending on the cytokine in question and the cell 
type  being  studied.  Cytokines  such  as  IL-1β,  TNFα  and  IL-6  may  be  regulated 
differentially by IL-4. Furthermore, IL-4 signalling differs between monocytes and 
macrophages, murine cells, human cells and cell lines. This chapter sought to define 
the  mechanisms  by  which  IL-4  suppresses  LPS-induced  inflammatory  cytokine   66 
production by primary human monocytes. Elutriated human monocytes that had been 
cultured overnight in M-CSF were used initially for many of the experiments in this 
thesis, because they can be used earlier in a working day making them more practical 
for examining a range of time-points. However, because of the differences in IL-4 
signalling that occurred with culture, I examined whether the mechanism by which 
IL-4  suppressed  LPS-induced  cytokine  production  differed  in  monocytes  and 
monocytes after overnight culture. In both freshly isolated monocytes and monocytes 
cultured overnight in M-CSF, it was investigated whether the suppression of TNFα 
production by IL-4 occurred at the level of transcription, by reducing mRNA stability 
or by inhibiting translation of TNFα mRNA.  Finally, the ability of IL-4 to activate 
STAT6 was compared between the two cell types.  
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3.2  Results 
3.2.1  Changes in Cellular Morphology as Human Monocytes Differentiate in vitro 
Freshly isolated monocytes were large cells relative to lymphocytes, with kidney or 
horseshoe-shaped nuclei (Fig. 3.1A). After overnight culture in M-CSF (Fig. 3.1B), 
the morphology of monocytes began to resemble that of MdMacs (Fig. 3.1C), namely 
that they became larger and more granular cells with rounder nuclei. 
 
 
 
 
 
 
 
 
 
Figure 3.1:   Changes  in  cellular  morphology  of  cultured  blood  monocytes 
during M-CSF differentiation. Cells were centrifuged onto glass slides, stained with 
Diff-Quik, and examined by light microscopy (100 x magnification). One lymphocyte 
(L) is shown in each field of view to demonstrate relative differences in cell size. A. 
Freshly isolated peripheral blood monocytes are cells with classic monocyte nuclear 
morphology (kidney- or horseshoe-shaped nuclei). B. After overnight culture in M-
CSF, monocytes increased in size, had rounder nuclei and became more granular. C. 
After 7 days culture in M-CSF, more dramatic morphological changes and increases 
in size were evident.  
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3.2.2  Suppression of LPS-induced TNFα, IL-1β and IL-10 Production by IL-4 
The effect of IL-4 on LPS-induced TNFα, IL-1β and IL-10 production were compared 
in monocytes immediately after isolation (freshly isolated monocytes) and monocytes 
cultured  overnight  in  M-CSF  (Fig.  3.2).  LPS-induced  TNFα  levels  in  the  culture 
supernatants at 24 h were significantly greater for the monocytes cultured overnight in 
M-CSF,  compared  to  the  freshly  isolated  cells  (Fig.  3.2A).  For  freshly  isolated 
monocytes, IL-4 significantly suppressed LPS-induced TNFα production by 78% + 
2% (mean + SEM, n=12 donors).  IL-4  also  significantly  suppressed  LPS-induced 
TNFα production by monocytes cultured overnight in M-CSF, however the extent of 
this suppression (30% + 3%, mean + SEM, n=9 donors) was much reduced (Fig. 
3.2A).  The  ability  of  IL-4  to  suppress  LPS-induced  IL-10  production  was  also 
impaired in monocytes after overnight culture in M-CSF; in fact IL-4 enhanced LPS-
induced IL-10 production by 25% + 9% at 24 h in these cells (mean + SEM, n=4 
donors), while it strongly suppressed LPS-induced IL-10 production by 61% + 3% 
(mean  +  SEM,  n=5  donors)  in  freshly  isolated  monocytes  (Fig.  3.2B).  Similar  to 
previous  studies,  LPS-induced  IL1β  levels  were  reduced  in  monocytes  cultured 
overnight in M-CSF, most likely due to the impaired ability of monocytes to secrete 
IL-1 as they mature in vitro (24). However, there was no significant difference in the 
suppression  of  LPS-induced  IL-1β  production  by  IL-4  between  freshly  isolated 
monocytes (64% + 3%, mean + SEM, n=4 donors) to monocytes cultured overnight 
(55% + 6%, mean + SEM, n=4 donors) (Fig. 3.2C). The reduced ability of IL-4 to 
suppress LPS-induced TNFα production in monocytes after overnight culture was not 
due to an inadequate concentration of IL-4, because the percentage suppression of 
TNFα production by IL-4 did not change across a range of doses of IL-4 (1-50 ng/ml) 
(Fig. 3.2D) or when the concentration of LPS was reduced to 5 ng/ml (Fig. 3.2E).    69 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2:   Suppression of LPS-induced TNFα, IL-10 and IL-1β production 
by IL-4 in freshly isolated monocytes (Fresh) and monocytes cultured overnight 
in M-CSF (Overnight). TNFα (A), IL-10 (B) and IL-1β (C) protein were measured 
in supernatants 24 h after incubation with LPS (500 ng/ml) ± IL-4 (10 ng/ml), Mean + 
SEM, for TNFα, Fresh n=12 donors, Overnight n=9 donors; For IL-10, Fresh n=5 
donors,  Overnight  n=4  donors;  For  IL-1β,  Fresh  and  Overnight  n=4  donors.  An 
asterisk indicates a significant suppression by IL-4 (p < 0.05). A hash indicates a 
significant enhancement by IL-4 (p < 0.05) D and E. Increasing or decreasing the 
concentration of IL-4 (D) or LPS (E) does not alter the magnitude of suppression of 
LPS-induced TNFα production by IL-4.   
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3.2.3  Effect of the Timing of IL-4 Addition on the Suppression of LPS-induced TNFα 
Production by IL-4  
In freshly isolated monocytes, delaying the addition of IL-4 resulted in progressively 
less  inhibition  of  LPS-induced  TNFα  production  by  IL-4  (Fig.  3.3A).  While  the 
addition  of  IL-4  at  1,  2  or  3  h  after  LPS  still  significantly  suppressed  TNFα 
production measured at 24 h post activation, the suppression by IL-4 when added at 3 
h (19% + 5%, mean + SEM, n=3 donors)  was far less pronounced than when IL-4 
was added together with LPS (73% + 6%, mean + SEM, n=3 donors). In conclusion, 
it appears crucial that IL-4 be present early to exert a significant inhibitory effect on 
LPS-induced TNFα production. 
 
Several  studies  have  determined  the  suppression  of  pro-inflammatory  cytokine 
production by IL-4 is mediated by new protein synthesis (141-143). Therefore we 
questioned whether the continued presence of IL-4 was necessary for the suppression 
of LPS-induced TNFα production by IL-4 (Fig. 3.3B). Monocytes were incubated 
with IL-4 for 3 h before being washed three times with serum-free medium prior to 
the addition of LPS. Unexpectedly, the addition of IL-4 for 3 h prior to cell activation 
strongly enhanced LPS-induced TNFα production. In contrast, when IL-4 was added 
at the same time of LPS, following a 3 h preincubation with medium, it strongly 
suppressed TNFα production.  
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Figure 3.3:   Effect  of  the  timing  of  IL-4  addition,  relative  to  LPS,  on  the 
suppression  of  LPS-induced  TNFα  production  by  IL-4.  A.  Effect  of  delayed 
addition  of  IL-4.    TNFα  was  measured  in  the  supernatants  of  freshly  isolated 
monocytes that were treated with LPS for 24 h with or without IL-4 (10 ng/ml), added 
either simultaneously with LPS, or 1, 2 or 3 h post-LPS. B. Effect of preincubation 
and removal of IL-4 prior to LPS stimulation. Monocytes were incubated for 3 h with 
or without IL-4, before extensive washing with warm medium and incubation for a 
further  24  h  with  LPS  or  LPS  +  IL-4.  TNFα  levels  have  been  calculated  as  the 
percentage of the LPS-induced levels (Mean + SEM), n=3 donors. 
 
 
 
 
   72 
3.2.4  Suppression of LPS-induced TNFα mRNA by IL-4  
To determine whether the effects of IL-4 on LPS-induced TNFα production were 
transcriptional, TNFα mRNA production was quantified using real-time PCR. TNFα 
mRNA levels were measured in freshly isolated monocytes (6 donors) and monocytes 
cultured overnight in M-CSF (4 donors) after treatment with LPS ± IL-4 for 2 h (Fig. 
3.4). In both cell types, LPS-induced TNFα mRNA was detectable from 30 min. In 
monocytes cultured overnight in M-CSF, LPS caused a more rapid accumulation of 
TNFα mRNA and by 3 h, levels of LPS-induced TNFα mRNA were 60% greater than 
in  LPS-stimulated  freshly  isolated  monocytes.  In  freshly  isolated  monocytes  IL-4 
significantly  suppressed  LPS-induced  TNFα  mRNA  from  60  min  (Fig.  3.4A).  In 
contrast,  in  monocytes  cultured overnight  in  M-CSF,  IL-4 had no effect  on  LPS-
induced TNFα mRNA over the 2 h timecourse (Fig. 3.4B) and was without effect 
after 24 h (results not shown). These results suggest that IL-4 suppresses LPS-induced 
TNFα production by different mechanisms in the two cell types.  
 
3.2.4  Effect of IL-4 on TNFα mRNA Stability 
Reports  have  conflicted  as  to  whether  IL-4  suppresses  pro-inflammatory  cytokine 
production at the level of transcription (145-147) or via affecting mRNA stability
 
(142,  148).  Actinomycin  D  (20  μg/ml)  was  added  to  freshly  isolated  monocyte 
cultures  1  h  after  stimulation  with  LPS  or  LPS  +  IL-4  to  block  further  mRNA 
production. The rate of TNFα mRNA decay was measured using real-time PCR (Fig. 
3.5). The addition of IL-4 had no effect on the rate of TNFα mRNA decay in LPS-
exposed  cells  suggesting  that  the  strong  suppression  of  TNFα  mRNA  in  freshly 
isolated monocytes is likely to occur at the level of transcription, rather than mRNA 
stability.    73 
 
Figure 3.4:   Suppression  of  LPS-induced  TNFα  mRNA  by  IL-4  in  freshly 
isolated  monocytes  (Fresh)  and  monocytes  cultured  overnight  in  M-CSF 
(Overnight). Freshly isolated monocytes (A) and monocytes cultured overnight in M-
CSF (B) were treated with LPS (500 ng/ml) ± IL-4 (10 ng/ml). TNFα mRNA levels 
were quantified using real-time PCR and calculated as a ratio to expression of the 
house-keeping gene ubiquitin-conjugating enzyme E2D2 (UBE2D2). Mean ± SEM, 
Fresh  n=6  donors,  Overnight  n=4  donors.  An  asterisk  indicates  a  significant 
suppression by IL-4 (p < 0.05). 
 
 
 
 
 
 
 
 
 
Figure 3.5:   Effect  of  IL-4  on  TNFα  mRNA  stability  in  freshly  isolated 
monocytes. Actinomycin D (Act D, 20 μg/ml) was added 1 h after stimulation with 
LPS ± IL-4 and the rate of TNFα decay measured using real-time PCR (mean ± SD; 
triplicate samples for each time point from one representative donor). 
3.2.5  Effect of IL-4 on STAT6 Phosphorylation and STAT6 DNA Binding Activity 
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STAT6  is  responsible  for  the  activation  or  enhanced  expression  of  many  IL-4 
responsive genes, and many of the anti-inflammatory effects of IL-4 are dependent on 
STAT6  (136-139).  As  the  anti-inflammatory  effects  of  IL-4  differed  in  freshly 
isolated monocytes and monocytes cultured overnight in M-CSF, we hypothesised 
that IL-4 activation of STAT6 would be weaker in monocytes cultured overnight in 
M-CSF. The effect of IL-4 on STAT6 tyrosine phosphorylation and STAT6 DNA 
binding activity was compared in the two cell types using Western Blotting on cell 
lysates and STAT6 EMSAs on nuclear extracts prepared from cells treated with IL-4 
over  a  2  h  timecourse.  IL-4-induced  phosphorylation  of  STAT6  and  increases  in 
STAT6 DNA binding activity peaked 30 min after treatment. There was no significant 
difference  in  STAT6  phosphorylation  or  nuclear  DNA  binding  activity  following 
treatment  with  IL-4  between  freshly  isolated  monocytes  and  monocytes  cultured 
overnight in M-CSF (Fig. 3.6). 
 
3.2.5  Summary of the Differences between Freshly Isolated Monocytes and 
Monocytes after Overnight Culture in M-CSF 
After overnight culture in M-CSF the morphology of monocytes began to resemble 
that of MdMacs, namely that they became larger and more granular cells with rounder 
nuclei  (Fig.  3.1).  Similar  to  what  has  been  previously  observed  with  MdMacs, 
monocytes cultured overnight in M-CSF produced higher levels of TNFα and IL-10, 
but reduced IL-1β in response to LPS than freshly isolated monocytes.  In addition, 
the  ability  of  IL-4  to  suppress  LPS-induced  TNFα  and  IL-10,  but  not  IL-1β 
production, was impaired in monocytes after overnight culture. However, in contrast 
to what has previously been reported for MdMacs (152), there was no difference in 
the  ability  of  IL-4  to  induce  STAT6  phosphorylation  and  DNA  binding  activity   75 
between  monocytes  cultured  overnight  in  M-CSF  relative  to  freshly  isolated 
monocytes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6:   Effect of IL-4 on activation of STAT6 in freshly isolated monocytes 
(Fresh) and monocytes cultured overnight in M-CSF (Overnight). A. Activation 
of STAT6 by phosphorylation determined in the first 2 h following IL-4 exposure 
using Western Blotting. A representative blot from one donor is shown. Quantitative 
analysis of phosphorylated STAT6 in protein lysates is from three separate donors 
(mean ± SEM), normalised to the amount of α-tubulin. Values shown are fold changes 
relative to phosphorylated STAT6 in untreated samples. B. STAT6 EMSA. Effect of 
IL-4 on STAT6 DNA binding capacity in nuclear lysates to a radiolabelled STAT6 
probe.  A  representative  EMSA  from  one  donor  is  shown  as  well  as  quantitative 
analysis of STAT6 DNA binding in nuclear extracts from two separate donors. Values 
shown are fold changes relative to DNA binding in untreated samples. 
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3.3  Discussion 
An  advanced  understanding  of  the  mechanisms  by  which  IL-4  exerts  its  anti-
inflammatory actions in human monocytes and macrophages may lead to improved 
therapies for the treatment of chronic inflammation. However, the anti-inflammatory 
actions of IL-4 differ between human cells, murine cells and cell lines (142-150) and 
as cells differentiate in vitro (152, 153). Therefore, I examined the effects of IL-4 in 
purified  primary  human  monocytes  in  two  differentiation  states;  namely  freshly 
isolated  monocytes  and  monocytes  that  were  cultured  overnight  in  M-CSF.    IL-4 
suppressed  LPS-induced  TNFα  in  the  freshly  isolated  monocytes  at  the  level  of 
transcription but acted by a different mechanism in monocytes cultured overnight in 
M-CSF, possibly translational.  In fact, many of the actions of IL-4 on monocytes 
cultured overnight in M-CSF more closely resembled those of monocytes cultured for 
7  days  in  M-CSF  (MdMacs).  However,  the  ability  of  IL-4  to  activate  STAT6  in 
monocytes  cultured  overnight  in  M-CSF  was  similar  to  that  in  freshly  isolated 
monocytes. 
 
In freshly isolated monocytes, IL-4 strongly suppressed LPS-induced TNFα mRNA 
and  TNFα  protein,  but  had  no  effect  on  the  rate  of  TNFα  mRNA  decay.  This 
suggested that the suppression of TNFα mRNA in freshly isolated monocytes occurs 
at the level of transcription, not mRNA stability. However, in monocytes cultured 
overnight  in  M-CSF,  IL-4  had  a  much  weaker  effect  on  LPS-induced  TNFα 
production compared to freshly isolated monocytes and no effect on  LPS-induced 
TNFα mRNA. This suggested that the suppression by IL-4 in these cells occurred by 
another mechanism, possibly translational (Figs. 3.2 and 3.4).  
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The suppression of LPS-induced TNFα production by IL-4 occurred within the first 3 
h and was lost when the addition of IL-4 was delayed (Fig. 3.3A), suggesting that IL-
4  specifically  targets  the  early  components  of  LPS-signalling.  Because  the 
suppression of LPS-induced inflammatory cytokine production by IL-4 requires new 
protein  synthesis  (141-143),  it  was  proposed  that  IL-4  would  exert  effects  after 
preincubation,  even  when  removed  from  culture  (141)  Unexpectedly,  a  3  h 
preincubation  and  subsequent  removal  of  IL-4  enhanced  LPS-induced  TNFα 
production (Fig. 3.3B). This was similar to findings by Varin et al. 2010 (93) and 
D’Andrea  et  al.  1995  (158)  who  proposed  that  prolonged  exposure  (8-20  h)  of 
monocytes to IL-4 before addition of microbial stimuli potentiates pro-inflammatory 
cytokine secretion by enhancing TLR-activation of ERK and p38 MAPK pathways 
(93, 158, 159), (see Chapter 4). However, it was in contrast to findings by Hart et al. 
1992  (141)  where  the  inhibitory  actions  of  IL-4  for  monocyte  TNF-α  production 
persisted during a 16 h incubation with IL-4 prior to LPS stimulation, and several 
other  researchers  for  other  LPS-induced  cytokines  (142,  143).    The  differences 
observed between studies may result from variations in the ability of IL-4 to activate 
MAPK signalling, which may arise due to differences in the culture conditions and 
reagents used, including the methods used by manufacturers to purify the recombinant 
IL-4. 
 
After overnight culture in M-CSF, the cellular morphology of monocytes began to 
take on many of the features of MdMacs (Fig. 3.1). Likewise, IL-4 had an impaired 
ability to suppress LPS-induced TNFα and IL-10 production by these cells (Fig. 3.2). 
Similar to MdMacs, IL-4 retained the ability to suppress LPS-induced IL-1β after 
overnight  culture,  suggesting  that  IL-4-mediated  regulation  of  LPS-induced  TNFα   78 
and IL-1β occur by separate mechanisms (152). MdMacs may be more representative 
of tissue macrophages (151, 152). After overnight culture in M-CSF, monocytes have 
increased expression of integrin receptors (160). We also found they also expressed 
express higher levels of Triggering Receptor Expressed on Myeloid Cells-2 (TREM-
2)  mRNA,  a  marker  of  newly  differentiated  macrophages  that  is  up-regulated  in 
macrophages infiltrating tissues from the circulation (Chapter 7). Therefore, in the in 
vivo situation, monocytes cultured overnight in M-CSF may be more representative of 
monocytes newly migrated to tissues.  
 
The expression of the γc chain of the IL-4 receptor in monocytes declines after 3 days 
culture in M-CSF. This decline correlates with reduced phosphorylation of STAT6 by 
IL-4 and an impaired ability of IL-4 to suppress LPS-induced TNFα production (152, 
153).  Hence,  similar  to  MdMacs,  the  impaired  responses  to  IL-4  observed  in 
monocytes after overnight culture in M-CSF may also result from an altered IL-4 
receptor conformation and reduced ability of IL-4 to activate IL-4 receptor signalling 
components.  It  is  possible  that  culture  overnight  in  M-CSF  stimulates  CD16 
expression on monocytes. CD16 expression is induced by, and increases with, in vitro 
maturation (161). CD14
lo CD16
hi monocytes have reduced expression of both the IL-
4Rα chain and γc chain of the IL-4 receptor, resulting in diminished sensitivity to IL-4 
and  reduced  activation  of  STAT6  at  low  doses  of  IL-4  (162).  However,  unlike 
MdMacs (152), no significant differences in the tyrosine phosphorylation of STAT6, 
or induction of STAT6 DNA binding activity in the nucleus by IL-4, were found 
between  monocytes  cultured  overnight  and  freshly  isolated  monocytes  (Fig.  3.6). 
Thus, the differences in suppression of TNFα production by IL-4 in the two cell types 
may not be due to differences in signalling through STAT6.    79 
 
In addition to activating STAT6, IL-4 initiates several STAT6-independent pathways, 
including signalling through the insulin IL-4 receptor (I4R) motif of the IL-4Rα chain 
(90, See Section 1.9). Differential activation of these pathways, which include Akt, 
PKC, and Ras/MAPK signalling, by IL-4 may explain the differences in response to 
IL-4  between  freshly  isolated  and  monocytes  cultured  overnight  in  M-CSF. 
Additionally, significant increases in LPS-induced TNFα production were observed in 
monocytes cultured overnight in M-CSF, with greater LPS-induced accumulation of 
TNFα mRNA. This may be due to changes in post-transcriptional processing which 
occur during in vitro differentiation of human monocytes, resulting in increased TNFα 
mRNA stability (163). An increase in stability and accumulation of TNFα mRNA in 
monocytes cultured overnight in M-CSF may also make it more difficult for IL-4 to 
have its suppressive effects.  
 
In conclusion, in freshly isolated monocytes, IL-4 strongly suppressed LPS-induced 
TNFα  production,  most  likely  at  the  level  of  transcription.  This  suppression  was 
observed within the first 3 h, suggesting that IL-4 targets the early components of 
LPS-signalling. However, in monocytes cultured overnight in M-CSF, IL-4 caused a 
weaker  suppression  of  LPS-induced  TNFα,  by  a  different  mechanism,  possibly 
translational.  Previous  studies  on  IL-4’s  actions  involve  monocytes  in  a  range  of 
differentiation  states  (142-150).  The  inconsistent  findings  reported  between  these 
studies may be explained by the fact responses to IL-4 are altered even after overnight 
culture in M-CSF. Monocytes cultured overnight in M-CSF had many features of 
monocytes that have newly infiltrated tissues. Thus, these cells may be more relevant 
than blood monocytes for the study of in vivo disease situations, such as rheumatoid   80 
arthritis, which involve recruitment of monocytes into the joints. Further identification 
of  the  differences  in  how  IL-4  signals  between  freshly  isolated  monocytes  and 
monocytes  cultured  overnight  in  M-CSF  may  increase  our  understanding  of  the 
mechanisms by which IL-4 suppresses LPS-induced TNFα production. Hence, the 
responses to IL-4 by monocytes in these two differentiation states were compared 
throughout the remainder of this thesis. 
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Chapter Four 
 
Effect of IL-4 on LPS-activation of Toll-like 
Receptor Signalling Components and 
Transcription Factors 
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4.1  Introduction 
In human monocytes LPS is transferred to its transmembrane receptor, TLR4, by the 
cell surface molecule CD14, resulting in the recruitment of several adaptor proteins, 
including MyD88, Mal, TRAF6 (tumour necrosis factor receptor activated factor 6) 
and  IRAK  (interleukin-1  receptor  associated  kinase).  LPS-recruitment  of  adaptor 
molecules  to  the  TLR4  receptor  complex  activates  several  intracellular  signalling 
pathways  including  the  IκB  kinase  (IKK)-NF-κB  pathway  and  three  mitogen-
activated  protein  kinase  (MAPK)  pathways:  p38,  extracellular  signal-regulated 
kinases (ERK)-1 and -2 and c-Jun N-terminal kinase (JNK) (16) (Fig. 4.1).  
 
LPS-activation  of  TAK1  (transforming  growth  factor  β  activated  kinase) 
phosphorylates  and  activates  the  IKK  complex  (164).  This  complex  induces  the 
phosphorylation of IκB, an inhibitor protein which associates with the transcription 
factor  NF-κB  in  the  cytoplasm  (165).  Phosphorylation  of  IκB  targets  it  for 
ubiquitination  and  proteosomal  degradation  which  liberates  NF-κB  allowing  it  to 
translocate  to  the  nucleus  where  it  regulates  the  transcription  of  numerous  pro-
inflammatory genes (12) (Fig. 4.1). LPS also induces phosphorylation of ERK, JNK 
and  p38  MAPK  which  phosphorylate  and  activate  numerous  other  transcription 
factors involved in pro-inflammatory cytokine production, including Activator Protein 
1 (AP-1), cAMP Response Element Binding (CREB), Activating Transcription Factor 
(ATF) -1 and -2, Serum Response Factor (SRF) and  Elk-1 (16) (Fig. 4.1). The p38 
MAPK pathway is also important in determining mRNA stability and translation of 
pro-inflammatory cytokines by modulating AU-rich elements (AREs) located in the 
3’  untranslated  region  of  transcripts  (166).    LPS  signalling  and  transcriptional 
regulation in human monocytes is described in further detail in Guha et al. 2001 (16).    83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1:  LPS-activation of signalling pathways and transcription factors in 
monocytes. LPS binds to CD14 at the cell surface and is transferred to TLR4. LPS 
stimulates  the  activation  of  various  MAPK,  including  the  ERK,  JNK  and  p38 
pathways. These pathways phosphorylate and activate various transcription factors, 
including Elk-1, c-Jun, c-Fos, ATF-1, SRF and CREB, which bind to serum response 
element  (SRE),  cAMP  response  element  and  AP-1  sites  in  the  promoters  of 
inflammatory genes. In addition LPS activates the IKK pathway via MyD88, IRAK 
and TRAF6. TAK1 phosphorylates the IKK complex which in turn phosphorylates 
IκB.  Subsequent  degradation  of  IκB  permits  the  nuclear  translocation  of  NF-κB 
complexes, such as p50/p65. Adapted from Guha et al. 2001 (16). 
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Since  IL-4  down-regulates  the  transcription  of  LPS-induced  inflammatory  genes 
(145-147),  (Chapter  3),  it  is  likely  that  the  anti-inflammatory  actions  of  IL-4  are 
mediated  by  interacting  with,  and  inhibiting,  upstream  pathways  of  the  TLR4 
signalling cascade. However, reports conflict whether IL-4 acts by directly affecting 
NF-κB activation or binding activity (145-149) and it is unclear whether IL-4 targets 
signalling intermediates such as IκB, or adaptor proteins such as Mal or MyD88. 
Whether  IL-4  alters  LPS  activation  of  the  MAPK  pathways  has  been  studied  in 
cultured cells and depends on the timing that IL-4 was added relative to LPS and the 
cell type studied. Prolonged exposure to IL-4 may enhance LPS-activation of MAPK 
and potentiate cytokine secretion. For instance, pre-incubation with  IL-4 enhances 
LPS activation of p38 MAPK in human monocytes (159), and enhances Neisseria 
meningitidis  stimulated  ERK  and  p38  phosphorylation  in  murine  thioglycollate-
elicited  peritoneal  macrophages  (93).  However,  prolonged  exposure  to  IL-4  in  a 
murine macrophage cell line reduces  LPS-induced p38 MAPK  and inhibits TNFα 
production (159). IL-4 added at the same time as LPS decreases ERK, but not p38, 
phosphorylation in human monocytes at 20 h, resulting in caspase activation and IL-
4-induced apoptosis (167). However, in the present study we did not observe any 
effect of IL-4 on monocyte apoptosis or cell viability. IL-4 inhibits RANKL-induced 
JNK in osteoclasts, but it is unclear what effects IL-4 has on LPS-activation of JNK in 
monocytes (168). 
 
In this chapter, the possibility that IL-4 regulates LPS-induced TNFα production by 
human  monocytes  by  altering  activation  of  TLR4  signalling  components  was 
investigated. Firstly, the effect of IL-4 on LPS-induced phosphorylation of IκB, p38, 
ERK  and  JNK  MAPK,  and  activation  of  the  transcription  factors,  NF-κB,  were   85 
measured. Secondly, the ability of IL-4 to suppress LPS-induced TNFα production in 
the presence of specific inhibitors to these pathways was examined. 
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4.2  Results 
4.2.1  IL-4 has no Effect on LPS-induced Phosphorylation and Degradation of IκB  
In human monocytes LPS induces phosphorylation and degradation of IκB, releasing 
the  transcription  factor  NF-κB,  which  activates  the  transcription  of  numerous 
inflammatory cytokines including TNFα. The possibility that the anti-inflammatory 
actions of IL-4 are mediated by targeting the IKK-NF-κB pathway was investigated. 
Firstly,  the  effect  of  IL-4  on  LPS-induced  phosphorylation  and  subsequent 
degradation of  IκB was measured using Western blotting (Fig. 4.2). Results  from 
freshly isolated monocytes were compared to monocytes cultured overnight in M-
CSF, because IL-4 has an impaired ability to suppress TNFα transcription in the latter, 
suggesting  that  IL-4  may  have  differential  effects  on  TLR4  signalling  cascade 
between the two cell types. LPS-induced phosphorylation of IκB peaked at 30 min. 
Phosphorylation  of  IκB  was  stronger  and  more  sustained  after  overnight  culture. 
Likewise degradation of IκB, was more prominent in these cells. However, in both 
freshly isolated monocytes and monocytes cultured overnight, IL-4 had no significant 
effect on LPS-induced phosphorylation of IκB or degradation of IκB (Fig. 4.2). 
 
4.2.2  IL-4 has No Effect on LPS-activation of NF-κB 
While IL-4 had no effect on IκB degradation or phosphorylation, IL-4 may inhibit 
LPS-activation  of  NF-κB  further  downstream.  Therefore,  NF-κB  DNA  binding 
activity was measured in nuclear extracts of monocytes treated with LPS ± IL-4 for up 
to 2 h using an NF-κB EMSA (Fig. 4.3). By 30 min, LPS activated a 4-fold increase 
NF-κB binding in the nucleus. There was no significant difference in the activation of 
NF-κB by LPS in freshly isolated monocytes and monocytes cultured overnight in M-  87 
CSF. In both cell types, IL-4 had no significant effect on LPS-induced NF-κB DNA 
binding activity in the nucleus (Fig. 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2:   Effect of IL-4 on LPS-induced phosphorylation and degradation of 
IκB in freshly isolated monocytes (Fresh) and monocytes cultured overnight in 
M-CSF  (Overnight).  A.  Effect  of  LPS  and  IL-4  on  IκB  phosphorylation  and 
degradation as determined in the first 2 h following IL-4 exposure using Western 
Blotting.  A  representative  blot  from  one  donor  is  shown.  B  and  C.  Quantitative 
analysis of phosphorylated IκB (B) and total levels of IκB (C) in cell lysates from 
three separate donors (mean ± SEM), normalised to the amount of β-tubulin. Values 
shown are fold changes relative to levels of IκB or phosphorylated IκB in untreated 
samples.  
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Figure 4.3:   Effect of IL-4 on LPS-activation of NF-κB. DNA binding capacity of 
NF-κB was measured using NF-κB EMSAs on nuclear lysates prepared from freshly 
isolated monocytes (Fresh) and monocytes cultured overnight in M-CSF (Overnight), 
cultured for up to 120 min with LPS (500 ng/ml) ± IL-4 (10 ng/ml). A. Representative 
EMSA. B. Cumulative results from three donors (mean ± SEM). 
 
4.2.3  IL-4  Enhances  LPS-activation  of  ERK  MAPK  but  has  No  Effect  on  LPS-
activation of p38 and JNK MAPK  
LPS also activates all three MAPK pathways resulting in the phosphorylation of p38, 
ERK  and  JNK  MAPK.  To  determine  whether  IL-4  targets  MAPK  activation,  the 
phosphorylation of p38, ERK and JNK were measured using Western blotting. LPS 
treatment resulted in a rapid and transient phosphorylation of p38 which peaked at 30 
min (Fig. 4.4). Phosphorylated p38 was not detected at 2 h (results not shown). LPS 
induced phosphorylation of ERK (Fig. 4.5) and JNK (Fig. 4.6), which also peaked at 
30 min, though some phosphorylated ERK and JNK was detected after 2 h. Activation 
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of  the  MAPK  pathways,  p38  ERK  and JNK,  by  LPS  was  stronger  in  monocytes 
cultured overnight in M-CSF (Figs 4.4- 4.6). In both freshly isolated monocytes and 
monocytes  cultured  overnight  in  M-CSF,  IL-4  had  no  effect  on  LPS-induced 
phosphorylation  of  p38  (Fig.  4.4)  and  JNK  MAPK  (Fig.  4.6),  but  significantly 
enhanced LPS-activation of ERK in the first 1 h after treatment (Fig. 4.5).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4:   Effect  of  IL-4  on  LPS-induced  p38  phosphorylation  in  freshly 
isolated  monocytes  (Fresh)  and  monocytes  cultured  overnight  in  M-CSF 
(Overnight). A. Effect of LPS and IL-4 on p38 phosphorylation as determined in the 
first 1 h following IL-4 exposure using Western Blotting. A representative blot from 
one donor is shown. B. Quantitative analysis of p38 phosphorylation in cell lysates 
from three separate donors (mean ± SEM), normalised to the amount of total p38. 
Values shown are fold changes relative to levels of phosphorylated p38 in untreated 
samples.  
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Figure 4.5:   Effect  of  IL-4  on  LPS-induced  ERK  phosphorylation  in  freshly 
isolated  monocytes  (Fresh)  and  monocytes  cultured  overnight  in  M-CSF 
(Overnight). A. Effect of LPS and IL-4 on ERK phosphorylation as determined in the 
first 2 h following IL-4 exposure using Western Blotting. A representative blot from 
one donor is shown. B. Quantitative analysis of ERK phosphorylation in cell lysates 
from three separate donors (mean ± SEM), normalised to the amount of total ERK. 
Values shown are fold changes relative to levels of phosphorylated ERK in untreated 
samples. Significant changes in LPS-induced ERK phosphorylation induced by IL-4 
are shown with an asterisk.  
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Figure 4.6:   Effect  of  IL-4  on  LPS-induced  JNK  phosphorylation  in  freshly 
isolated  monocytes  (Fresh)  and  monocytes  cultured  overnight  in  M-CSF 
(Overnight). A. Effect of LPS and IL-4 on JNK phosphorylation as determined in the 
first 2 h following IL-4 exposure using Western Blotting. A representative blot from 
one donor is shown. B. Quantitative analysis of JNK phosphorylation in cell lysates 
from three separate donors (mean ± SEM), normalised to the amount of total JNK. 
Values shown are fold changes relative to levels of phosphorylated JNK in untreated 
samples.  
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4.2.4  IL-4 Weakly Activates ERK and p38 MAPK in the Absence of LPS 
In addition to activating STAT6, IL-4 may also activate the Ras/MAPK pathway. This 
pathway  initiates  activation  of  the  MAPKs,  and  plays  an  important  role  in  IL-4-
regulation  of  cellular  proliferation  in  certain  cell  types  (90),  including  monocytes 
(167). The possibility that  IL-4 enhances  LPS-induced ERK phosphorylation as a 
result of signalling through the Ras/MAPK pathway was investigated by measuring 
IL-4  activation  of  MAPK  in  the  absence  of  LPS  (Fig.  4.7).  IL-4  weakly 
phosphorylated  ERK  MAPK;  this  phosphorylation  was  stronger  in  monocytes 
cultured overnight in M-CSF (Fig. 4.7A). IL-4 also phosphorylated p38 MAPK in the 
absence of LPS (Fig. 4.7B). The phosphorylation of both p38 and ERK MAPK by IL-
4 was strongest at 120 min and relatively weak compared to that induced by LPS (Fig. 
4.7).  
 
 
 
 
 
 
 
 
 
 
Figure 4.7:   IL-4-activation  of  ERK  and  p38  MAPK  in  freshly  isolated 
monocytes (Fresh) and monocytes cultured overnight in M-CSF (Overnight). A. 
Effect of IL-4, in the absence of LPS, on ERK phosphorylation as determined in the 
first 2 h following IL-4 exposure using Western Blotting. B. Effect of IL-4, in the 
absence of LPS, on p38 phosphorylation as determined in the first 2 h following IL-4 
exposure using Western Blotting. A representative blot from one donor is shown from 
experiments  repeated  on  three  separate  donors.  Lysates  from  freshly  isolated 
monocytes treated with LPS for 60 min were used as a positive control. 
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4.2.5  Blocking  MAP  Kinase  Pathways  and  Proteosomal  Degradation  does  not 
Prevent IL-4 Suppression of LPS-induced TNFα Production by Human Monocytes 
IL-4 weakly phosphorylated ERK and p38 MAPK and enhanced LPS-induced ERK 
phosphorylation. Therefore the possibility that signalling through the ERK and p38 
MAPK pathways by IL-4 is responsible for the suppression of LPS-induced TNFα 
production by IL-4 was investigated using inhibitors to these pathways (Fig. 4.8A). 
Freshly  isolated  monocytes  were  incubated  with  or  without  the  MEK-1  inhibitor, 
PD98059  (5  µM),  which  blocks  ERK  phosphorylation,  and  the  p38  inhibitor, 
SB203580 (1 µM) for 1 h prior to the addition of LPS with or without IL-4 for a 
further 24 h. SB203580 significantly reduced LPS-induced TNFα production at 24 h, 
suggesting  that  the  p38  pathway  plays  a  crucial  role  LPS-activation  of  TNFα 
production.  However,  neither  inhibitor  prevented  the  suppression  of  LPS-induced 
TNFα production by IL-4 (Fig. 4.8A). 
 
Given  the  findings  above  that  IL-4  regulated  LPS-induced  TNFα  production  by 
monocytes independently of changes to phosphorylation and activation of IκB, ERK, 
p38  and  JNK  MAPK,  the  possibility  that  IL-4  suppresses  inflammatory  cytokine 
production by stimulation of proteosomal degradation of LPS signalling components 
was  investigated.  Freshly  isolated  monocytes  were  incubated  with  or  without  the 
proteosomal inhibitor MG-132 (10 µM) for 1 h prior to the addition of with LPS with 
or without IL-4 for a further 3 h (Fig. 4.8B). No toxic effects as measured by trypan 
blue staining were observed. Incubations with MG-132 beyond 4 h were not tested 
because MG-132 may be toxic to cells if left for longer periods in culture. After 3 h, 
MG-132 reduced TNFα production by 90% in LPS-treated monocytes (Fig 4.8B), 
suggesting  that  the  proteasome  plays  an  important  role  in  the  regulation  of  LPS-  94 
induced proinflammatory cytokine production. However, MG-132 did not prevent the 
suppression of LPS-induced TNFα production by IL-4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8:   Effect of MAP kinase inhibitors and proteosomal inhibitors on IL-
4  suppression  of  TNFα  production  by  LPS-stimulated  monocytes.  A.  Freshly 
isolated monocytes were pre-incubated with inhibitors to p38 (1 µM SB203580) or 
ERK (5 µM PD98059) for 60 min prior to the addition of LPS (shaded bars) with or 
without IL-4 (white bars) for 24 h. B. Freshly isolated monocytes were pre-incubated 
with the proteosomal inhibitor MG-132 (10 µM) for 60 min prior to the addition of 
LPS ± IL-4 for 3 h. An asterisk indicates a significant suppression of LPS-induced 
TNFα production by IL-4. A hash indicates a significant inhibition of LPS-stimulated 
TNFα production caused by the inhibitors (mean + SEM, pooled results from three 
separate experiments). 
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4.3  Discussion 
IL-4  down-regulated  LPS-induced  inflammatory  cytokine  production  by  freshly 
isolated human monocytes at the level of transcription (Chapter 3). Therefore it was 
hypothesised that IL-4 interacts with, and inhibits upstream pathways of the TLR4 
signalling cascade. However, IL-4 had no effect on LPS-induced phosphorylation and 
degradation  of  IκB,  p38  and  JNK  MAPK  or  the  subsequent  activation  of  the 
transcription factor, NF-κB. While IL-4 activated p38 and ERK MAPK in the absence 
of LPS, and enhanced LPS-induced ERK phosphorylation, IL-4 maintained the ability 
to suppress TNFα production in the presence of specific MAPK inhibitors. From these 
data, the suppression of pro-inflammatory cytokine production by IL-4 is mediated 
independently of an inhibition of  LPS-induced  IKK-NF-κB signalling and MAPK 
activation.  
 
IL-4  had  no  effect  on  LPS-induced  IκB  phosphorylation  or  NF-κB  DNA  binding 
activity in the nucleus, suggesting that IL-4 does not alter LPS activation of NF-κB or 
its translocation to the nucleus. These findings support a previous study which found 
IL-4 inhibited  IL-6 transcription  in  human monocytes  without suppressing  NF-κB 
binding activity (147). The proteasome inhibitor MG-132 (10 µM) potently inhibited 
of  LPS-induced  TNFα  production  (Fig.  4.8B),  most  likely  by  preventing  IκB 
degradation  which  is  required  for  the  subsequent  activation  of  NF-κB  (169). 
However, IL-4 maintained the ability to suppress LPS-induced TNFα production in 
the presence of MG-132. This suggests that IL-4 acts independently of proteosomal 
degradation of TLR4 signalling components and further confirms that IL-4’s actions 
are independent of the IKK-NF-κB pathway.  
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It must be noted that EMSAs may not necessarily reflect the transcriptional activity of 
LPS-induced  NF-κB.  IL-4  may  act  downstream  of  NF-κB  binding  to  inhibit  the 
transcriptional  activity  of  NF-κB  once  it  has  bound  to  the  TNFα  promoter.  For 
example, IL-4 inhibited NF-κB dependent transcription in transfected HEK293 cells 
by  sequestering  the  transcriptional  co-activator  CREB-binding  protein  (139). 
Furthermore,  IL-4-induced  STAT6  inhibited  E-selectin  transcription  by  competing 
with NF-κB binding sites in the E-selectin promoter in human vascular endothelial 
cells (140). IL-4 may also reduce serine 536 phosphorylation of the p65 subunit of 
NF-κB, as phosphorylation at this site may regulate the transcriptional activity of NF-
κB without changing its binding capacity to promoters (179, 171). NF-κB reporter 
assays  may  more  accurately  determine  if  IL-4  inhibits  LPS-induced  TNFα 
transcription independently of NF-κB. However, these were not used in this study 
because of the difficulty of transfecting human monocytes and macrophages (172). 
Alternatively,  gene  arrays  may  further  confirm  whether  or  not  NF-κB-dependent 
genes in human monocytes are specifically targeted by IL-4 (see Chapter 8).
  
 
While IL-4 activated p38 and ERK MAPK in the absence of LPS and enhanced LPS-
induced ERK phosphorylation, MAPK inhibitors confirmed that the suppression of 
LPS-induced  TNFα  production  by  IL-4  is  independent  of  MAPK  signalling.  The 
phosphorylation of p38 and ERK MAPK by IL-4 in the absence of LPS most likely 
occurs  through  activation  the  Ras/MAPK  pathway,  a  pathway  important  for  IL-4 
regulation  of  cell  survival  and  proliferation  (90,  173).  The  enhancement  of  LPS-
induced ERK phosphorylation by IL-4 in human monocytes (Fig. 4.5) suggests that 
the Ras/MAPK signalling pathway may directly interact with and potentiate LPS-
activation of MAPK. In the current study, enhancement of ERK phosphorylation by   97 
IL-4 played no role in the regulation of LPS-induced cytokine production by IL-4. 
However,  previous  studies  have  found  IL-4  priming  before  addition  of  microbial 
stimuli enhances microbial activation of p38 and ERK and concomitantly potentiates 
secretion of pro-inflammatory cytokines (93, 159). While IL-4 potently suppressed 
LPS-induced TNFα production when added at the same time as LPS, IL-4 added 3 h 
before  the  addition  of  LPS,  enhanced  LPS-induced  TNFα  production  by  human 
monocytes  (Fig.  3.3B).  Hence,  IL-4-activation  of  MAPK  may  partly  explain  the 
potential ‘inflammatory actions’ of IL-4, and the exacerbation of inflammation by IL-
4 in some disease models (see Section 1.11.2).  
 
In conclusion, IL-4 suppressed LPS-induced TNFα production independently of an 
inhibition  of  IKK/NF-κB  signalling  and  LPS  activation  of  MAPK.  Rather  than 
specifically  targeting  activation  of  transcription  factors,  IL-4  may  suppress 
inflammatory gene transcription at the level of the chromatin. For instance IL-4 may 
alter covalent modifications of histones at the promoters of inflammatory genes (see 
Chapter  5).  Alternatively,  IL-4  may  be  acting  via  induction  of  a  transcriptional 
repressor or transcription factor, or by inhibiting cofactors required for inflammatory 
gene  transcription.  Western  blotting  and  EMSAs  only  allowed  measurement  of 
selected number of proteins and transcription factors. Proteomic analysis may allow 
more detailed analysis of the protein profiles of monocytes following activation with 
LPS and IL-4 (174). Pathway tailored gene arrays will allow further characterisation 
of  LPS  signalling  genes  that  are  transcriptionally  regulated  by  IL-4  and  also  the 
specific transcription factors targeting these genes (see Chapter 8). 
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Chapter Five 
 
Role of Histone Acetylation in IL-4 
Regulation of LPS-induced TNFα, PGE2 and 
IL-10 Production by Human Monocytes 
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5.1  Introduction 
IL-4 suppressed LPS-induced TNFα production in freshly isolated monocytes at the 
level  of  transcription  (see  Chapter  3),  without  inhibiting  activation  of  upstream 
signalling components, IκB, ERK, JNK and p38 MAPK, or the DNA binding capacity 
of  NF-κB  (see  Chapter  4).  This  suggests  that  suppression  of  inflammatory  gene 
transcription  by  IL-4  may  be  mediated  further  downstream  of  transcription  factor 
activation, possibly at the level of the chromatin. Acetylation of histones, proteins 
which package DNA into structural units, is an important mechanism regulating the 
expression of inflammatory genes (175-177), including LPS-induced TNFα (34, 178).  
 
Histone acetylation is regulated by the opposing actions of histone acetyl transferase 
(HAT)  and  histone deacetylase (HDAC)  enzymes (Fig.  5.1).  HATs, including the 
transcriptional  coactivators  CREB-binding  protein  (CBP)  and  p300,  acetylate 
histones.  This  reduces  the  affinity  between  histones  and  DNA,  resulting  in  local 
unwinding of the chromatin, enhanced binding of transcription factors and increased 
transcriptional activity (179, 180). In contrast, HDACs deacetylate promoters and are 
associated  with  transcriptional  repression  (181).  Several  classes  of  HDACs  exist, 
based on their homology to yeast HDACs (182) (Table 5.1).  
 
 
 
 
 
 
 
 
Figure 5.1:  Regulation of gene expression by HDAC and HAT enzymes. 
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Table 5.1:  Histone Deacetylase (HDAC) Enzymes. 
  Subtypes  Cellular Location 
Class I  HDAC1, 2, 3, 8 and 11  Nucleus 
Class II  HDAC4, 5, 6, 7, 9, 10  Shuttle between the nucleus and 
cytoplasm 
Class III  ‘Sirtuins’ Sirt1-Sirt7  Nucleus, cytoplasm and mitochondria 
 
In rheumatoid arthritis synovial tissue HDAC activity is significantly down-regulated 
(183).  Likewise,  in  alveolar macrophages  of  asthmatic patients,  HDAC activity is 
suppressed and HAT activity is increased (184). In both diseases, alteration of the 
tight  equilibrium  between  HDAC  and  HAT  activity  results  in  a  hyperacetylated 
chromatin, which is thought to drive the activation of pro-inflammatory transcription 
factors and inflammatory genes. Contradicting this, broad spectrum HDAC inhibitors 
show therapeutic benefit in many inflammatory disease models, due to their ability to 
inhibit production of pro-inflammatory cytokines, including TNFα (Table 5.2). The 
anti-inflammatory actions of HDAC inhibitors may be mediated not by direct effects 
on the promoters of inflammatory genes, but by (1) transcriptionally activating genes 
that regulate inflammation, (2) inhibiting cellular proliferation or (3) acetylating non-
histone proteins including transcription factors (176, 177, 185, 186). 
 
Table 5.2:  Therapeutic  benefits  of  HDAC  inhibitors  in  the  treatment  of 
inflammatory disease. 
Inhibitor  Model  Effect  Reference 
Butyrate  Colitis  Anti-inflammatory  Segain et al. 2000 (187) 
SAHA
a  Septic shock  Anti-inflammatory  Leoni et al. 2002 (188) 
 
SAHA/ MS-275  Rheumatoid 
arthritis 
 
Anti-inflammatory  Lin et al. 2007  
(189) 
 
TSA/ butyrate  Rheumatoid 
arthritis 
 
Anti-inflammatory  Chung et al. 2003  
(190) 
 
TSA
b  Multiple 
Sclerosis  
 
Anti-inflammatory  Camelo et al. 2005  
(191) 
TSA  Asthma  Anti-inflammatory  Choi et al. 2005 (192) 
 
TSA/ SAHA 
 
Microglial cells 
 
Inflammatory  Suronen et al. 2003 
(193)  
aSuberoylanilide Hydroxamic Acid, 
bTrichostatin A   102 
Many of the changes in gene expression triggered by LPS, including the activation of 
TNFα  (34)  and  COX-2  (194)  transcription,  are  mediated  by  histone  acetylation. 
Between 2-7 h, when the majority of LPS-inducible genes reach peak expression in 
macrophages, LPS transiently represses the expression of several HDACs while up-
regulating expression of members of the HATs. This promotes histone acetylation and 
inflammatory gene transcription (194). However, in murine BMM, broad spectrum 
inhibition of HDAC activity with TSA enhances only a subset of LPS-induced genes, 
including Cox-2, Cxcl2 and Ifit2. Another class of genes, which includes Ccl2, Ccl7 
and  Edn1,  is  suppressed  by  TSA,  most  likely  by  degradation  of  PU.1  which  is 
required for basal transcription of these genes (194). The differential regulation of 
subclasses of LPS-responsive genes is likely to be due to the individual effects of 
different  classes  of  HDACs.  The  HDAC1  (Class  I)  selective  inhibitor,  MS-275, 
retains  the  pro-inflammatory  effects  of  TSA  but  suppresses  only  some  of  the 
inflammatory  response.  Likewise  the  HDAC6  (Class  II)  selective  inhibitor,  17a, 
retains the anti-inflammatory, but not the pro-inflammatory properties of TSA (195). 
In conclusion, Class I HDACs more specifically target histones to negatively regulate 
expression of inflammatory genes. However, class II HDACs may act on a wider 
range of cellular proteins, including transcription factors, and promote inflammatory 
responses (195). 
 
An  18  h  polarisation  of  monocytes  with  IFNγ,  but  not  IL-4,  increases  histone 
acetylation  of  the  TNFα  promoter,  enhancing  TNFα  production  after  subsequent 
exposure to LPS (196). However, the effects of IL-4 on histone acetylation when it is 
added at the same time as LPS are unclear. The suppression of LPS-induced TNFα 
and COX-2 transcription by IL-4 in monocytes occurs within the first 3 h of treatment   103 
(Figs.  3.4A  and  5.3A),  similar  to  the  timing  by  which  LPS  modulates  histone 
acetylation at the promoters of these genes (194). Therefore IL-4 may repress the 
transcription of inflammatory genes by inhibiting LPS-induced histone acetylation, 
possibly by reversing the LPS-induced down-regulation of HDAC expression. Hence 
this  chapter  investigated  whether  the  suppression  of  LPS-induced  TNFα,  
prostaglandin  E2  (PGE2)  and  IL-10  production  by  IL-4  could  be  prevented  by 
inhibition of HDAC activity with the broad spectrum inhibitor, TSA, or the class I 
specific inhibitor, MS-275. 
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5.2  Results 
5.2.1  HDAC Inhibitors have Biphasic Effects on LPS-induced TNFα Production but 
do not Prevent IL-4 Suppression of LPS-induced TNFα Production 
Initially, the effects of TSA (Fig. 5.2A), and MS-275 (Fig. 5.2B), on LPS-induced 
TNFα production by human monocytes were trialled across a range of doses (1 nM- 
100  nM).  No  toxic  effects,  as  measured  by  increased  trypan  blue  staining,  were 
observed. Higher concentrations were not tested because TSA has been reported to 
reduce the viability of murine BMM at concentrations >100 nM (197). After 24 h, 
TSA  dose-dependently  suppressed  LPS-induced  TNFα  production  by  monocytes. 
Suppression occurred from concentrations as low 1 nM, with a maximal suppression 
of 76% ± 4% (mean ± SEM, n=3 donors) occurring with 50 nM TSA (Fig. 5.2A). 
MS-275  significantly  suppressed  LPS-induced  TNFα  production  from  1  nM,  but 
caused weaker suppression than TSA at higher doses (26% ± 4% at 50 nM) (Fig. 
5.2B). Neither inhibitor prevented the suppression of LPS-induced TNFα production 
by IL-4 at 24 h at any of the doses tested (Fig. 5.2A and B). A concentration of 50 nM 
for  TSA  and  MS-275  was  chosen  for  use  in  further  experiments  because  it  gave 
maximal suppression of LPS-induced TNFα production without causing cell death. 
 
The repression of HDAC expression by LPS is transient; by 24 h HDAC mRNA 
levels return to greater than those seen in unstimulated cells (194). Hence HDAC 
inhibition may have distinct effects on early TNFα production, as opposed to late 
TNFα  production.  Indeed,  50  nM  TSA  and  MS-275  significantly  enhanced  LPS 
induced TNFα production at 2 h (Fig. 5.2D). The enhancement of TNFα production 
was confirmed at the mRNA level (Fig. 5.2C), suggesting HDAC inhibition super-
induces early LPS-induced TNFα transcription. Once again, both TSA and MS-275   105 
failed to prevent the suppression of LPS-induced TNFα protein or mRNA by IL-4 at 2 
h (Fig. 5.2C and D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2:   Effect  of  HDAC  inhibitors  on  the  suppression  of  LPS-induced 
TNFα production by IL-4. A and B. Dose response to Trichostatin A (TSA) and 
MS-275.  TNFα was measured in supernatants harvested from freshly isolated human 
monocytes after 24 h incubation with the indicated doses of TSA (A) or MS-275 (B) 
with  LPS  (500  ng/ml)  with  or  without  IL-4  (10  ng/ml).  C-E.  Comparison  of  the 
effects of HDAC inhibitors on early and late TNFα production. TNFα mRNA and 
protein was measured in human monocytes treated with and without 50 nM TSA or 
MS-275  as  well  as  LPS  ±  IL-4  for  2  h  (C  and  D)  or  24  h  (E).  A  significant 
suppression of TNFα production by IL-4 from LPS-induced levels (p<0.05) is shown 
with an asterisk. A hash indicates a significant suppression, while a cross indicates a 
significant  enhancement  of  TNFα  from  LPS-induced  levels  induced  by  HDAC 
inhibitors. Results are for three independent experiments (mean + SEM). 
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5.2.2  HDAC Inhibitors Enhance LPS-induced PGE2 Production but do not Prevent 
IL-4 Suppression of LPS-induced PGE2 Production 
IL-4  suppressed  LPS-induced  mRNA  levels  for  COX-2  (Fig.  5.3A),  a  likely 
mechanism by which IL-4 suppresses LPS-induced PGE2 production.  COX-2 has 
previously been identified to belong to a subset of LPS-induced genes that is super-
induced  by  HDAC  inhibition  (194).  Therefore  we  investigated  whether  HDAC 
activity was involved in the suppression of LPS-induced PGE2 production by IL-4. As 
expected, TSA (50 nM) significantly enhanced LPS-induced PGE2 production at both 
2 and 24 h (Fig. 5.3B and C). However, TSA failed to reverse the suppression of LPS-
induced PGE2 production by IL-4 (Fig. 5.3B and C).  
 
5.2.3  Broad Spectrum, but not Class I HDAC inhibitors, Suppress LPS-induced IL-
10 Production, but have No Effect on IL-4 Suppression of IL-10  
IL-10 was measured to determine whether the late suppression of LPS-induced TNFα 
production  by  HDAC  inhibitors  was  indirectly  due  to  an  enhancement  of  IL-10 
production  by  the  HDAC  inhibitors.  However,  TSA  dose  dependently  suppressed 
LPS-induced  IL-10  production  from  concentrations  as  low  as  12.5  nM  causing  a 
maximal suppression of 66% ± 0.3% (mean ± SEM, n=3 donors) at 100 nM (Fig. 
5.4A). Unlike TNFα production, where biphasic effects  of HDAC  inhibitors  were 
observed, LPS-induced IL-10 protein and mRNA were also suppressed by TSA at 2 h 
(Fig. 5.4C and D). MS-275 had no effect on LPS-induced IL-10 production at 2 h 
(Fig.  5.4C  and  D)  or  24  h  (Fig.  5.4B  and  E).  Neither  inhibitor  prevented  the 
suppression of LPS-induced IL-10 production by IL-4 at 24 h (Fig. 5.4 A and B).  At 
2 h IL-4 significantly enhanced LPS-induced IL-10 production (Fig 5.4C and D); the 
role of IL-4-induced IL-10 in mediating the anti-inflammatory actions of IL-4 are   107 
discussed  further  in  Chapter  8.  TSA,  but  not  MS-275,  significantly  reduced  the 
enhancement of LPS-induced IL-10 mRNA and protein by IL-4 at 2 h.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3:   Effect  of  HDAC  inhibition  on  the  suppression  of  LPS-induced 
PGE2 production by IL-4. A. Effect of IL-4 on COX-2 mRNA in LPS treated human 
monocytes.  Results  were  pooled  from  3  separate  donors  (mean  ±  SEM)  and  are 
expressed as fold increases relative to mRNA levels in freshly isolated monocytes. B 
and C. Effect of TSA on PGE2 production. Human monocytes were treated with and 
without 50 nM TSA and incubated for 2 h (B) and 24 h (C) with LPS (500ng/ml) with 
or without IL-4 (10 ng/ml). A representative experiment from one donor is shown 
(mean  +  S.D).  An  asterisk  indicates  significant  (p<0.05)  suppression  by  IL-4.  A 
significant  enhancement  in  PGE2  from  LPS-induced  levels  by  the  inhibitors  are 
indicated with a hash. 
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Figure 5.4:   Effect of HDAC inhibitors on the suppression of LPS-induced IL-
10 production by IL-4. A and B. Dose response to Trichostatin A (TSA) and MS-
275.    IL-10  was  measured  in  supernatants  harvested  from  freshly  isolated  human 
monocytes after 24 h incubation with the indicated doses of TSA (A) or MS-275 (B) 
with LPS (500ng/ml) with or without IL-4 (10 ng/ml). C-E. Comparison of the effects 
of HDAC inhibitors on early and late IL-10 production. IL-10 protein and mRNA was 
measured in human monocytes treated with and without 50 nM TSA or MS-275 as 
well as LPS ± IL-4 for 2 h (C and D) and 24 h (E). A significant suppression or 
enhancement  of  IL-10  production  by  IL-4  from  LPS-induced  levels  (p  <  0.05)  is 
shown with an asterisk. A hash indicates a significant suppression of IL-10 from LPS 
induced  levels  induced  by  HDAC  inhibitors.  Results  are  for  three  independent 
experiments (mean + SEM). 
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5.3.4  Summary of Effects of HDAC Inhibitors 
As  outlined  on  Table  5.3,  HDAC  inhibition  had  biphasic  effects  on  LPS-induced 
TNFα production, enhancing TNFα mRNA and protein at 2 h but suppressing TNFα 
production after 24 h. The suppression of TNFα at 24 h was weaker with the Class I 
specific  inhibitor  MS-275.  HDAC  inhibition  enhanced  both  early  and  late  PGE2 
production.  Broad  spectrum,  but  not  Class  I  specific  inhibitors,  suppressed  LPS-
induced  IL-10  production.  IL-4  maintained  the  ability  to  suppress  LPS-induced 
TNFα, IL-10 and PGE2 production in the presence of both broad spectrum and Class-I 
specific HDAC inhibitors.  
 
 
Table 5.3:   Summary of the effect of HDAC inhibition on TNFα, IL-10 and 
PGE2 production by human monocytes incubated with LPS ± IL-4 
 
Inhibitor  Effect on LPS-induced levels  Effect on IL-4 suppression  
TNFα  PGE2  IL-10  TNFα  PGE2  IL-10 
Broad Spectrum 
(TSA) 
 early 
 late 
 early 
 late 
 early 
 late 
 
None         None        None 
Class I specific 
(MS-274) 
 early 
 late 
Not 
Done 
No 
effect 
 
None         None        None 
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5.3  Discussion 
Histone  acetylation  is  an  important  regulator  of  LPS-induced  transcription  of 
inflammatory  genes  (34,  194).  It  was  therefore  hypothesised  that  IL-4  suppresses 
inflammatory  cytokine  production  by  inhibiting  LPS-induced  acetylation  at  the 
promoters of these genes, possibly by reversing the early down-regulation of HDAC 
expression by LPS. However, our data revealed that while histone acetylation plays a 
key role in the regulation of LPS-induced TNFα, PGE2 and IL-10 production, the anti-
inflammatory actions of IL-4 are mediated independently of histone acetylation.  
 
Inhibition  of HDAC  activity  with  the broad spectrum  inhibitor, TSA,  and Class-I 
specific inhibitor, MS-275, had no effect on IL-4-regulation of TNFα, PGE2 or IL-10 
production  by  LPS-activated  monocytes  (Figs.  5.1-  5.3).  Therefore,  the  anti-
inflammatory  actions  of  IL-4  are  mediated  independently  of  an  up-regulation  of 
HDAC  expression  or  activation.  It  remains  possible  that  IL-4  suppresses  histone 
acetylation  by  other  mechanisms,  for  instance  by  suppressing  LPS-activation  of 
HATs, including CBP and p300. However, inhibition of HDAC activity enhanced 
LPS-induced TNFα (Fig. 5.2 C and D) and COX-2 (Fig. 5.3) expression, suggesting 
that  HDAC  inhibition  hyperacetylates  the  promoters  of  these  genes,  resulting  in 
enhanced transcriptional activity. Because IL-4 retained the ability to suppress LPS-
induced transcription of the TNFα and COX-2 genes in their hyperacetylated state, it 
can be concluded that IL-4’s actions are also likely to be independent of an inhibition 
of HAT activity. These results could be confirmed further using assays to quantify the 
effect  of  IL-4  on  total  HDAC  and  HAT  activity  (183)  and  chromatin 
immunoprecipitation (ChIP) assays to more specifically characterise the effects of IL-  111 
4  on  histone  acetylation  and  transcription  factor  binding  at  the  TNFα,  IL-10  and 
COX-2 promoters. 
 
Dual mechanisms of HDACs in the control of LPS-induced PGE2, TNFα and IL-10 
production were identified; these are summarised in Figs. 5.5- 5.7. The COX-2 gene, 
encodes  for  cyclooxygenase-2,  an  enzyme  responsible  for  the  formation  of 
prostaglandins, including PGE2. In murine BMM the Cox-2 gene has previously been 
identified to belong to a subset of LPS-induced genes that is super-induced by HDAC 
inhibition (194). As expected, broad spectrum HDAC inhibition enhanced both early 
and late LPS-induced PGE2 production in human monocytes (Fig. 5.3). Early TNFα 
production was also enhanced by both broad spectrum and Class-I specific HDAC 
inhibition (Fig. 5.2C). This occurred at the level of mRNA, suggesting that the TNFα 
gene,  like  COX-2,  belongs  to  the  subclass  of  genes  that  is  super-induced  by  the 
inhibition of histone deacetylation. This is supported by studies which have found that 
histone acetylation is a prerequisite for TNFα transcription (44, 178)  
 
Unlike COX-2, LPS-induced TNFα production was suppressed by HDAC inhibitors 
at  24  h  (Fig.  5.2A  and  B).  This  late  suppression  by  HDAC  inhibitors  was  not 
indirectly due to an enhancement of IL-10 production by the inhibitors, because MS-
275 had no effect on IL-10 production and TSA inhibited IL-10 production (Fig. 5.4). 
It is likely that the suppression of TNFα production by HDAC inhibitors results from 
deacetylation of non-histone proteins, such as transcription factors. For instance broad 
spectrum HDAC inhibitors abrogate RelA and IFN-regulatory factor-1 (IRF1) binding 
to  the  IL-12  promoter  (185)  and  target  and  degrade  the  transcription  factor  PU.1 
(194). Only late TNFα production was suppressed by HDAC inhibition, suggesting   112 
that a transcription factor or a component of late TLR signalling pathways may be 
targeted.  HDAC  activity  is  essential  for  the  transcriptional  induction  of  IFN-
stimulated  genes  by  modifying  STAT  and  IRF-3  activity  (198),  identifying  the 
MyD88-independent, IFN-mediated signalling pathway as a possible target of HDAC 
inhibitors.  
 
The  biphasic  effects  of  HDAC  inhibition  on  LPS-induced  TNFα  production  may 
reflect the different activities of Class I and Class II HDACs. The Class I specific 
inhibitor, MS-275, strongly enhanced early LPS-induced TNFα production, but only 
weakly  suppressed  late  TNFα  production,  suggesting  that  Class  I  HDACs  more 
specifically target the promoters of inflammatory genes. Conversely, the suppression 
of TNFα production at 24 h was far stronger in the presence of the broad spectrum 
inhibitor,  TSA,  This  suggests  that  the  anti-inflammatory  actions  of  the  HDAC 
inhibitors, which most likely arise from targeting of transcription factors and other 
non-histone proteins, is preferentially mediated by the inhibition of Class II HDACs 
or non-specific effects of the inhibitors (Fig. 5.2).  
 
TSA and MS-275 also had distinct effects on LPS-induced IL-10 production (Fig. 
5.4). Broad spectrum HDAC inhibition by TSA strongly down-regulated LPS-induced 
IL-10 mRNA and IL-10 secretion, while the Class I specific inhibitor MS-275 had no 
effect on IL-10 production. This suggests that IL-10 production is regulated by Class 
II  HDACs,  possibly  through  targeting  of  a  transcription  factor  required  for  IL-10 
production, or by non-specific effects of TSA. The kinetics of the suppression of LPS-
induced IL-10 production by TSA was similar to the suppression of LPS-induced 
Ccl2, Ccl7 and Edn1 by TSA in murine BMM. Here, TSA targeted and degraded the   113 
transcription factor PU.1 (194). However, in contrast to Ccl2, Ccl7 and Edn1, PU.1 is 
involved  in  transcriptional  repression  of  IL-10  (199)  suggesting  that  another 
transcription factor may be involved.  TSA also impaired the enhancement of LPS-
induced IL-10 mRNA and protein by IL-4 at 2 h (Fig. 5.3 C and D). While this may 
be due to the strong suppression of LPS-induced IL-10 by TSA, it is possible that 
HDACs contribute to the enhancement of LPS-induced IL-10 production by  IL-4. 
One  possibility  is  that  HDACs  are  required  for  deacetylation  and  activation  of  a 
transcription  factor such as  c-Maf,  which is  required for both  LPS-induced  IL-10 
transcription and the enhancement of IL-10 transcription by IL-4 (200). The role of c-
Maf  in  mediating  the  anti-inflammatory  actions  of  IL-4  in  human  monocytes  is 
discussed in detail in Chapter 8.  
 
In  conclusion,  individual  effects  of  Class  I  and  Class  II  HDAC  inhibitors  were 
identified in the control of LPS-induced cytokine production by human monocytes 
(summarised in Figs. 5.5-5.7). Class I HDACs specifically mediated transcriptional 
repression of the TNFα and COX-2 genes. In contrast, Class II HDACs may enhance 
IL-10  production  and  late  TNFα  production,  most  likely  via  targeting  of  a 
transcription factor regulating these genes. However, while histone acetylation played 
a key role in the regulation of LPS-induced cytokines, the transcriptional repression of 
inflammatory cytokines by IL-4 was mediated independently of histone acetylation. It 
remains possible that IL-4 modifies chromatin structure by one of many other histone 
modifications,  for  example  methylation,  phosphorylation,  ubiquitination, 
SUMOylation  and  ADP-ribosylation  (175).  IL-4  treatment  up-regulates  Jumonji 
domain containing-3 (Jmjd3) in macrophages which concomitantly leads to decreased 
histone methylation at the promoters of M2 genes (201). Histone demethylation of   114 
these  genes  by  Jmjd3  is  crucial  for  the  regulation  of  alternative  activation  of 
macrophages  to  a  M2  phenotype  (202).  ChIP  assays  would  be  useful  to  more 
specifically characterise histone modifications, including methylation, and the binding 
of transcription factors to the promoters of inflammatory genes following LPS and IL-
4 treatment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5:   HDAC  regulation  of  TNFα  production.  Dual  mechanisms  of 
HDACs  in  the  control  of  LPS-induced  TNFα  production  were  identified.  Class  I 
HDACs deacetylate the TNFα promoter, suppressing TNFα transcriptional activity. 
Hence early LPS-induced TNFα production is super-induced by the broad-spectrum 
HDAC inhibitor, TSA, and Class I-specific inhibitor, MS-275. Class II HDACs may 
be  important  for  the  deacetylation  and  activation  of  late-acting  TLR  signalling 
components, such as the transcription factor IRF-3. Therefore late TNFα production is 
strongly suppressed by broad spectrum HDAC inhibition. IL-4 suppressed both late 
and  early  LPS-induced  TNFα  production  in  the  presence  of  HDAC  inhibitors, 
suggesting its actions are mediated independently of histone acetylation. 
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Figure 5.6:   HDAC regulation of PGE2 production. Class I HDACs deacetylate 
the COX-2 promoter, suppressing COX-2 transcriptional activity. Hence LPS-induced 
COX-2  gene  transcription  and  PGE2  production  is  super-induced  by  the  HDAC 
inhibitors, TSA and MS-275. IL-4 suppressed LPS-induced COX-2 transcription and 
PGE2  production  in  the  presence  of  HDAC  inhibitors,  suggesting  its  actions  are 
mediated independently of histone acetylation.  
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Figure 5.7:   HDAC  regulation  of  IL-10  production.  LPS-induced  IL-10 
production  is  regulated  by  Class  II  HDACs,  possibly  through  targeting  of  a 
transcription factor required for IL-10 production. Hence the broad spectrum HDAC 
inhibitor,  TSA,  strongly  down-regulates  LPS-induced  IL-10  production  while  the 
Class  I  specific  inhibitor,  MS-275,  has  no  effect  on  IL-10  production.  TSA  also 
significantly impaired the enhancement of LPS-induced IL-10 production by IL-4 at 2 
h. Therefore it is possible that HDAC inhibitors prevent deacetylation and activation 
of  the  transcription  factor  c-Maf,  which  is  required  for  both  LPS-induced  IL-10 
transcription and the enhancement of IL-10 transcription by IL-4 (200). However, the 
suppression  of  LPS-induced  IL-10  production  by  IL-4  at  24  h  is  mediated 
independently of histone acetylation. 
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Chapter Six 
 
Role of Negative Regulators of Cytokine 
Signalling in the Suppression of LPS-
induced Inflammatory Cytokine Production 
by IL-4 in Human Monocytes 
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6.1  Introduction 
The anti-inflammatory actions of IL-4 in human monocytes are dependent on new 
protein synthesis, however the protein/s involved have never been identified (141-
143).  Cytokine-stimulated  signal  transduction  is  regulated  via  the  induction  or 
recruitment  of  several  feedback  regulatory  proteins.  These  include  the  SH2-
containing Phosphatases (SHP), SH2-containing Inositol 5’ Phosphatase (SHIP), 
the Protein Inhibitors of Activated STATs (PIAS) and the Suppressors Of Cytokine 
Signalling (SOCS) family of proteins (203, 204). These proteins may regulate not 
only IL-4 signalling in human monocytes and macrophages, but also inflammatory 
cytokine signalling and TLR responses (205-207).  
 
The SOCS family of proteins consists of eight members, namely Cytokine-Inducible 
SH2-containing protein (CIS) and SOCS-1 to SOCS-7, each sharing a central SH2 
domain and a C-terminal SOCS box (208). SOCS proteins are induced by cytokine 
signalling through the JAK-STAT pathway and act  as  classical  negative feedback 
modulators,  by  inhibiting  JAK  activity  to  prevent  the  downstream  activation  of 
STATs. The modes of actions of SOCS proteins and their functions are summarised in 
Fig. 6.1 and Table 6.1. 
 
 
The anti-inflammatory actions of IL-4 may occur directly via STAT6 (136-138) or by 
new  protein/s  induced  by  STAT6  (141-143).  SOCS1  is  an  important  regulator  of 
STAT6 signalling in M12 B cell lines
 (209) and Th2 (210) cells. Three functional 
STAT6 binding motifs of the sequence TTC(N)4GAA are located upstream of the 
transcriptional  initiation  site  in  the  SOCS1  promoter  (211).  In  primary  human 
macrophages,  IL-4  induces  rapid  de  novo  expression  of  SOCS1  in  a  STAT6-  119 
dependent manner. Forced expression of SOCS1 inhibits activation of STAT6 by IL-4 
and  STAT6  activation  and  IL-4-mediated  gene  expression  are  much  greater  and 
prolonged  in  SOCS1-deficient  (SOCS1
-/-)  murine  macrophages  than  in  wild-type 
macrophages. This suggests that SOCS1 is an important endogenous regulator of IL-4 
signalling in macrophages (212).
 In addition to regulating IL-4 signalling, SOCS1 is 
also a critical inhibitor of the inflammatory cytokine, IFNγ (157, 213), negatively 
regulating the phosphorylation and activation of IFNγ-induced STAT1 (214).
 SOCS1 
also negatively regulates LPS-induced macrophage activation in mice (215, 216), and 
we have shown SOCS1 blocks LPS-induced TNFα production by human monocytes 
(172). Thus, SOCS1 is a candidate for the mechanism by which IL-4 regulates LPS-
induced production of pro-inflammatory cytokines. 
 
CIS, SOCS3, SOCS4 and SOCS5 may also potentially mediate the anti-inflammatory 
actions of IL-4 in human monocytes (see Table 6.1). IL-4 up-regulates CIS, a key 
regulator of responses to cytokines that signal via STAT5 (212, 217-220). IL-4 also 
induces SOCS2 in macrophages; however, SOCS2 does not regulate IL-4-activation 
of  STAT6  in  these  cells  (212).  SOCS3,  an  important  regulator  of  inflammatory 
responses, is not induced by IL-4 in human macrophages. However forced expression 
of  SOCS3  in  these  cells  inhibited  activation  of  STAT6  by  IL-4,  suggesting  that 
SOCS3 may potentially regulate IL-4 signalling in macrophages (212).  
 
 
SOCS5 interacts with the IL-4Rα chain and precludes association of JAK1 with the 
IL-4 receptor in Th1 cells, negatively regulating IL-4-dependent STAT6 activation 
and Th2 differentiation (221). Less is known about the physiological role of SOCS4, 
though analysis of its amino acid sequence and genomic structure suggest that SOCS4   120 
is closely related to SOCS5 (208). However, the role of SOCS4 and SOCS5 in the 
regulation  of  IL-4  signalling  in  human  monocytes  and  macrophages  is  yet  to  be 
determined.  There  is  little  evidence  that  SOCS6  and  SOCS7  are  involved  in  the 
regulation of cytokine signalling in monocytes and macrophages (Table 6.1).  
 
The  PIAS  family  of  proteins,  which  consists  of  five  members,  PIAS1,  PIAS3α, 
PIAS3β, PIASx and PIASy, regulate cytokine signalling by binding to and inhibiting 
STATs  (222).  PIAS1  binds  to  STAT1  and  is  a  physiological  regulator  of  IFNγ 
signalling (223),  while PIAS3  suppresses the transcriptional activity  of  NF-κB by 
interfering with p65 binding to the CREB-binding protein (CBP) co-activator (224). 
Therefore, PIAS1 and PIAS3 were considered potential candidates in the regulation of 
inflammatory responses by IL-4. 
 
SHPs  are  tyrosine  phosphatases  which  regulate  cytokine  signal  transduction  by 
dephosphorylating signalling components including JAKS (204). Both members of 
the SHP family, SHP-1 (225) and SHP-2 (226), have been implicated in the regulation 
of TLR-induced signalling and cytokine production. In addition, both SHP-1 (227) 
and  SHP-2  (228),  associate  with  IL-4  receptor  signalling  components  and  may 
negatively regulate IL-4-dependent signal transduction (229).  
 
SH2-containing inositol 5’ phosphatase (SHIP) proteins are induced by LPS and play 
a  key  role  in  the  regulation  of  endotoxin  tolerance  and  restraint  of  LPS-induced 
proinflammatory cytokine production (230).  IL-4 induces tyrosine phosphorylation of 
SHIP,  which  associates  with  JAK1  and  JAK3  on  the  IL-4  receptor  (231). 
Overexpression and knockdown of SHIP in cell lines suggest that SHIP acts as a 
positive regulator of IL-4 signalling (232). However, in macrophages SHIP protein   121 
levels  are  downregulated  by  IL-4  (233)  and  SHIP  functions  in  vivo  to  repress 
alternative macrophage activation (234).  
 
Not only do negative regulators of cytokine signalling regulate responses to IL-4, they 
also  regulate  signalling  cascades  induced  by  inflammatory  cytokines  and  TLR 
ligands.  We hypothesised that crosstalk  may  occur where  SOCS, PIAS, SHP  and 
SHIP  proteins  that  are  induced  or  recruited  by  IL-4  may  not  only  regulate  IL-4 
signalling, but also mediate the anti-inflammatory actions of IL-4 in LPS-activated 
human monocytes and macrophages. Firstly, we screened for mRNA expression of a 
panel of negative regulators of cytokine signalling in human monocytes, namely CIS, 
SOCS1, 3, 4, and 5, PIAS 1 and 3, SHP-1 and -2 and SHIP. Following analysis of the 
kinetics by which these regulators were induced by IL-4, relative to  LPS and the 
inflammatory cytokine IFNγ, the expression of potential candidates was confirmed at 
the protein level. Finally, the role of these proteins in mediating the suppression of 
LPS-induced pro-inflammatory cytokine production by  IL-4 was determined using 
gene knockout mice.  
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Table 6.1:  Summary of the factors that induce SOCS family proteins and the 
physiological  processes  that  are  regulated  by  SOCS  proteins.  SOCS  proteins 
which are induced by IL-4 and also involved in the regulation inflammatory responses 
potentially mediate the anti-inflammatory actions of IL-4 in human monocytes and 
macrophages. 
 
  Induction 
by IL-4 
Other inducing 
factors 
Physiological processes 
which are regulated 
 
CIS 
 
Macrophages (212) 
B and T lymphocytes 
(217, 218) 
 
IL-2 , IL-3,  
GM-CSF, 
Erythropoietin 
(219) 
Prolactin (220) 
 
 
STAT5 signalling 
(219, 220) 
 
SOCS1
 
 
Macrophages (212) 
B-cell line (209) 
 
LPS (235)  
IFNγ (213) 
 
IFNγ induced 
inflammation (213) 
LPS/TLR signalling 
(215, 216) 
STAT6 signalling  
(209-212) 
 
 
SOCS2 
 
Macrophages  (212) 
 
Growth hormone, 
IGF-I, IL-2, IFNγ 
(236) 
 
 
Growth (236) 
Th2 differentiation  
(237) 
 
 
SOCS3 
 
Neutrophils (173) 
B cells (174) 
 
 
IL-6 (239)  
LIF (240) 
IL-10 (241) 
LPS (242) 
IFNγ (243) 
GM-CSF (244) 
 
 
IL-6 mediated STAT3 
signalling (239) 
LIF signalling (240) 
Granulopoiesis (245) 
Inflammatory arthritis 
(246) 
 
SOCS4 
 
- 
 
EGF (247) 
 
EGF receptor signalling 
(247) 
 
 
SOCS5 
 
Interacts with the 
cytoplasmic region of 
the IL-4Rα chain in 
Th1 cells 
(221) 
 
 
 
EGF 
(247) 
 
EGF receptor signalling 
(247) 
Promotion of Th1 cell 
differentiation (221) 
 
SOCS6 
 
- 
 
Binds to insulin 
receptor (248)  
 
 
Insulin signalling  
(248, 249) 
 
 
SOCS7 
 
- 
 
Interacts with 
IRS2 (250) 
 
Glucose homeostasis and 
insulin signalling  
(250) 
 
EGF, epidermal growth factor, IGF, insulin-like growth factor, IRS, insulin receptor 
substrate, LIF, leukaemia inhibitory factor. 
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Figure 6.1:   Induction  and  function  of  negative  regulators  of  cytokine 
signalling. After binding of cytokines, JAK kinases are activated and phosphorylate 
themselves, their respective receptors and STAT proteins. STAT proteins dimerise 
and translocate to the nucleus where they initiate transcription. Among the induced 
proteins  are  SOCS  proteins.  SOCS  proteins  inhibit  the  catalytic  activity  of  JAKs 
either by binding directly to  JAKs  or by binding to  JAK attachment sites  on the 
receptor. They may also prevent STAT phosphorylation by preventing STAT binding 
to  the  receptor.  PIAS  proteins  act  more  distally  than  SOCS  by  binding  to,  and 
inhibiting,  STATs.  SHP  and  SHIP  proteins  regulate  cytokine  signalling  by 
dephosphorylating  signalling  components  such  as  JAKs.  Whether  the  negative 
regulators  of  cytokine  signalling  induced  by  IL-4,  are  capable  of  blocking  TLR 
signalling is under debate.  Adapted from Greenhalg and Hilton, 2001 (203) and Heeg 
and Dalpke, 2003 (207). 
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6.2  Results 
6.2.1  IL-4 Induces SOCS1 and CIS mRNA in Human Monocytes 
SOCS proteins induced by IL-4 in monocytes and macrophages may in turn inhibit 
not only IL-4 signalling, but also LPS-induced production of inflammatory cytokines, 
including TNFα. Therefore the kinetics by which LPS and IL-4 induced a panel of 
SOCS mRNAs was examined over a 2 h time course (Fig. 6.2). In monocytes that had 
been cultured overnight in M-CSF, IL-4 significantly induced CIS (Fig. 6.2A) and 
SOCS1 mRNA (Fig. 6.2B), but had no effect on SOCS3 (Fig. 6.2C), SOCS4 (Fig. 
6.2D)  and  SOCS5  (Fig.  6.2E)  mRNA  levels.  This  induction  of  SOCS1  and  CIS 
mRNA by IL-4 was rapid, occurring within 30 min and peaking 1 h after treatment 
(Fig. 6.2A and B). SOCS3 mRNA was strongly induced by IL-10, also peaking 1 h 
after treatment (Fig. 6.2C). IL-10 also caused small but significant induction of CIS 
mRNA (Fig. 6.2A), but had no significant effect on SOCS1 (Fig. 6.2B), SOCS4 and 
SOCS5 mRNA (Fig. 6.2D and E).  LPS significantly induced SOCS1 and SOCS3 
mRNA (Fig. 6.2B and C), but had no effect on CIS (Fig. 6.2A), SOCS4 and SOCS5 
mRNA (Fig. 6.2D and E). This induction of SOCS1 and SOCS3 by LPS did not peak 
until after 2 h, which was later than the inductions by IL-4 and IL-10, respectively 
(Fig. 6.2B and C). The induction of CIS mRNA by IL-4 occurred in the presence of 
LPS (Fig. 6.2A), and IL-4 significantly increased LPS-induced SOCS1 mRNA 30, 60 
and 120 min after treatment (Fig. 6.2B). 
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Figure 6.2:   Induction  of  SOCS  mRNA  by  IL-4,  IL-10  and  LPS.  Monocytes 
were cultured overnight in M-CSF and then treated with medium, IL-4 (10 ng/ml) or 
IL-10 (10 ng/ml) (upper graphs), or LPS (500 ng/ml) with and without IL-4 (lower 
graphs) for up to 2 h. CIS (A), SOCS1 (B), SOCS3 (C), SOCS4 (D) and SOCS5 (E) 
mRNA  levels  were  quantified  using  real  time  PCR  and  calculated  as  a  ratio  to 
expression of the house-keeping gene ubiquitin-conjugating enzyme E2D2 (UBE2D2) 
(mean ± SEM; n=4 donors). Significant (p<0.05) increases in mRNA levels by IL-4 
are indicated with an asterisk, while significant increases by IL-10 are indicated with 
a cross. For LPS-treated cells, a hash indicates significant increases by LPS relative to 
untreated monocytes. Further increases induced by IL-4 in the presence of LPS are 
denoted by an asterisk. 
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6.2.2  LPS and IL-4 Induction of CIS, SOCS1, SOCS3, SOCS4 and SOCS5 mRNAs in 
Freshly Isolated Monocytes is Similar to that in  Monocytes Cultured Overnight in M-
CSF  
IL-4  had  a  much  weaker  regulatory  effect  on  LPS-induced  TNFα  production  in 
monocytes  cultured  overnight  in  M-CSF  compared  to  freshly  isolated  monocytes 
(Chapter  3).  Therefore  we  hypothesised  that  if  SOCS  proteins  induced  by  IL-4 
mediate the suppression of LPS-induced TNFα production by IL-4, the induction of 
SOCS mRNAs by IL-4 may be stronger, or occur with different kinetics, in freshly 
isolated  monocytes  (Fig.  6.3).  Untreated  freshly  isolated  monocytes  expressed 
signficanly lower levels of CIS mRNA than monocytes after overnight culture (see 
Fig 6.5). However, there was no significant difference in the kinetics and magnitude 
by which IL-4 induced CIS (Fig. 6.3A) or SOCS1 mRNA (Fig. 6.3B) between the 
two cell types. In freshly isolated monocytes IL-4 also failed to induce SOCS3 (Fig. 
6.3C),  SOCS4  (Fig.  6.3D)  and  SOCS5  (Fig.  6.3E)  mRNA.  The  kinetics  and 
magnitude that LPS induced SOCS1 (Fig. 6.3B) and SOCS3 (Fig. 6.3C) mRNA was 
also similar between the two cell types.  
 
6.2.3  LPS and IL-4 do not Modulate Expression of SHP, SHIP and PIAS mRNAs in 
Human Monocytes  
In addition to SOCS proteins, both LPS and IL-4 signalling may be regulated by the 
induction or recruitment of SHP, SHIP and PIAS proteins (203, 204). Therefore these 
proteins were also considered as potential candidates in the regulation of LPS-induced 
inflammatory  cytokine  production  by  IL-4.    However,  in  monocytes  cultured 
overnight in M-CSF, both LPS and IL-4 had no significant effect on the mRNA levels   127 
of SHP-1 (Fig. 6.4A), SHP-2 (Fig. 6.4B), SHIP (Fig. 6.4C), PIAS1 (Fig. 6.4D) and 
PIAS3 (Fig. 6.4E), relative to untreated cells over a 2 h time course. 
 
Figure 6.3:   Comparison of the induction of SOCS mRNA in freshly isolated 
monocytes  (Fresh)  and  monocytes  cultured  overnight  in  M-CSF  (Overnight). 
Kinetics of induction of CIS (A), SOCS1 (B), SOCS3 (C), SOCS4 (D) and SOCS5 
(E) mRNA by IL-4 (10 ng/ml), LPS (500 ng/ml) and LPS + IL-4 were compared in 
fresh and overnight monocytes (mean ± SEM; n=3 donors).   128 
 
 
 
 
 
 
 
 
 
 
Figure 6.4:   Induction  of  SHP,  SHIP  and  PIAS  mRNA  by  IL-4  and  LPS. 
Monocytes were cultured overnight in M-CSF and then treated with medium, IL-4 (10 
ng/ml), LPS (500 ng/ml) and LPS + IL-4 for up to 2 h. SHP1 (A), SHP2 (B), SHIP 
(C), PIAS1 (D) and PIAS3 (E) mRNA levels were quantified using real time PCR 
(mean ± SEM; n=3 donors). No significant (p<0.05) increases or decreases in mRNA 
levels by LPS or IL-4 relative to untreated monocytes were observed. 
 
6.2.4  Expression  of  SOCS  mRNA  in  Synovial  Fluid  Mononuclear  Cells  from 
Patients with Inflammatory Arthritis 
SOCS proteins may play an important regulatory role in inflammatory diseases such 
as  rheumatoid  arthritis  (252).  Therefore  SOCS  mRNA  levels  were  measured  in 
synovial  fluid  mononuclear  cells  isolated  from  the  joints  of  patients  with 
inflammatory  arthritis  and  compared  to  the  expression  in  blood  monocytes  from 
healthy controls (Fig. 6.5). The synovial fluid mononuclear cells from patients with 
inflammatory arthritis expressed significantly lower baseline levels of SOCS1 relative 
to both freshly isolated monocytes and monocytes cultured overnight in M-CSF from 
healthy controls (Fig. 6.5A). This was not due to increased numbers of lymphocytes 
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in the synovial fluid samples, which typically comprise of 50% lymphocytes and 50% 
monocytes/macrophages, because SOCS1 mRNA levels were also lower than those in 
PBMCs from healthy controls which typically comprised of 70% lymphocytes and 
30%  monocytes  (Fig.  6.5A).  Both  freshly  isolated  monocytes  and  synovial  fluid 
mononuclear cells, expressed lower baseline levels of CIS mRNA than monocytes 
cultured overnight in M-CSF (Fig. 6.5B). No significant differences in the baseline 
expression of SOCS3 (Fig. 6.5C), SOCS4 (Fig. 6.5D) or SOCS5 (Fig. 6.5D) mRNA 
were observed between the three cell types. 
 
 
  
 
 
 
 
 
 
 
Figure 6.5  SOCS mRNA expression in synovial fluid mononuclear cells from 
rheumatoid arthritis patients. CIS (A), SOCS1 (B) SOCS3 (C), SOCS4 (D) and 
SOCS5 (E) mRNA levels were measured in synovial fluid mononuclear cells isolated 
from the joints of patients with rheumatoid arthritis (SF) and compared to expression 
in  blood  monocytes  from  healthy  controls;  freshly  isolated  peripheral  blood 
mononuclear  cells  (PBMCs),  elutriated  monocytes  (Fresh)  and  monocytes  after 
overnight culture in M-CSF (M-CSF) (mean ± SEM; from experiments on at least 3 
donors). Significant differences (p<0.05) in mRNA expression between groups are 
indicated. 
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6.2.5  Kinetics of Induction of SOCS1 mRNA and Protein by IL-4, IFNγ and LPS 
 IL-4  induces  SOCS1  in  human  macrophages,  which  in  turn  acts  to  inhibit  IL-4 
signalling (212). SOCS1 is also induced by LPS and is a negative regulator of TLR 
signalling that suppresses LPS-induction of inflammatory cytokines, including TNFα 
(215, 216).
 In Fig. 6.2B and Fig. 6.3B, IL-4 induced SOCS1 mRNA earlier than the 
SOCS1  mRNA  induced  by  LPS.  Therefore,  the  kinetics  of  induction  of  SOCS1 
mRNA and protein by IL-4 were compared to the kinetics by which LPS and the 
inflammatory cytokine, IFNγ, induce SOCS1 over a 24 h time course. For cells from 
four independent donors, IL-4 rapidly induced SOCS1 mRNA which peaked after 1 h. 
This was much earlier than the induction of SOCS1 mRNA by IFNγ and LPS which 
peaked at 2 h and 4 h, respectively (Fig. 6.6).  
 
Induction of SOCS1 protein by IL-4 closely followed the kinetics of SOCS1 mRNA 
synthesis (Fig. 6.7). IL-4-induced SOCS1 protein peaked after 1 h, earlier than IFNγ-
induced  SOCS1  protein  which  had  plateaued  after  3  h  and  LPS-induced  SOCS1 
which was still increasing 4 h post-stimulation (Fig. 6.7A). Similar to the mRNA data 
(Fig. 6.3B), there was no significant difference in the kinetics by which IL-4 induced 
SOCS1 protein in freshly isolated monocytes and monocytes cultured overnight in M-
CSF (Fig. 6.7B). 
 
 
 
 
 
   131 
 
 
 
 
 
 
 
Figure 6.6:   Comparison of the kinetics of induction of SOCS1 mRNA by IL-4, 
IFNγ and LPS. Monocytes were cultured overnight in M-CSF and then treated with 
IL-4 (10 ng/ml), LPS (500 ng/ml) or IFNγ (10 ng/ml) for up to 24 h. SOCS1 mRNA 
levels  were  quantified  using  real  time  PCR  (mean  ±  SEM;  n=4  donors).  Arrows 
indicate the time point of maximal induction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7:   Induction of SOCS1 protein by IL-4, IFNγ and LPS. A. Kinetics of 
induction of SOCS1 protein in monocytes cultured overnight in M-CSF by IL-4 (10 
ng/ml), LPS (500 ng/ml) or IFNγ (10 ng/ml).  B. Comparison of the induction of 
SOCS1 protein by IL-4 in freshly isolated monocytes (Fresh) and monocytes cultured 
overnight in M-CSF (Overnight). SOCS1 protein levels were measured using Western 
blotting. Shown are representative blots from one donor. In A, quantitative analysis is 
shown upon normalisation to the total amount of α-tubulin. 
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6.2.6  Effect of IL-4 on LPS-induced TNFα Production by Murine Socs1
-/-Ifnγ
-/- Bone 
Marrow Derived Macrophages  
To determine whether IL-4-induced SOCS1 is involved in the suppression of LPS-
induced TNFα production, the effects of IL-4 on bone marrow-derived macrophages 
(BMM)  from  mice  lacking  SOCS1  were  examined.  SOCS1  knockout  mice  are 
hypersensitive  to  IFNγ  and  die  within  3  weeks  after  birth.  Therefore  concurrent 
disruption of the IFNγ and SOCS1 genes (Socs1
-/-Ifnγ
-/-) is required in order to reduce 
lethal  pathological  changes  and  early  death  in  SOCS1  knockout  mice  (157). 
Responses by Socs1
-/-Ifnγ
-/- BMM were compared to those by BMM from Ifnγ
-/- and 
wildtype  (C57BL/6)  mice  (Fig.  6.8).  IL-4  significantly  suppressed  LPS-induced 
TNFα production in wildtype, Socs1
-/-Ifnγ
-/- and Ifnγ
-/- murine BMM. There was no 
significant difference in the percentage suppression by IL-4 in Socs1
-/-Ifnγ
-/- BMM 
(34% + 4%) compared to wildtype (36% + 6%) and Ifnγ
-/- BMM (31% + 4%).  
 
 
 
 
 
 
 
 
 
Figure 6.8:   Effect of IL-4 on LPS-induced TNFα production by BMM from 
wildtype, Ifnγ
-/- and Socs1
-/-Ifnγ
-/- mice. BMM were incubated for 24 h with IL-4 (10 
ng/ml),  LPS (10 ng/ml) or  LPS +  IL-4 (mean  + SEM, n=3 individual mice). An 
asterisk indicates a significant suppression by IL-4 from LPS-induced levels (p<0.05). 
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6.3  Discussion 
In  a screen for expression of negative regulators  of cytokine signalling in  human 
monocytes, IL-4 induced SOCS1 and CIS mRNA. The induction of SOCS1 mRNA 
and protein by IL-4 occurred earlier than that induced by LPS and IFNγ. Therefore 
SOCS1 was considered potentially responsible for IL-4-mediated suppression of LPS-
induced TNFα production. IL-4 suppressed LPS-induced TNFα production by freshly 
isolated monocytes at the level of transcription but acted by a different mechanism in 
monocytes cultured overnight in M-CSF, possibly at the translational level (Chapter 
3). However, the kinetics and magnitude by which IL-4 and LPS induced SOCS1 
mRNA and protein was very similar in the two cell types. Furthermore, IL-4 was still 
able to  suppress  LPS-induced TNFα production in  murine BMM  lacking SOCS1. 
Allowing for human/ murine differences, this suggested that SOCS1 is not part of the 
mechanism by which IL-4 suppresses LPS-induced TNFα production by monocytes. 
 
The rapid induction of SOCS1 mRNA by IL-4 peaked at 1 h, much earlier than IFNγ- 
and  LPS-induced  SOCS1,  which  were  maximal  at  2  h  and  4  h  post-stimulation, 
respectively (Fig. 6.6). The induction of SOCS1 protein by IL-4 also peaked much 
earlier than SOCS1 protein induced by LPS and IFNγ (Fig. 6.6).  These kinetics of 
induction  by  IL-4  suggested  that  SOCS1  may  be  a  potential  component  of  the 
mechanism by which IL-4 regulated LPS-induced TNFα production in monocytes. 
Crosstalk by which SOCS1 is induced by one cytokine and regulates signalling by 
another has been previously reported. For example, IFNs inhibit IL-4-activation of 
STAT6 and STAT6-dependent gene transcription by inducing expression of SOCS1 
(251). In contrast to previous findings (252), SOCS1 mRNA levels were reduced in 
synovial fluid cells from patients with inflammatory arthritis relative to PBMCs and 
purified monocytes from healthy controls (Fig. 6.5), suggesting that an absence of   134 
SOCS1 may promote inflammatory responses. Hence the induction of SOCS1 by IL-4 
may also in part explain its beneficial actions in inflammatory arthritis. 
 
Ideally, we would have liked to investigate the role of IL-4-induced SOCS1 in human 
monocytes  transfected  with  a  dominant  negative  form  of  SOCS1  or  a  siRNA  to 
SOCS1. However monocytes are difficult to transfect using traditional methods and 
while adenoviral vectors achieve transfection efficiencies of >50%, they enhance type 
I  IFN  levels  and  activate  the  IFN-dependent  pathway  of  TLR  signalling, 
demonstrating  transfection  systems  to  be  of  little  use  in  human  monocytes  (172). 
Instead, we investigated the effects of IL-4 on macrophages from Socs1
-/-Ifnγ
-/- mice. 
However,  there  was  no  significant  difference  in  the  suppression  of  LPS-induced 
TNFα production by IL-4 between wildtype, Ifnγ
-/- and Socs1
-/-Ifnγ
-/- murine BMM, 
suggesting  that  SOCS1  is  not  involved  in  the  suppression  of  LPS-induced  TNFα 
production by IL-4 in murine macrophages.     
 
IL-4  suppressed  LPS-induced  TNFα  in  freshly  isolated  monocytes  at  the  level  of 
transcription but acted by a different mechanism in monocytes cultured overnight in 
M-CSF, possibly by a translational process (see Chapter 3). Despite different modes 
of regulation by IL-4 in freshly isolated monocytes and monocytes cultured overnight 
in M-CSF, the kinetics and magnitude by which IL-4 induced SOCS1 mRNA in the 
two cell types were very similar, further suggesting that SOCS1 was not involved.  
 
In addition, the TLR pathways regulated by SOCS1 in human monocytes did not 
match what we observed with IL-4. LPS initiates two distinct signalling pathways 
downstream  of  TLR-4,  the  early  MyD88-dependent  pathway  and  the  later-acting   135 
TRIF-dependent, IFN-dependent pathway. IL-4 reduced TNFα mRNA levels by 1 h 
in  freshly  isolated  monocytes,  suggesting  regulation  of  early  components  of  LPS 
signalling, while in monocytes cultured overnight in M-CSF, IL-4 had no effect on 
TNFα mRNA over 24 h (see Chapter 3). In contrast, in human monocytes infected 
with an adenovirus over-expressing SOCS1 (AdV-SOCS1), SOCS1 suppressed LPS-
induced TNFα mRNA and protein production at 24 h, but had no effect on TNFα 
levels in the first 2 h. SOCS1 did not modulate components of the early Myd88-
dependent  pathway  of  LPS  signalling.  Rather,  SOCS1  reduced  LPS-induced 
expression  of  IFN-β  and  myxovirus  resistance-A  mRNA  and  reduced  IFN-β 
production  and  STAT-1  phosphorylation,  showing  that  SOCS1  regulates  the  later 
IFN-dependent  components  of  LPS-induced  TLR-4  signalling  (172).  Thus  IL-4, 
unlike SOCS1, does not suppress LPS-induced TNFα production by inhibiting the 
IFN-dependent pathways of LPS signalling, and is therefore unlikely to be acting via 
SOCS1. 
 
While SOCS interactions are generally thought to take place in the cytoplasm at the 
vicinity of cell surface receptors, recently SOCS1 was discovered to translocate to the 
nucleus  (253).  In  human  HEK293,  cells  SOCS1  regulated  the  duration  of  NF-κB 
signalling by binding to the NF-κB subunit, p65, leading to its ubiquitination and 
subsequent  proteosomal  degradation  (253).  In  contrast,  IL-4  had  no  effect  on  the 
DNA binding capacity of NF-κB in LPS-treated monocytes, as measured by EMSA 
(Fig. 4.3). 
 
The possibility that the anti-inflammatory actions of IL-4 may be mediated by other 
SOCS proteins was considered. In human monocytes IL-4 also induced mRNA for   136 
CIS  (Fig.  6.2A),  a  negative  regulator  of  STAT5  signalling.  While  IL-4  does  not 
activate STAT5, it may induce CIS via STAT6 which is capable of activating STAT5 
responsive  genes  (254).  CIS  is  unlikely  to  be  involved  in  the  regulation  of  LPS 
responses because LPS does not directly signal through STAT5 and LPS failed to 
induce CIS mRNA (Figs  6.2 and  6.3). Therefore  IL-4-induced CIS is  unlikely to 
mediate  the  suppression  of  LPS-induced  TNFα  production  by  IL-4.  However,  it 
remains  possible  that  IL-4-induced  CIS  regulates  the  signalling  of  LPS-induced 
cytokines,  such  as  GM-CSF,  which  signal  through  STAT5.  Monocytes  expressed 
higher levels of CIS mRNA after overnight culture in M-CSF (Fig. 6.5), suggesting 
that CIS may also be induced by M-CSF, which itself signals through STAT5 (255). 
Therefore the role of IL-4-induced CIS in the regulation of monocyte/ macrophage 
differentiation  and  inflammatory  responses  mediated  by  GM-CSF  and  M-CSF 
requires further investigation 
 
SOCS3, SOCS4 and SOCS5 mRNA were not induced by IL-4 in human monocytes 
(Fig. 6.2) and therefore are unlikely to mediate the anti-inflammatory actions of IL-4. 
However, while SOCS5 protein is preferentially expressed in committed Th1 cells, it 
is not directly induced by IL-4. Rather, SOCS5 interacts with the IL-4Rα chain to 
inhibit  IL-4  signalling  irrespective  of  receptor  tyrosine  phosphorylation  (221).  It 
would  be  interesting  to  investigate  whether  such  an  interaction  occurs  in  human 
monocytes  using  co-immunoprecipitation  (Co-IP)  studies.  PIAS,  SHP  and  SHIP 
mRNA were not induced by LPS or IL-4. Unlike SOCS genes, these may not be 
inducible  genes  and  instead  may  be  expressed  constitutively  within  cells  (256). 
Rather, the expression of these regulators could be altered at the protein level by IL-4. 
For  example,  IL-4  reduces  protein  levels  of  SHIP  by  promoting  its  proteosomal   137 
degradation (233). Therefore, Western blotting and Co-IP studies may be more useful 
approaches to determine whether the expression of PIAS, SHP and SHIP proteins are 
altered by LPS and IL-4 in monocytes.  
 
In conclusion, while IL-4 caused a rapid induction of SOCS1 mRNA and protein in 
human monocytes which immediately preceded the induction of SOCS1 by LPS and 
IFNγ, SOCS1 is unlikely to mediate the anti-inflammatory actions of IL-4 in human 
monocytes. Further studies are required to identify new proteins induced by IL-4 and 
to  clarify  their  interactions  with  pathways  involved  in  inflammation  in  human 
monocytes. Other IL-4-induced candidates may be proteins induced during alternative 
activation  of  macrophages,  namely  PPARγ  and  TREM-2,  which  can  suppress 
inflammatory cytokine production (see Chapter 7). Alternatively, gene arrays may 
identify  novel  genes  up-regulated  by  IL-4  and  the  LPS-induced  genes  that  are 
downregulated by IL-4 in human monocytes (see Chapter 8). 
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Chapter Seven 
 
 The Role of PPARγ and TREM-2 in the 
Suppression of LPS-induced TNFα 
Production by IL-4 in Human Monocytes 
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7.1  Introduction 
Our initial approach to identifying new proteins induced by IL-4 that may mediate its 
anti-inflammatory  actions,  was  to  screen  for  expression  of  negative  regulators  of 
cytokine signalling (Chapter 6). However, while IL-4 up-regulated SOCS1 mRNA 
and protein, the suppression of LPS-induced TNFα production by IL-4 was mediated 
independently of  SOCS1  (Chapter 6)  (257).  IL-4 directs  macrophages  towards an 
alternative pathway of macrophage activation resulting in an ‘M2’ phenotype, which 
is characterised by the up-regulation of specific markers, reduced secretion of pro-
inflammatory  cytokines,  enhanced  production  of  anti-inflammatory  mediators  and 
promotion  of  wound  healing  and  tissue  repair  (Fig.  1.9)  (99-102).  Two  of  these 
markers of alternative activation, Peroxisome Proliferator-Activated Receptor gamma 
(PPARγ) and Triggering Receptors Expressed on Myeloid cells-2 (TREM-2) have 
also been implicated in the suppression of inflammatory cytokine production (258, 
259). Therefore it was hypothesised that PPARγ and TREM-2 may mediate the anti-
inflammatory actions of IL-4 in human monocytes. 
 
PPARγ is a ligand-dependent transcription factor of the nuclear hormone receptor 
superfamily, predominantly expressed in the adipose tissue and the immune system. 
Here it plays a key role in the regulation of lipid metabolism, glucose homeostasis 
(260, 261), as well as inflammatory and immune responses (258, 261). PPARγ is 
activated by naturally occurring fatty  acid-derived molecules, including  15-deoxy-
Δ
12,
14-Prostaglandin  J2  (15d-PGJ2)  and  several  synthetic  compounds,  such  as  the 
thiazolidinediones  (TZDs),  which  are  used  in  type  2  diabetes  therapy  (262,  263). 
Following  ligand  binding,  PPARγ  heterodimerises  with  the  retinoid  X  receptor 
(RXR),  and  ligates  to  peroxisome  proliferator  response  elements  (PPREs)  in  the   141 
promoter region of target genes, resulting in gene transcription (260, 261). In addition, 
PPARγ  may  function  as  a  transcriptional  repressor  independent  of  direct  DNA 
binding (Fig. 7.1) (264). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1:   PPARγ signalling. Upon binding with fatty acid derived molecules or 
synthetic ligands, PPARγ heterodimerises with the retinoid X receptor (RXR) in the 
nucleus  and  activates  gene  transcription.  In  addition,  PPARγ  functions  as  a 
transcriptional  repressor  by  preventing  removal  of  nuclear  receptor  corepressor 
(NCoR) complexes. Adapted from Hong and Tontonez, 2008 (261).  
 
In  monocytes  and  macrophages,  PPARγ  agonists  suppress  inflammatory  cytokine 
production (265, 266) and have therapeutic potential in the treatment of inflammatory 
bowel  disease  (267),  atherosclerosis  (268,  269)  and  rheumatoid  arthritis  (270). 
Suppression of inflammatory gene transcription by PPARγ is in part mediated by 
transrepression  of  the  transcription  factors  NF-κB  (271),  STAT1  (272)  and  AP-1 
(273). Similar to the actions of IL-4 reported in Chapter 3, PPARγ suppresses NF-κB 
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transcriptional activity without altering the DNA binding capacity of NF-κB. Rather, 
PPARγ transrepression may be mediated by ligand-dependent SUMOlyation, which 
targets PPARγ to nuclear receptor corepressor (NCoR) complexes to prevent their 
clearance from the promoters of target genes (271) (Fig. 7.1).  
 
IL-4 induces coordinate increases in expression of PPARγ and endogenous ligands for 
PPARγ through activation of 12/15-lipoxygenase in macrophages. This increase in 
PPARγ and its ligands, mediate IL-4-dependent increases in CD26 and decreases in 
iNOS  expression  (274,  275).  Recent  studies  suggest  that  alternative  activation  of 
macrophages  by  IL-4  requires  PPARγ  (276-280).  PPARγ  directly  regulates  the 
expression of  M2 markers (277, 278)  and  promotes mitochondrial biogenesis and 
oxidative metabolism to support the M2 phenotype (279). Furthermore, the balance 
between  M2  cells  and  classically  activated  M1  macrophages  is  altered  in  murine 
macrophages lacking PPARγ (280). IL-4, added 24 h before LPS, has an impaired 
ability to attenuate LPS-induced IL-6 production in PPARγ-deficient macrophages 
(280). While IL-4-induced PPARγ activation inhibits NF-κB transactivation in central 
nervous  system  glial  cells  (281)  and  osteoclasts  (282),  whether  PPARγ  directly 
mediates  the  suppression  of  inflammatory  cytokine  production  by  IL-4  in  human 
monocytes remains unclear.  
 
TREM-2 is transmembrane glycoprotein receptor expressed on DCs, macrophages, 
osteoclasts and microglia, and is required for normal maturation of these cells (283-
285). TREM-2 has a short cytoplasmic tail with no intrinsic signalling capacity and it 
relies on the cytosolic adapter, DAP12, to activate downstream pathways (285, 286) 
(Fig. 7.2). In macrophages TREM-2 regulates giant cell formation (287), phagocytosis   143 
of bacteria (288) and attenuates responses to microbial stimuli (259, 289, 290). The 
latter is demonstrated in DAP12 and TREM-2 knockout macrophages which produce 
higher levels of inflammatory cytokine production in response to TLR ligands (259, 
289,  290).  TREM-2  is  not  expressed  on  circulating  monocytes  or  resident 
macrophages but its expression is induced on monocytes as they infiltrate into tissues 
(259). Alternative activation of resident macrophages by IL-4 also induces TREM-2, 
while  TREM-2  expression  is  abrogated  by  activation  with  LPS  or  IFNγ  (259). 
However, whether TREM-2 directly mediates the anti-inflammatory actions of IL-4 is 
unclear. 
 
Figure 7.2:   TREM-2 signalling. TREM-2 is transmembrane glycoprotein receptor 
that signals through the cytosolic adapter, DAP12, to activate downstream pathways 
including Syk and Src kinases. Adapted from Colonna, 2003 (285). 
 
In this chapter, the question of whether IL-4-induced PPARγ and TREM-2 directly 
mediate the suppression of LPS-induced pro-inflammatory cytokine production by IL-
4 was investigated. While it is known that PPARγ and TREM-2 are induced by IL-4 
during alternative activation of macrophages, IL-4 suppressed LPS-induced TNFα by   144 
monocytes within the first  3 h of treatment  (Chapter 3, 257). Therefore the early 
kinetics by which IL-4 induces PPARγ and TREM-2 in LPS-treated monocytes were 
defined. As IL-4 has an impaired ability to suppress TNFα production after overnight 
culture,  PPARγ  and  TREM-2  expression  in  these  cells  was  compared  to  their 
expression  in  freshly  isolated  monocytes.  Finally,  the  function  of  IL-4-induced 
PPARγ was investigated using PPARγ agonists and antagonists.  
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7.2  Results 
7.2.1  TREM-2  and  PPARγ  Expression  is  Up-regulated  by  IL-4-induced  (M2) 
Polarisation and Down-regulated by IFNγ-induced (M1) Polarisation  
Firstly, TREM-2 and PPARγ were confirmed as markers of alternative activation by 
measuring  mRNA  levels  in  IL-4-induced,  (M2)-polarised  monocytes  and  IFNγ-
induced, (M1)-polarised monocytes. The expression of TREM-2 mRNA mirrored that 
of  PPARγ  mRNA  (Fig.  7.3).  Freshly  isolated  monocytes  expressed  low  levels  of 
PPARγ (Fig. 7.3A) and did not express detectable levels of TREM-2 mRNA (Fig. 
7.3B). Overnight  culture of monocytes in M-CSF followed by an additional 24 h 
culture  in  medium  with  M-CSF  alone  induced  expression  of  TREM-2  and  up-
regulated baseline levels of PPARγ mRNA. An additional 24 h culture in medium 
with M-CSF plus IL-4 up-regulated TREM-2 and PPARγ mRNA levels relative to 
culture alone. In contrast a further 24 h culture in M-CSF plus IFNγ strongly down-
regulated PPARγ and TREM-2 mRNA levels. 
  
 
 
 
 
 
 
 
Figure 7.3:   Effect  of  M1  and  M2  polarisation  on  TREM-2  and  PPARγ 
expression in human monocytes. PPARγ (A) and TREM-2 (B) mRNA levels were 
quantified using real-time PCR in freshly isolated monocytes (Fresh) and monocytes 
cultured overnight in M-CSF followed by an additional 24 h culture with medium 
alone  (M-CSF)  or  with  IFNγ  (10  ng/ml)  or  IL-4  (10  ng/ml).  mRNA  levels  were 
calculated as a ratio to expression of the house-keeping gene ubiquitin-conjugating 
enzyme E2D 2 (UBE2D2), (mean ± SEM; PPARγ n=5 donors, TREM-2 n=4 donors). 
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7.2.2  IL-4 Causes an Early Up-regulation of PPARγ mRNA which is Stronger in 
Freshly Isolated Monocytes than in Monocytes Cultured Overnight in M-CSF 
Because IL-4 suppressed LPS-induced TNFα by monocytes within the first 3 h of 
treatment (Chapter 3) (257), the kinetics by which IL-4 induces PPARγ and TREM-2 
mRNA were defined.  Freshly  isolated monocytes  expressed low levels of PPARγ 
mRNA which were up-regulated by culture in RPMI (Fig. 7.4A). Overnight culture 
with  M-CSF  also  up-regulated  PPARγ  mRNA  levels,  but  in  these  cells  PPARγ 
mRNA expression did not change with an additional 24 h of culture (Fig. 7.4A). LPS 
strongly down-regulated PPARγ mRNA expression in monocytes cultured overnight 
in M-CSF, but had less effect early on freshly isolated monocytes (Fig. 7.4B), likely 
due to the up-regulation of PPARγ that occurred in these cells with culture in RPMI 
(Fig. 7.4A). IL-4 caused a strong, early induction of PPARγ mRNA which peaked at 2 
h and remained significantly up-regulated at 24 h (Fig. 7.4C). This induction by IL-4 
occurred with similar kinetics but was weaker in monocytes cultured overnight in M-
CSF (Fig. 7.4C and D). LPS down-regulated the induction of PPARγ mRNA by IL-4 
(Fig. 7.4D). 
 
7.2.3  IL-4 Induces TREM-2 mRNA in Monocytes after Overnight Culture in M-CSF, 
but Freshly Isolated Monocytes do not Express TREM-2 
Freshly isolated monocytes did not express TREM-2 and culture of these cells for 24 
h in medium (Fig. 7.5A) with or without IL-4 (Fig. 7.5B), LPS (Fig. 7.5C) and LPS + 
IL-4 (Fig. 7.5D) failed to induce TREM-2 expression. In contrast, monocytes cultured 
overnight in M-CSF expressed TREM-2 mRNA. In these cells TREM-2 mRNA levels 
were not changed with culture (Fig. 7.5A), but were down-regulated by LPS from 2 h 
(Fig.  7.5B).  IL-4  up-regulated  TREM-2  mRNA  levels  in  monocytes  cultured 
overnight in M-CSF. This up-regulation was observed only at 8 h and 24 h but not in   147 
the first 4 h (Fig. 7.3C). The induction of TREM-2 mRNA by IL-4 was weaker in the 
presence of LPS (Fig. 7.5D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4:   Kinetics  of  LPS-induced  down-regulation  and  IL-4-induced  up-
regulation  of  PPARγ  mRNA  levels  in  human  monocytes.  Freshly  isolated 
monocytes (Fresh) or monocytes cultured overnight in M-CSF (O/N M-CSF) were 
treated with LPS (500 ng/ml), IL-4 (10 ng/ml) and LPS + IL-4 for up to 24 h. PPARγ 
mRNA  levels  were  quantified  using  real  time  PCR  and  calculated  as  a  ratio  to 
expression  of  the  house-keeping  gene,  UBE2D2  (mean  ±  SEM;  n=5  donors). 
Significant up-regulation (p<0.05) of PPARγ mRNA by IL-4, relative to untreated 
cells,  are  indicated  by  an  asterisk.  A  hash  indicates  significant  down-regulation 
induced by LPS. 
 
 
 
   148 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5:   Kinetics  of  LPS-induced  down-regulation  and  IL-4-induced  up-
regulation  of  TREM-2  mRNA  levels  in  human  monocytes.  Freshly  isolated 
monocytes (Fresh) or monocytes cultured overnight in M-CSF (O/N M-CSF) were 
treated with LPS (500 ng/ml), IL-4 (10 ng/ml) and LPS + IL-4 for up to 24 h. TREM-
2 mRNA levels were quantified using real time PCR and calculated as a ratio to 
expression  of  the  house-keeping  gene,  UBE2D2  (mean  ±  SEM;  n=3  donors). 
Significant up-regulation (p<0.05) of TREM-2 mRNA by IL-4, relative to untreated 
cells,  are  indicated  by  an  asterisk.  A  hash  indicates  significant  down-regulation 
induced by LPS. 
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7.2.4  Expression of PPARγ and TREM-2 in Synovial Fluid Mononuclear Cells from 
Patients with Inflammatory Arthritis 
PPARγ and TREM-2 mRNA levels were measured in synovial fluid mononuclear 
cells isolated from the joints of patients with inflammatory arthritis and compared to 
expression  in  blood  monocytes  from  healthy  controls  (Fig.  7.6).  Cell  counts 
determined that synovial fluid samples typically comprised of 50% lymphocytes with 
the  remaining  cells  predominantly  monocytes.  To  control  for  the  presence  of 
lymphocytes, PPARγ and TREM-2 mRNA levels were also compared to levels in 
freshly isolated PBMCs from healthy controls,  which typically comprised of 70% 
lymphocytes and 30% monocytes. However, both freshly isolated purified monocytes 
and PBMCs expressed very low levels of PPARγ mRNA (Fig. 7.6A) and did not 
express TREM-2 mRNA (Fig. 7.6B). Instead the expression of PPARγ and TREM-2 
mRNA  in  the  synovial  fluid  mononuclear  cells  more  closely  mirrored  that  of 
monocytes from healthy controls after overnight culture in M-CSF (Fig. 7.6), though 
synovial fluid mononuclear cells tended to express less PPARγ (Fig. 7.6A) and more 
TREM-2 mRNA (Fig. 7.6B).  
 
7.2.5  Summary  of  PPARγ  and  TREM-2  Expression  in  Human  Monocytes  and 
Macrophages 
The absence of TREM-2 mRNA in freshly isolated monocytes and its late induction 
by  IL-4  in  monocytes  after  overnight  culture  in  M-CSF  did  not  support  its 
involvement in the regulation of inflammatory cytokine production by IL-4. However, 
the early induction of PPARγ mRNA by IL-4, in the presence and absence of LPS, 
was stronger in freshly isolated monocytes, identifying PPARγ as a candidate in the 
regulation of inflammatory cytokine production by IL-4 (Table 7.1).   150 
 
 
 
 
 
 
 
Figure 7.6:   TREM-2  and  PPARγ  mRNA  expression  in  synovial  fluid 
mononuclear cells from rheumatoid arthritis patients. PPARγ (A) and TREM-2 
(B) mRNA levels were measured in synovial fluid mononuclear cells isolated from 
the joints of patients with inflammatory arthritis (SF) and compared to expression of 
blood  cells  isolated  from  healthy  controls;  freshly  isolated  peripheral  blood 
mononuclear  cells  (PBMCs),  freshly  isolated  elutriated  monocytes  (Fresh)  and 
monocytes  after  overnight  culture  in  M-CSF  (M-CSF),  (mean  ±  SEM;  from 
experiments on at least 4 donors). 
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7.2.4  PPARγ  antagonists  do  not  prevent  the  suppression  of  LPS-induced  TNFα 
production by IL-4 in human monocytes 
To determine whether PPARγ mediates the anti-inflammatory actions of IL-4, the 
effects of the PPARγ antagonist, GW9662, and PPARγ agonist, GW1929, on IL-4 
regulation of LPS-induced TNFα production were investigated (Fig. 7.7). GW9662 
dose-dependently enhanced LPS-induced TNFα production (Fig. 7.7A) but failed to 
prevent the suppression of LPS-induced TNFα production by IL-4 (Fig. 7.7B). The 
PPARγ agonist, GW1929 (Fig. 7.7C), and PPAR delta (PPARagonist, GW0742 
(Fig. 7.7D), both had no effect on LPS-induced TNFα production.  
 
 
 
Table 7.1:   Summary of TREM-2 and PPARγ expression. The effect on LPS 
and IL-4 on TREM-2 and PPARγ expression was compared in freshly isolated human 
monocytes (Fresh) and monocytes cultured overnight in M-CSF (Overnight). 
 
 
Fresh  Overnight 
LPS  +IL-4  LPS  +IL-4 
 
TREM-2 
 
Not expressed 
 
   
(8-24 h) 
 
PPARγ 
 
 
 
 
- Peaks at 2 h 
 
 
 
- Peaks at 2 h 
- Weaker 
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Figure 7.7:   Effect of PPARγ antagonists and agonists on LPS-induced TNFα 
production  and  the  suppression  by  IL-4  in  human  monocytes.  Agonists  and 
antagonists were pre-incubated with freshly isolated human monocytes for 1 h before 
addition of LPS (500 ng/ml) ± IL-4 (10 ng/ml). After 24 h incubation, TNFα levels 
were assayed in supernatants A. Effect of the PPARγ antagonist, GW9662, (1-20 µM) 
on LPS-induced TNFα production B. Effect of GW9662 (20 µM) on the suppression 
of LPS-induced TNFα production by IL-4. C. Effect of PPARγ agonist, GW1929, (1-
10 µM) on LPS-induced TNFα production. D. Effect of PPAR agonist, GW0742, 
(10 µM)  on  LPS-induced TNFα production. Shown are pooled  results  from  three 
separate  experiments  (mean  +  SEM).  Significant  enhancement  (p<0.05)  in  TNFα 
from LPS-induced levels are indicated with a hash. An asterisk indicates a significant 
suppression by IL-4.  
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7.3  Discussion 
Several  studies  have  demonstrated  that  the  anti-inflammatory  actions  of  IL-4  in 
human monocytes require synthesis of a new protein (141-143); however this protein 
has  never been identified. We investigated whether two markers induced by  IL-4 
during  alternative  activation  of  macrophages,  PPARγ  and  TREM-2,  mediated  the 
suppression of LPS-induced inflammatory cytokine production by IL-4. However, our 
data revealed that the suppression of LPS-induced inflammatory cytokine production 
by IL-4 is likely to be mediated independently of both PPARγ and TREM-2. 
 
The  PPARγ  antagonist,  GW9662,  dose-dependently  enhanced  LPS-induced  TNFα 
production (Fig. 7.7A). Similarly, PPARγ knockout macrophages have dramatically 
increased  expression  of  basal  levels  of  proinflammatory  molecules,  indicating 
endogenous  levels  of  PPARγ  are  critical  for  regulating  basal  or  physiological 
inflammation (291). Analysis of mRNA expression of the nuclear receptor, PPARγ, 
favoured it as a candidate for the regulation of LPS-induced inflammatory cytokine 
production by  IL-4  in  human monocytes  (Table 7.1). Firstly, PPARγ mRNA was 
strongly induced by  IL-4 within the first 3 h (Fig. 7.4), similar to  the timing for 
suppression by IL-4 of LPS-induced inflammatory cytokine production (Chapter 3). 
Furthermore, the ability of  IL-4 to  induce PPARγ mRNA, on its  own  and in  the 
presence of LPS, was impaired in monocytes after overnight culture in M-CSF (Fig. 
7.4 C and D); in these cells IL-4 has a reduced ability to suppress LPS-induced TNFα 
production  (Fig.  3.2A).  However,  IL-4  maintained  the  ability  to  suppress  LPS-
induced  TNFα  production  in  the  presence  of  a  PPARγ  antagonist  (Fig.  7.7B) 
suggesting  that  the  suppression  of  inflammatory  cytokine  production  by  IL-4  is 
mediated independently of PPARγ.   154 
The PPARγ agonist, GW-1929, had no effect on LPS-induced TNFα production (Fig. 
7.7C), when the concentrations used should have been sufficient to exert a biological 
effect (292). Other synthetic PPARγ agonists, including 10 µM roglitazone also failed 
to suppress TNFα production by LPS-treated human monocytes (C. Prêle, personal 
communication). Often synthetic ligands do not have an effect (295) or require far 
greater concentrations to suppress inflammatory cytokine production (265, 273) than 
endogenous PPARγ ligands such as 15d-PGJ2, which can suppresses inflammation by 
PPARγ-independent mechanisms (293, 294). However, 10 µM 15d-PGJ2 also failed 
to regulate TNFα production by LPS-treated human monocytes (C. Prêle, personal 
communication).  Several  studies  have  found  that  the  anti-inflammatory  actions  of 
PPARγ agonists are often specific to IFN- and phorbol ester myristate (PMA)-induced 
cytokine production, but not LPS-induced cytokine production (265, 295). Therefore, 
while PPARγ may regulate anabolism and inflammation in chronic processes, it may 
not regulate the presumably acute event of LPS stimulation (265, 295). Finally, LPS-
induced NF-κB rapidly drives down PPARγ expression and thereby may obviate any 
potential  anti-inflammatory  effects  of  PPARγ in  LPS-stimulated  monocytes  (291). 
However, in our study, while LPS strongly down-regulated PPARγ mRNA by 24 h, 
PPARγ  mRNA  levels  increased  within  the  first  2  h  of  LPS  treatment  in  freshly 
isolated monocytes (Fig. 7.4B).  
 
PPARγ may mediate primarily the expression of M2 phenotypic markers (277, 278) 
and metabolic functions (279, 280) induced by IL-4 during alternative activation of 
monocytes.  It  remains  possible  that  the  suppression  of  inflammatory  cytokine 
production  by  IL-4  involves  other  members  of  the  PPARs.  Whereas  gene  array 
analysis (Chapter 8) found that IL-4 had no effect on PPAR alpha (PPARα) mRNA   155 
levels  (Table  8.1),  an  increasing  number  of  studies  reveal  a  role  for  PPAR  delta 
(PPAR  in  IL-4-induced  alternative  activation  of  macrophages  (296-298)  and 
suppression  of  inflammatory  cytokine  production  (299,  300).  PPAR  and  PPARγ 
have distinct and overlapping activities in alternatively activated macrophages (266, 
301)  and  PPAR  may  be  more  important  than  PPARγ  for  the  regulation  of  the 
immune repertoire and cytokine secretion of these cells (99). However, the PPAR 
agonist,  GW0742,  had  no  effect  on  LPS-induced  TNFα  production  (Fig.  7.7D). 
Unfortunately, a PPAR specific antagonist only became commercially available after 
the completion of these experiments (302). Therefore the role of PPAR in regulating 
the  suppression  of  inflammatory  cytokine  production  by  IL-4  requires  further 
investigation. 
 
TREM-2  is  a  receptor  induced  during  differentiation  and  alternative  activation  of 
macrophages that may function to attenuate cytokine production in these cells (259). 
However, the kinetics by which IL-4 induced TREM-2 mRNA did not support that it 
is involved in the regulation of LPS-induced inflammatory cytokine production by IL-
4 (Fig. 7.5). Firstly, TREM-2 mRNA was not detected in freshly isolated monocytes 
but in these cells IL-4 strongly suppressed LPS-induced TNFα production. Secondly, 
while IL-4 induced TREM-2 mRNA in monocytes after overnight culture with M-
CSF,  this  induction  was  not  observed  until  8  h,  while  IL-4  suppression  of  LPS-
induced  TNF  production  occurs  within  the  first  few  hours.  Therefore  IL-4,  when 
added at the same time as LPS, suppresses inflammatory cytokine production by a 
mechanism other than one involving TREM-2.    
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TREM-2 is not expressed on resident macrophages but it is induced on cells newly 
infiltrating the tissues, during murine models of peritoneal inflammation and lung 
inflammation (259). Similarly, synovial fluid mononuclear cells, but not blood cells 
from healthy controls, expressed TREM-2 mRNA (Fig. 7.6B). This may be because 
these cells have recently migrated into the joint, or perhaps TREM-2 is induced by 
mediators including M-CSF or IL-4 that may be present in the joint. PPARγ was also 
expressed at relatively high levels in synovial mononuclear cells, compared to blood 
monocytes  from  healthy  controls  (Fig.  7.6A).  Similarly,  atherosclerotic  lesions 
express  high  levels  of  PPARγ  relative  to  resident  macrophages  (303)  and 
macrophages from normal artery specimens (304). In these studies, PPARγ expression 
could be induced in resident macrophages and undifferentiated myeloid cell lines by 
differentiation in M-CSF, GM-CSF and tetradecanoyl phorbol acetate (TPA). Hence 
the  presence  of  M-CSF  and  GM-CSF  in  inflammatory  lesions  could  be  in  part 
responsible for the induction of PPARγ in infiltrating cells (303). Our finding that 
PPARγ  and  TREM-2  expression  in  monocytes  after  overnight  culture  in  M-CSF 
mirrored that of synovial fluid cells supports our proposal in Chapter 3 that after 
overnight culture monocytes become representative of cells newly infiltrated into the 
tissue rather than blood monocytes.  
 
Interestingly,  the  concurrent  induction  of  TREM-2  and  up-regulation  of  PPARγ 
mRNA in monocytes following overnight culture in M-CSF also closely resembled 
the expression profiles of IL-4 polarised (M2) monocytes (Fig. 7.8). This suggests 
that culture in M-CSF in the absence of other stimuli may result in a default shift to an 
M2 phenotype. Supporting this, transcriptional profiling of monocyte differentiation 
has revealed that culture with M-CSF leads to expression of a substantial part of the   157 
M2 transcriptome. These cells are consequently relatively insensitive to IL-4-induced 
alterations  in  gene  expression.  (305).  Hence  the  acquisition  of  a  M2  phenotype 
following culture in M-CSF could in part explain the impaired suppression of LPS-
induced TNF production by IL-4 seen in these cells (Chapter 3). 
 
In conclusion, analysis of PPARγ and TREM-2 mRNA expression revealed that a 
default switch to M2 phenotype may occur when monocytes are cultured in M-CSF 
and  that  these  cells  become  more  representative  of  cells  newly  migrated  into  the 
tissues than blood monocytes. This may possibly explain impaired responses to IL-4 
by these cells. However, while TREM-2 is induced during alternative activation of 
macrophages and may attenuate subsequent exposures to microbial stimuli in these 
cells,  TREM-2  is  unlikely  to  directly  mediate  the  suppression  of  inflammatory 
cytokine production by IL-4. Likewise, PPARγ may be important for regulating the 
expression of phenotypic markers and metabolic programming of macrophages during 
alternative  activation,  but  IL-4  suppresses  LPS-induced  TNFα  production 
independently of PPARγ. Further investigation into the role of PPAR in mediating 
the  suppression  of  inflammatory  cytokine  production  by  IL-4  is  required.  In 
conclusion, this study of two markers of the M2 phenotype induced by IL-4 during 
alternative activation, failed to identify a candidate protein which mediates the anti-
inflammatory actions of IL-4 in human monocytes. A more useful approach may be to 
identify  novel  genes  up-regulated  by  IL-4  in  monocytes  using  gene  arrays  (see 
Chapter 8). 
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Figure 7.8:   Summary of PPARγ and TREM-2 expression at different stages of 
monocyte  differentiation.  Unstimulated  freshly  isolated  blood  monocytes  express 
low levels of PPARγ mRNA and do not express TREM-2. These are representative of 
naive ‘M0’ monocytes. Polarisation to a M2 phenotype with IL-4 up-regulates PPARγ 
and  TREM-2  mRNA,  while  polarisation  to  a  M2  phenotype  with  IFNγ  or  LPS 
strongly  down-regulates  PPARγ  and  TREM-2  mRNA.  Overnight  culture  of 
monocytes  in  M-CSF  increases  PPARγ  mRNA  and  induces  TREM-2  expression, 
suggesting a default shift to the M2 phenotype occurs in the absence of other stimuli. 
The expression of PPARγ and TREM-2 in synovial fluid mononuclear cells  from 
patients with inflammatory arthritis resemble that of monocytes cultured overnight in 
M-CSF.  This  suggests  that  after  overnight  culture  in  M-CSF,  monocytes  become 
more representative of monocytes newly migrated to the tissues, rather than blood 
monocytes.  
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Chapter Eight 
 
Identification of LPS-induced Genes that are 
Regulated by IL-4 in Human Monocytes 
Using Gene Arrays 
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8.3  Introduction 
TLR-related  signalling  pathways  are  part  of  the  mechanisms  driving  autoimmune 
disease and chronic inflammation (18). TLR ligands, bacterial DNA and bacterial cell 
wall components, have been detected in the joints of some patients with inflammatory 
arthritis  (14) and  synovial membrane cells  from  patients  with rheumatoid  arthritis 
release ligands for TLR (13). Since IL-4 down-regulates the transcription of LPS-
induced inflammatory genes in freshly isolated human monocytes (see Chapter 3), the 
anti-inflammatory actions of IL-4 in these cells are likely to reflect transcriptional 
regulation of genes involved in TLR signalling pathways. However, in Chapter 4, IL-
4 did not target the TLR signalling intermediates IκB, JNK and p38 and had no effect 
on  NF-κB  activation or binding  activity. While  IL-4  enhanced  LPS-induced ERK 
MAPK activation, IL-4 was still able to suppress LPS-induced TNFα production in 
the  presence  of  specific  ERK  and  p38  inhibitors,  suggesting  that  IL-4  acts 
independently of the MAPK pathways (Chapter 4).  
 
Studies using cycloheximide indicate that the anti-inflammatory actions of IL-4 in 
monocytes are dependent on new protein synthesis; however the protein/s involved 
have not been identified (141-143). Whilst IL-4 up-regulated suppressor of cytokine 
signalling-1 (SOCS1), a molecule generally considered to be induced for negative 
feedback of inflammatory processes, the anti-inflammatory actions of IL-4 occurred 
independently of SOCS1 (Chapter 6) (257). IL-4 also induced the nuclear receptor, 
PPARγ,  and  the  receptor  TREM-2,  during  alternative  activation  of  monocytes. 
However, TREM-2 did not directly mediate the suppression of inflammatory cytokine 
production by IL-4 in human monocytes and while PPARγ may regulate metabolic   161 
programs  in  alternatively  activated  macrophages  (6),  it  did  not  mediate  the 
suppression of inflammatory genes by IL-4 in these cells (Chapter 7).  
 
Gene arrays may identify novel genes up-regulated by IL-4 and the TLR signalling 
components targeted by IL-4 in human monocytes. Gene arrays have previously been 
used to characterise changes in gene expression induced by IL-4 in the presence of 
LPS  in  murine  B  cells  (217)  and  during  differentiation  of  human  monocytes  to 
macrophages  or  dendritic  cells  cultured  with  GM-CSF  or  GM-CSF  plus  IL-4, 
respectively  (306).  Several  studies  on  macrophages  have  compared  the  gene 
signatures induced by IL-4 during alternative activation, in contrast to that induced by 
LPS and IFNγ during classical activation (305, 307, 308). Recently, the changes in 
LPS-induced  gene  transcription  induced  by  IL-4  when  added  18  h  before  LPS 
exposure were described in murine macrophages (309). However, priming with IL-4 
induces different patterns of cytokine and chemokine expression and is functionally 
distinct to the outcomes when IL-4 is added at the same time as LPS (310). Therefore 
further studies are required to determine the transcriptional changes induced by IL-4 
when added concomitantly with LPS in human monocytes and macrophages.  
 
In  this  chapter,  tailored  gene  arrays  were  conducted  to  profile  the  expression  of 
multiple TLR signalling genes in human monocytes treated with the TLR4 ligand 
LPS, with or without IL-4. It was initially hypothesised that in human monocytes, IL-
4 would inhibit the transcription of LPS-induced signalling genes. However, although 
IL-4  significantly  down-regulated  LPS-induced  inflammatory  cytokines  and 
chemokines,  the  mRNA  levels  of  TLRs,  TLR-related  signalling  molecules  or 
transcription  factors  remained  unaltered.  Instead,  the  down-regulation  of   162 
inflammatory genes by IL-4 correlated with an up-regulation of IL-10, RIPK2, RP105 
and c-Maf mRNA. Therefore the function of IL-10, RIPK2, and c-Maf in mediating 
the anti-inflammatory actions of IL-4 in human monocytes was investigated. The role 
of IL-4-induced RP105 mRNA is discussed further in Chapter 9 of this thesis. 
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8.2  Results 
8.2.1  Effect of LPS on TLR-related Gene Expression 
The tailored gene arrays profiled the expression of 84 genes related to TLR signal 
transduction in human monocytes exposed to LPS (500 ng/ml), with or without IL-4 
(10 ng/ml); (see Table 8.1). The most dramatic effect of LPS was on expression of 
genes  encoding  for  cytokines  and  chemokines,  the  majority  of  which  were  up-
regulated  within  1  h.  At  the  same  time,  LPS  up-  and  down-regulated  mRNA 
expression  of  several  cell  surface  receptors,  TLR-adaptor  molecules  and  TLR 
signalling  components.  LPS  also  up-regulated  mRNA  levels  for  a  number  of 
transcription factors involved in inflammatory gene expression.  
 
8.2.2  IL-4 Down-regulates LPS-induced Inflammatory Cytokines and Chemokines, 
Without  Altering  mRNA  Levels  of  TLRs,  Signalling  Molecules  or  Transcription 
Factors 
The  anti-inflammatory  actions  of  IL-4  on  activated  human  monocytes  may  be 
mediated by transcriptional regulation of genes involved in inflammatory signalling 
pathways. Hence our initial analysis aimed to identify the changes in gene expression 
induced by IL-4 when added together with inflammatory stimuli, not IL-4 alone. The 
concurrent addition of IL-4 with LPS, significantly down-regulated mRNA levels for 
14  of  the  84  genes  in  the  array  (greater  than  2-fold  change  by  IL-4,  p<0.05  as 
determined  using  a  paired  t-test).  These  included  mRNA  for  the  inflammatory 
cytokines IL-1α, IL-1β, IL-6, IL-8, TNF, IFNβ, IFNγ and IL-12α; chemokines CCL2 
and CXCL10; GM-CSF (CSF2), G-CSF (CSF3), cyclooxygenase (PTGS2) and the C-
type lectin domain (CLEC4E) (Fig. 8.1, Table 8.1). The down-regulation of these 
genes  occurred  with  similar  kinetics,  with  the  greatest  down-regulation  of  LPS-  164 
induced genes by IL-4 occurring after 3 h (Fig. 8.1C). Despite inhibiting LPS-induced 
inflammatory cytokine and chemokine mRNA,  IL-4 did not significantly decrease 
mRNA levels of other TLR-related genes in the array, including those encoding for 
TLRs and other receptors, TLR adaptor molecules, signalling molecules of the IκB 
and MAP kinase pathways and TLR activated transcription factors (Table 8.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1:   IL-4 down-regulates LPS-induced mRNA levels of inflammatory 
cytokines and chemokines. The expression of 84 mRNAs in freshly isolated human 
monocytes treated with LPS and IL-4 was assessed using the Human TLR-signalling 
pathway RT2 Profiler PCR; results for genes significantly down-regulated by IL-4 
after 1 h (A), 2 h (B) and 3 h (C) are shown (see also Table 8.1). An asterisk indicates 
significant (p<0.05) and more than 2-fold decreases by IL-4. Results are for three 
independent experiments (mean + SEM). 
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Table 8.1   Fold-change (mean ± SEM) in mRNA expression for 84 genes in 
human monocytes treated for 1, 2 or 3 h with LPS (500 ng/ml) with or without 
IL-4 (10 ng/ml). Shading indicates significant (p<0.05) greater than 2-fold up- (light) 
or down-regulation (dark) by LPS relative to untreated cells. Genes shown in bold are 
those significantly (p<0.05) and greater than 2-fold up-regulated (shaded) or down-
regulated (unshaded) by IL-4 in LPS-treated monocytes, over 2 or more consecutive 
time-points. Shown are pooled results from three individual experiments.  nd= mRNA 
not detected for this gene.  
 
  Fold regulation by LPS  Fold regulation by IL-4 
(+LPS) 
Gene  1h  2h  3h  1h  2h  3h 
Cytokines             
IL6  675 ± 23  4850 ± 386  12971 ± 198  1.0 ± 0.1  0.5 ± 0.1  0.2 ± 0.1 
IFNB1  796 ± 67  2322 ± 533  786 ± 706  0.6 ±  0.0  0.3 ± 0.0  0.2 ± 0.0 
IL1A  301 ± 12  274 ± 45  767 ± 186  1.1 ± 0.1  0.6 ± 0.1  0.4 ± 0.2 
IL1B   281 ± 19  125 ±  10  344 ± 77  0.9 ± 0.0  0.6 ± 0.0  0.3 ± 0.1 
TNF  112 ± 12  123 ± 38  119 ± 30  0.7 ± 0.0  0.5 ± 0.1  0.3 ± 0.0 
IL8  80 ± 11  89 ± 10  101 ± 21  0.8 ± 0.0  0.5 ± 0.0  0.3 ± 0.1 
IFNG  4.5 ± 0.9  4.7 ± 0.7  135 ± 15  0.7 ± 0.0  0.4 ± 0.1  0.2 ± 0.0 
IL12A  1.8 ± 0.3  7.2 ± 1.3  11 ± 6.2  1.3 ± 0.1  0.8 ± 0.0  0.5 ± 0.0 
LTA  3.7 ± 0.3  5.5 ± 0.1  7.6 ± 0.3  0.8 ± 0.1  1.1 ± 0.1  0.9 ± 0.1 
IL10  2.5 ± 0.4  2.6 ± 0.6  21 ± 13  3.0 ± 0.3  2.3 ± 0.1  1.3 ± 0.3 
IL2  nd  nd  nd  nd  nd  nd 
IFNA1  nd  nd  nd  nd  nd  nd 
Chemokines and other ligands 
PTGS2  68 ± 13  106 ± 10  260 ± 107  0.6 ± 0.0  0.3 ± 0.0  0.2 ± 0.1 
CSF2  111 ± 21  436 ± 99  361 ± 125  0.5 ± 0.1  0.5 ± 0.1  0.6 ± 0.3 
CSF3  19 ± 4.9  343 ± 86  872 ± 285  1.1 ± 0.1  0.4 ± 0.1  0.2 ± 0.2 
CXCL10  16 ± 5.0  88 ± 49  497 ± 333  0.9 ± 0.0  0.3 ± 0.1  0.2 ± 0.0 
CCL2  4.8 ± 1.6  4.4 ± 1.0  220 ± 140  0.4 ± 0.1  0.3 ± 0.0  0.3 ± 0.0 
HSPA1A  2.1 ± 1.0  2.0 ± 0.4  2.1 ± 0.1  0.8 ± 0.2  0.8 ± 0.1  0.8 ± 0.1 
HSPD1  1.2 ± 0.0  1.5 ± 0.2  1.2 ± 0.1  1.0 ± 0.0  1.0 ± 0.1  1.3 ± 0.1 
HMGB1  1.0 ± 0.1  1.3 ± 0.1  0.7 ± 0.0  0.8 ± 0.0  0.9 ± 0.1  0.7 ± 0.0 
Receptors 
CLEC4E  4.6 ± 0.4  15 ± 2.6  7.4 ± 1.9  0.7 ± 0.1  0.5 ± 0.1  0.4 ± 0.1 
CD80  2.1 ± 0.4  14 ± 4.2  44 ± 15  0.7 ± 0.0  0.6 ± 0.0  0.8 ± 0.1 
CD86  0.7 ± 0.1  0.5 ± 0.1  0.4 ± 0.0  0.8 ± 0.2  1.1 ± 0.1  1.1 ± 0.1 
SIGIRR  0.9 ± 0.2  1.4 ± 0.1  0.9 ± 0.1  1.0 ± 0.1  1.0 ± 0.1  0.8 ± 0.1 
TNFRSF1A  0.5 ± 0.1  0.4 ± 0.0  0.7 ± 0.0  0.9 ± 0.0  1.0 ± 0.1  1.1 ± 0.1 
CD14  0.8 ± 0.2  0.8 ± 0.3  0.4 ± 0.1  1.1 ± 0.1  1.0 ± 0.1  0.7 ± 0.2 
RP105  0.3 ± 0.1  0.2 ± 0.0  0.4 ± 0.1  2.6 ± 0.3  2.3 ± 0.3  2.7 ± 0.9 
Toll-like Receptors 
TLR1  0.2 ± 0.0  0.1 ± 0.0  0.1 ± 0.0  1.3 ± 0.1  1.0 ± 0.0  3.4  ± 0.7 
TLR2  2.0 ± 0.0  3.0 ± 0.8  5.8 ± 2.7  0.8 ± 0.0  0.8 ± 0.1  0.8 ± 0.2 
TLR3  1.2 ± 0.2  1.6 ± 0.3  2.8 ± 1.0  0.9 ± 0.1  0.7 ± 0.1  0.6 ± 0.0 
TLR4  0.8 ± 0.1  2.0 ± 0.2  1.9 ± 0.4  1.2 ± 0.1  1.0 ± 0.1  0.8 ± 0.1 
TLR5  1.2 ± 0.1  1.6 ± 0.3  0.6 ± 0.1  1.1 ± 0.1  0.6 ± 0.1  0.7 ± 0.1 
TLR6  0.4 ± 0.1   0.5 ± 0.1  0.2 ± 0.0  1.0 ± 0.0  0.9 ± 0.0  1.0 ± 0.1 
TLR7  1.6 ± 0.3  3.9 ± 0.6  4.3 ± 0.4  0.9 ± 0.1  0.8 ± 0.0  0.8 ± 0.1 
TLR8  0.6 ± 0.1  1.0 ± 0.0  0.9 ± 0.1  1.1 ± 0.0  0.8 ± 0.0  1.2 ± 0.1 
TLR9  0.5 ± 0.1  0.9 ± 0.1  0.9 ± 0.3  1.6 ± 0.2  1.7 ± 0.4  0.5 ± 0.1 
TLR10  0.8 ± 0.1  1.2 ± 0.4  0.5 ± 0.1  1.4 ± 0.4  1.4 ± 0.2  1.3 ± 0.1   166 
  Fold regulation by LPS  Fold regulation by IL-4 
(+LPS) 
Gene  1h  2h  3h  1h  2h  3h 
TLR Adaptor molecules 
TICAM1  2.1 ± 0.3  2.9 ± 0.0  4.8 ± 0.7  0.9 ± 0.1  0.8 ± 0.1  0.7 ± 0.1 
TICAM2  0.4 ± 0.1  0.7 ± 0.1  0.6 ± 0.1  0.6 ± 0.1  1.1 ± 0.1  1.2 ± 0.1 
LY86  1.2 ± 0.2  1.0 ± 0.2  1.2 ± 0.3  1.1 ± 0.1  1.0 ± 0.1  1.0 ± 0.1 
LY96  0.9 ± 0.1  1.0 ± 0.0  0.7 ± 0.1  1.1 ± 0.1  1.0 ± 0.1  1.1 ± 0.2 
MYD88  0.9 ± 0.2  1.3 ± 0.0  2.2 ± 0.3  0.8 ± 0.0  0.6 ± 0.0  0.6 ± 0.1 
SARM1  1.0 ± 0.3  1.2 ± 0.1  1.0 ± 0.3  0.9 ± 0.1  0.8 ± 0.1  1.1 ± 0.2 
ECSIT  0.7 ± 0.1  0.9 ± 0.1  0.5 ± 0.1  1.1 ± 0.0  1.1 ± 0.1  1.0 ± 0.1 
TOLLIP  0.9 ± 0.1  0.6 ± 0.1  1.0 ± 0.1  0.8 ± 0.0  1.1 ± 0.1  1.4 ± 0.0 
TRAF  0.6 ± 0.0  1.0 ± 0.0  0.9 ± 0.1  0.9 ± 0.0  1.1 ± 0.1  1.2 ± 0.1 
TIRAP  0.5 ± 0.1  0.5 ± 0.0  0.4 ± 0.0  0.8 ± 0.1  0.9 ± 0.1  0.9 ± 0.1 
IκB/NF-κB pathway 
NFKB1A  11.5 ± 0.4  8.4 ± 0.5  11.1 ± 0.5  1.0 ± 0.0  0.8 ± 0.0  0.7 ± 0.0 
PEL1  4.4 ± 1.1  33.5 ± 4.1  26.9 ± 9.6  1.2 ± 0.0  1.0 ± 0.0  0.8 ± 0.1 
IRAK2  6.0 ± 0.1  19.4 ± 0.1  30.5 ± 14.2  0.7 ± 0.0  0.8 ± 0.1  0.7 ± 0.2 
IRAK1  1.0 ± 0.3  2.0 ± 0.2  1.1 ± 0.3  0.8 ± 0.0  0.9 ± 0.2  1.4 ± 0.6 
NFKBIL1  2.0 ± 0.7  0.6 ± 0.2  1.9 ± 0.8  0.7 ± 0.0  2.9 ± 0.9  0.3 ± 0.0 
TBK1  1.2 ± 0.1  1.5 ± 0.2  2.2 ± 0.3  0.9 ± 0.1  0.7 ± 0.1  0.7 ± 0.0 
CHUK  1.0 ± 0.0  0.8 ± 0.0  1.0 ± 0.1  1.0 ± 0.0  0.9 ± 0.0  1.0 ± 0.1 
IKBKB  1.2 ± 0.1  1.0 ± 0.1  0.9 ± 0.1  1.1 ± 0.2  1.1 ± 0.0  1.3 ± 0.0 
BTK  0.7 ± 0.1  0.5 ± 0.0  0.2 ± 0.0  1.0 ± 0.0  1.0 ± 0.0  1.6 ± 0.1 
MAPkinase pathways 
MAP2K3  1.5 ± 0.2  3.4 ± 0.4  3.7 ± 0.8  0.8 ± 0.0  0.7 ± 0.1  0.8 ± 0.0 
MAP4K4  1.0 ± 01  2.4 ± 0.4  5.8 ± 1.5  1.0 ± 0.1  0.7 ± 0.1  0.5 ± 0.1 
MAPK8  1.2 ± 0.1  1.5 ± 0.2  1.5 ± 0.1  0.9 ± 0.1  0.9 ± 0.0  0.8 ± 0.1 
MAP3K7  0.8 ± 0.0  0.7 ± 0.0  0.7 ± 0.1  1.0 ± 0.1  0.9 ± 0.1  1.0 ± 1.2 
MAP3K1  0.7 ± 0.2  0.9 ± 0.1  0.8 ± 0.1  1.1 ± 0.1  1.0 ± 0.1  1.0 ± 0.0 
MAP2K4  0.9 ± 0.1  0.7 ± 0.0  0.5 ± 0.0  1.0 ± 0.0  0.9 ± 0.1  1.0 ± 0.0 
MAPK8IP3  0.9 ± 0.2  0.7 ± 0.1  0.6 ± 0.1  1.0 ± 0.1  1.0 ± 0.1  1.2 ± 0.1 
MAP3K7IP1  0.7 ± 0.2  0.6 ± 0.1  0.5 ± 0.1  0.9 ± 0.1  1.1 ± 0.1  1.0 ± 0.1 
Transcription Factors 
NFKB1  3.1 ± 0.6  9.5 ± 1.4  11.6 ± 2.4  0.9 ± 0.1  0.9 ± 0.0  0.8 ± 0.0 
NFKB2  2.9 ± 0.5  5.1 ± 0.4  3.1 ± 0.4  1.0 ± 0.0  1.0 ± 0.1  0.7 ± 0.1 
REL  1.8 ± 0.5  5.3 ± 0.3  5.4 ± 1.6  1.0 ± 0.1  1.0 ± 0.0  0.8 ± 0.1 
RELA  1.1 ± 0.2  2.1 ± 0.1  2.6 ± 0.2  1.0 ± 0.0  1.1 ± 0.1  1.0 ± 0.1 
JUN  2.3 ± 1.0  2.3 ± 0.2  1.2 ± 0.1  0.8 ± 0.0  1.0 ± 0.1  1.3 ± 0.2 
IRF1  1.0 ± 0.4  4.2 ± 0.4  5.4 ± 0.4  0.6 ± 0.0  0.6 ± 0.0  0.6 ± 0.1 
IRF3  1.2 ± 0.1  0.8 ± 0.1  0.7 ± 0.1  1.1 ± 0.1  1.0 ± 0.1  0.8 ± 0.0 
ELK1  1.0 ± 0.1  0.9 ± 0.1  1.3 ± 0.1  1.0 ± 0.0  1.2 ± 0.1  1.4 ± 0.0 
FOS  1.2 ± 0.4  0.9 ± 0.2  0.4 ± 0.1  1.0 ± 0.1  0.8 ± 0.0  0.7 ± 0.1 
NFRKB  0.7 ± 0.2  0.8 ± 0.1  0.5 ± 0.1  1.0 ± 0.1  1.0 ± 0.0  1.1 ± 0.1 
NR2C2  0.9 ± 0.1  0.9 ± 0.0  0.6 ± 0.0  1.0 ± 0.1  0.9 ± 0.1  1.0 ± 0.1 
PPARA  0.8 ± 0.2  1.4 ± 0.1  0.5 ± 0.1  1.0 ± 0.0  0.9 ± 0.0  1.2 ± 0.1 
Miscellaneous 
EIF2AK2  0.8  ± 0.2  3.0  ± 0.8  18  ± 5.6  0.9  ± 0.1  0.8  ± 0.2  0.8  ± 0.1 
RIPK2  2.8  ± 0.7  5.7  ± 0.6  7.8  ± 0.8  2.8  ± 0.3  2.6  ± 0.1  1.5  ± 0.2 
PRKRA  1.0  ± 0.1  1.0  ± 0.1  0.8  ± 0.1  1.0  ± 0.0  1.0  ± 0.0  0.9  ± 0.1 
UBE2N  1.1  ± 0.1  1.6  ± 0.1  2.0  ± 0.1  0.9  ± 0.0  1.0  ± 0.0  1.0  ± 0.0 
UBE2V1  0.8  ± 0.3  0.8  ± 0.3  0.5  ± 0.1  0.8  ± 0.1  0.7  ± 0.2  0.7  ± 0.2 
HRAS  0.9  ± 0.1  0.9  ± 0.1  0.5  ± 0.1  0.9  ± 0.0  1.1  ± 0.0  1.6  ± 0.7  
CASP8  0.7  ± 0.1  0.6  ± 0.1  0.3  ± 0.1  1.0  ± 0.0  0.9  ± 0.1  1.0  ± 0.2 
FADD  0.3  ± 0.1  0.6  ± 0.0  0.5  ± 0.1  0.9  ± 0.1  1.2  ± 0.1  1.4  ± 0.2 
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8.2.3  IL-4 Causes an Early Up-regulation of IL10, RIPK2, RP105 and c-Maf mRNA 
in LPS-treated Human Monocytes 
In the first 3 h, IL-4 consistently and significantly increased mRNA levels for three 
genes in LPS-treated monocytes, namely the anti-inflammatory cytokine IL-10, the 
receptor-interacting serine threonine kinase, RIPK2 (also known as RIP2) and the 
TLR-like molecule, RP105 (CD180) (Fig. 8.2A, Table 8.1). In untreated monocytes, 
IL-10 and RP105 mRNA levels did not change significantly with 3 h of culture (Fig. 
8.2A and D), while RIPK2 mRNA levels were downregulated by culture (Fig 8.2C). 
When comparing expression to untreated cells, LPS up-regulated IL-10 mRNA at 2 
and 3 h (Fig. 8.2B), reversed the downregulation of RIPK2 mRNA from 1 h (Fig. 
8.2C), and down-regulated RP105 mRNA at 1, 2 and 3 h (Fig. 8.2D). 
 
IL-4 enhanced LPS-induced IL-10 and RIPK2 mRNA expression at 1 and 2 h, but not 
at 3 h (Fig. 8.2B and C). This transient enhancement of IL-10 and RIPK2 mRNA by 
IL-4 preceded the down-regulation of inflammatory cytokines and chemokines by IL-
4  (Fig.  8.1),  identifying  them  as  candidate  genes  in  the  regulation  of  the  anti-
inflammatory actions of IL-4 in human monocytes. While IL-4 reversed the down-
regulation  of  RP105  mRNA  by  LPS  at  1,  2  and  3  h  (Fig.  8.3D),  an  analysis  of 
expression of the translated product of RP105 using flow cytometry determined that 
IL-4 failed to up-regulate expression of the RP105 receptor at the cell surface. The 
role  of  RP105  in  the  regulation  of  responses  to  LPS  and  IL-4  by  monocytes  is 
discussed in more detail in Chapter 9. 
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Figure 8.2:   IL-4  up-regulates  mRNA  levels  of  IL-10,  RIPK2  and  RP105  in 
LPS-treated human monocytes. The expression of 84 mRNAs in freshly isolated 
human monocytes treated with LPS and IL-4 was assessed using the Human TLR-
signalling pathway RT2 Profiler PCR; results for genes significantly up-regulated by 
IL-4 are shown (see also Table 8.1). (A) Fold increase in mRNA for IL-10, RIPK2 
and RP105 by IL-4 in LPS treated human monocytes after 1, 2 and 3 h. An asterisk 
indicates significant (p<0.05) and more than 2 fold increases by IL-4. (B-D) Fold 
increases in mRNA for IL-10, RIPK2 and RP105, assessed using the Human TLR-
signalling pathway RT2 Profiler PCR, in the first 3 h after treatment with medium, 
LPS and LPS + IL-4. Fold changes are calculated relative to mRNA levels in freshly 
isolated monocytes. Significant (p<0.05) increases or decreases by LPS relative to 
untreated  monocytes  are  indicated  by  a  hash.  Significant  and  more  than  2-fold 
increases by IL-4 from LPS-induced levels are indicated by an asterisk. Results are 
for three independent experiments (mean ± SEM).   169 
The up-regulation of IL-10 and RIPK2 mRNA by IL-4 over a 24 h time course was 
confirmed  using  real-time  PCR  with  primers  designed  in  house  (Fig.  8.3).  In 
concordance with the array data, IL-4 significantly enhanced LPS induced-IL-10 (Fig. 
8.3A) and RIPK2 mRNA (Fig. 8.3B), at 1 and 2 h. IL-4 had no effect on RIPK2 or 
IL-10 mRNA levels in the absence of LPS. In untreated monocytes, RIPK2 mRNA 
levels decreased with culture, while IL-10 mRNA levels were not changed by culture 
over 24 h. 
 
The mRNA expression of the transcription factor, c-Maf, was also profiled because it 
is induced by IL-4 and is required for the regulation of IL-10 gene expression in LPS-
activated  monocytes  and  macrophages  (200)  (Fig.  8.3C).  c-Maf  mRNA  levels 
increased  with  culture  and  at  24  h  this  up-regulation  was  reversed  by  LPS.  IL-4 
significantly increased c-Maf expression by monocytes from 1 h. This up-regulation 
of c-Maf mRNA by IL-4 was stronger in the absence of LPS, suggesting that LPS 
down-regulates IL-4-induced c-Maf.  
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Figure 8.3:   Confirmation of IL-10, RIPK2 and c-Maf expression using real-
time PCR. IL-10, RIPK2 and c-Maf mRNA expression was confirmed using real-
time PCRs with primers designed in house. Fold increases in mRNA for IL-10 (A), 
RIPK2 (B) and c-Maf (C), relative to mRNA levels in freshly isolated monocytes, 
were measured after incubation for 24 h with medium, IL-4, LPS and LPS + IL-4. 
Shown are pooled results (mean ± SEM) from 3 separate donors. An asterisk indicates 
a significant increase by  IL-4 in  LPS-treated cells. A significant increase by  IL-4 
alone is indicated with a cross. A significant increase or decrease by LPS relative to 
untreated monocytes is indicated by a hash.  
 
 
 
 
 
 
   171 
8.2.4  The Early Up-regulation of LPS-induced IL-10 Secretion by IL-4 Correlates 
with the Early Suppression of LPS-induced TNFα Production by IL-4 
IL-10  is  an  anti-inflammatory  cytokine  which  suppresses  inflammatory  cytokine 
release by activated monocytes and macrophages (54). Therefore it was hypothesised 
that the early up-regulation of IL-10 mRNA by IL-4 in LPS-treated human monocytes 
may  be  part  of  the  mechanism  by  which  IL-4  suppresses  LPS-induced  TNFα 
production.  The  enhancement  of  IL-10  production  by  IL-4  was  confirmed  at  the 
protein level and compared with the kinetics by which IL-4 suppressed LPS-induced 
TNFα production in human monocytes (Fig. 8.4A and B) and murine BMM (Fig. 
8.4C and D).  
 
LPS induced TNFα production (Fig. 8.4B and D) much earlier and more rapidly than 
it induced IL-10 production (Fig. 8.4A and C). Consistent with the mRNA data, IL-4 
had no effect on IL-10 production by human monocytes in the absence of LPS (Fig. 
8.4A), but significantly enhanced early LPS-induced IL-10 secretion by more than 3-
fold at 2 and 3 h (Fig. 8.4A). This early enhancement of IL-10 secretion by IL-4 
correlated with a significant suppression of LPS-induced TNFα production by IL-4 at 
2 and 3 h (Fig. 8.4B). In human monocytes the enhancement of LPS-induced IL-10 
production by IL-4 was transient and IL-4 significantly suppressed IL-10 and TNFα 
production  at  24  h  (Fig.  8.4A  and  B).  In  murine  BMM,  IL-4  caused  a  2.5-fold 
increase in LPS-induced IL-10 production at 3 h (Fig. 8.4C), which correlated with a 
weaker, but significant  suppression of LPS-induced TNFα production at 3 h (Fig. 
8.4D).  However,  in  contrast  to  human  monocytes,  the  enhancement  of  IL-10 
production by IL-4 in murine BMM was sustained over the 24 h period (Fig. 8.3C).  
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Figure 8.4:   IL-4  up-regulation  of  LPS-induced  IL-10  secretion  by  human 
monocytes  and  murine  BMM  correlates  with  a  suppression  of  LPS-induced 
TNFα production. IL-10 and TNFα protein in supernatants was assayed in freshly 
isolated human monocytes (mean + SEM, n=3 donors), 2, 3 and 24 h after incubation 
with LPS (500 ng/ml) ± IL-4 (10 ng/ml) and in murine BMM (mean + SEM, n=3 
individual mice), 3 and 24 h after incubation with LPS (10 ng/ml) ± IL-4 (10 ng/ml). 
The early up-regulation of IL-10 by IL-4 in human monocytes (A) and murine BMM 
(C) correlated with a suppression of LPS-induced TNFα production by both human 
monocytes (B) and murine BMM (D). An asterisk indicates a significant suppression 
of TNFα production by IL-4 from LPS-induced levels (p<0.05). A hash indicates a 
significant enhancement by IL-4 of LPS-induced levels of secreted IL-10 relative to 
controls. 
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8.2.5  The  Suppression  of  LPS-induced  TNFα  Production  by  IL-4  Occurs 
Independently of IL-10 
To  determine  if  the  suppression  of  LPS-induced  TNFα  production  by  IL-4  was 
mediated by the  early  enhancement of  LPS-induced  IL-10 secretion by  IL-4, two 
approaches were used (Fig. 8.5). Firstly, the activity of secreted IL-10 was blocked 
using a neutralising antibody to IL-10 in human monocytes (Fig. 8.5A and B) and 
secondly, using BMM from mice lacking IL-10 (IL10
-/-) (Fig. 8.5C and D).  
 
Activity of the IL-10 neutralising antibody was confirmed by pre-incubating 10 µg/ml 
of the antibody with recombinant human IL-10 (10 ng/ml) for 30 min prior to the 
addition  of  monocytes  and  LPS.  IL-10  strongly  suppressed  LPS-induced  TNFα 
production by human monocytes in the absences of antibodies and in the presence of 
an  IgG  control  antibody.  However,  IL-10  had  no  effect  on  LPS-induced  IL-10 
production in the presence of the neutralising antibody, indicating that the antibody 
effectively blocked the biological activity of IL-10.  In human monocytes, an IgG 
control antibody had no effect on the suppression of LPS-induced TNFα production 
by IL-4 at 3 h (Fig. 8.5A) or 24 h (Fig. 8.5B), while the IL-10 neutralising antibody 
significantly enhanced LPS-induced TNFα production by 6-fold at 24 h (Fig. 8.5B). 
However, IL-4 maintained the ability to suppress LPS-induced TNFα production in 
the presence of the IL-10 neutralising antibody at both 3 h and 24 h (Fig. 8.5A and B).  
 
 BMM from IL10
-/- mice did not produce detectable levels of IL-10 in response to 
LPS, confirming that the IL-10 gene was knocked out. In accordance with this, IL10
-/- 
BMM produced significantly higher levels of TNFα in response to LPS than wildtype 
(C57BL/6) mice, particularly at 24 h (Fig. 8.5 C and 4D). However, IL-4 maintained   174 
the ability to suppress LPS-induced TNFα production from IL10
-/- murine BMM, at 
both 3 h and 24 h.  
 
 
Figure 8.5:   The  suppression  of  LPS  induced  TNFα  production  by  IL-4  is 
independent of the early up-regulation of LPS-induced IL-10. A and B. Effect of 
IL-4 on LPS-induced TNFα production by freshly isolated human monocytes in the 
presence of an IL-10 neutralising antibody (mean + SEM, n=3 donors). TNFα levels 
were assayed in supernatants from human monocytes incubated for 3 h (A) and 24 h 
(B) with LPS (500 ng/ml) ± IL-4 (10 ng/ml) with or without 10 µg/ml of anti-IL-10 
antibody or isotype control antibody added at the same time as LPS and IL-4. (C and 
D) Effect of IL-4 on LPS-induced TNFα production by BMM from wildtype and 
IL10
-/-  mice  (mean  +  SEM,  n=3  individual  mice  per  group).  TNFα  levels  were 
assayed in supernatants from BMM incubated for 3 h (C) and 24 h (D) with LPS (10 
ng/ml) ± IL-4 (10 ng/ml) (mean + SEM, n=3 individual mice). An asterisk indicates a 
significant suppression by IL-4 from LPS-induced levels (p<0.05). A hash indicates a 
significant enhancement in LPS-induced levels relative to controls.    175 
8.2.6  The Up-regulation of RIPK2 and RP105 by IL-4 in LPS-treated Monocytes 
Occurs Independently of IL-10 
To  determine  whether  the  up-regulation  of  anti-inflammatory  genes  by  IL-4  was 
mediated indirectly by IL-10, firstly RIPK2 and RP105 mRNA levels were measured 
in  LPS-treated  monocytes  treated  with  either  IL-4  or  IL-10  (Fig.  5A  and  B).  In 
contrast to IL-4, which up-regulated RIPK2 and RP105 mRNA in the presence of 
LPS, IL-10 down-regulated LPS-induced RIPK2 mRNA to levels seen in untreated 
monocytes  (Fig. 8.6A) and had no effect on RP105 mRNA levels (Fig. 8.6B).  
 
 
 
Figure 8.6:   IL-10  and  IL-4  have  distinct  effects  on  RIPK2  and  RP105 
expression in LPS-treated human monocytes. Fold increases in mRNA for RIPK2 
(A) and  RP105 (B), relative to mRNA levels in freshly isolated monocytes, measured 
24 h after incubation with medium or LPS (500 ng/ml), with and without IL-4 (10 
ng/ml) or IL-10 (10 ng/ml). Shown are pooled results (mean ± SEM) from 3 separate 
donors. An asterisk indicates a significant (p<0.05) increase in mRNA levels by IL-4 
in  LPS  treated  cells.  A  significant  decrease  in  mRNA  expression  of  these  genes 
induced by IL-10 is indicated with a hash. 
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Secondly,  the  effect  of  IL-4  on  RIPK2  and  RP105  mRNA  was  analysed  in  the 
presence  or  absence  of  a  neutralising  antibody  to  IL-10  (Fig.  8.7A  and  B). 
Neutralisation of IL-10 did not prevent the up-regulation of RIPK2 (Fig. 8.7A) and 
RP105 (Fig. 8.7B) by IL-4 in LPS-treated human monocytes at 2 or 24 h. Thus, the 
up-regulation  of  RIPK2  and  RP105  mRNA  by  IL-4  is  independent  of  IL-10. 
However, the IL-10 neutralising antibody significantly enhanced LPS-induced RIPK2 
mRNA  at  24  h  (Fig.  5C),  suggesting  that  LPS-induced  IL-10  may  down-regulate 
RIPK2 expression.  
 
 
 
Figure 8.7:   IL-4 up-regulation of RIPK2 and RP105 expression in LPS-treated 
human monocytes occurs independently of IL-10. Fold increases in mRNA levels 
for  RIPK2  (A)  and    RP105  (B),  relative  to  mRNA  levels  in  freshly  isolated 
monocytes, measured 2 h and 24 h after treatment with LPS, with and without IL-4 in 
the presence (shaded bars) or absence (white bars) of a neutralising antibody to IL-10 
(10  µg/ml),  added  at  the  same  time  as  LPS  and  IL-4.  An  asterisk  indicates  a 
significant and more than 2-fold increase in mRNA levels by IL-4 relative to LPS-
treated  monocytes.  A  significant  change  in  gene  expression  caused  by  the  IL-10 
neutralising antibody are shown with a hash (mean + SEM, pooled results from three 
separate experiments).    177 
 
8.2.7  RIPK2  Kinase  Inhibitors  do  not  Prevent  the  Suppression  of  LPS-induced 
TNFα Production or Enhancement of LPS-induced IL-10 production by IL-4 
IL-4-induced  RIPK2  may  mediate  the  regulation  of  LPS-induced  TNFα  or  IL-10 
production by IL-4. SB-203580 and PP2 were originally identified as inhibitors of 
p38  MAPK  and  Src  family  kinases,  respectively.  However,  they  were  recently 
discovered to inhibit RIPK2 kinase activity with even greater potency (311, 312). 
Therefore, to determine the role of IL-4-induced RIPK2, the effect of PP2 (1 µM) and 
SB-203580 (1 µM) on IL-4 regulation of LPS-induced TNFα and IL-10 production by 
human monocytes was measured (Fig. 8.8).  
 
PP2  and  SB-203580  significantly  reduced  LPS-induced  TNFα  production  at  24  h 
(Fig. 8.8B). This may partly be due to inhibition of RIPK2, which plays a key role in 
TLR signalling (318, 319)  but is also likely to be due to inhibition of p38 MAPK and 
Src  family  kinases,  which  are  crucial  to  LPS-activation  of  TNF  transcription  and 
mRNA stability (16, 166, 313). However, neither inhibitor prevented the suppression 
of LPS-induced TNFα production by IL-4 at 3 h (Fig. 8.8A) or 24 h (Fig. 8.8B). 
 
Similarly,  while  PP2  and  SB-203580  significantly  reduced  LPS-induced  IL-10 
production at 24 h (Fig. 8.8D), neither inhibitor prevented the up-regulation of LPS-
induced  IL-10 production by  IL-4 at  3 h (Fig. 8.8C), or the suppression  of  LPS-
induced IL-10 production by IL-4 at 24 h (Fig. 8.8D).  
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Figure 8.8:   RIPK2  kinase  inhibitors  do  not  prevent  the  anti-inflammatory 
actions of IL-4 in LPS-treated human monocytes. TNFα and IL-10 levels were 
assayed in supernatants from freshly isolated human monocytes incubated for 3 and 
24 h with  LPS (500 ng/ml)  ±  IL-4 (10 ng/ml), with  or without PP2 (1  µM) and 
SB203580 (1 µM). Inhibitors were pre-incubated with cells for 1 h before addition of 
LPS, IL-4 and IL-10. (A and B) Effect of RIPK2 inhibitors on the suppression of 
LPS-induced  TNFα  production  by  IL-4  at  3  h  and  24  h.  (C)  Effect  of  RIPK2 
inhibitors on the enhancement of LPS-induced IL-10 production by IL-4 at 3 h. (D) 
Effect of RIPK2 inhibitors on suppression of LPS-induced IL-10 production by IL-4 
at 24 h. TNFα and IL-10 levels have been calculated as the percentage of the LPS-
induced levels (100%), when no inhibitors are present. Significant suppressions of IL-
10 and TNFα production by IL-4, from LPS-induced levels (p<0.05) are shown with 
an asterisk. A significant enhancement of IL-10 production by IL-4 from LPS-induced 
levels  is  indicated  by  a  cross.  Significant  changes  in  TNFα  or  IL-10  from  LPS 
induced  levels  caused  by  the  inhibitors  are  indicated  with  a  hash  (mean  +  SEM, 
pooled results from three separate experiments).   179 
8.3  Discussion 
Characterisation of the transcriptional changes induced by IL-4 on genes specific to 
TLR signalling pathways may improve our understanding of how IL-4 exerts its anti-
inflammatory  actions  in  human  monocytes  and  macrophages.  Consistent  with 
previous  studies  (49,  100),  IL-4  significantly  down-regulated  the  expression  of 
inflammatory cytokines and chemokines by LPS-treated human monocytes. Although 
this  inhibition  required  new  protein  synthesis  (141-143),  we  found  it  was  not 
mediated by direct transcriptional regulation of TLR-signalling genes, suggesting that 
the production of a second cytokine or the synergistic up-regulation of an unknown 
transcription factor might be responsible. Our gene array profiling identified three 
potential candidates: IL-10, RIPK2 and c-Maf, which were up-regulated by IL-4 in a 
timeframe consistent with the effects of IL-4 on LPS-induced TNFαproduction.  
 
The enhancement of early LPS-induced IL-10 secretion by IL-4 (Fig. 8.4 A and C) is 
likely to be mediated by c-Maf (200), a transcription factor which was induced by IL-
4 from 1 h and remained up-regulated over 24 h (Fig. 8.3C). However, in freshly 
isolated human monocytes, but not murine BMM, IL-4 suppressed LPS-induced IL-
10 at 24 h (Fig. 8.4A), indicating that IL-4 inhibits a second pathway mediating late 
LPS-induced  cytokine  production,  possibly  TRIF-dependent  signalling  (314).  The 
early enhancement of LPS-induced IL-10 secretion by IL-4 in human monocytes and 
murine BMM correlated with the early suppression of LPS-induced TNFα production 
by IL-4 (Fig. 8.4). While this enhancement of IL-10 by IL-4 was relatively small at 3 
h (<0.5 ng IL-10 per 10
6 cells in 1 ml culture medium) (Fig. 8.4A), it was at a level 
sufficient to initiate a suppression because exogenously added IL-10 at concentrations 
as low 0.1 ng/ml can suppress LPS-induced TNFα production (data not shown). LPS-
induced TNFα production at 24 h was dramatically enhanced in the presence of an IL-  180 
10 neutralising antibody in human monocytes and in murine IL10
-/- BMM suggesting 
that LPS-induced IL-10 plays a key role in terminating late LPS responses (315). 
However, in both cell types, IL-4 maintained the ability to suppress  LPS-induced 
TNFα production in the absence of IL-10 (Fig. 8.5). Therefore the suppression of 
inflammatory  cytokine  production  by  IL-4  is  mediated  independently  of  the  early 
enhancement of IL-10 production.  
 
The up-regulation of RIPK2 and RP105 mRNA by IL-4 also occurred independently 
of  IL-10  (Fig.  8.7).  Furthermore,  IL-10  had  effects  on  gene  expression  that  were 
distinct from IL-4; IL-10 down-regulated LPS-induced RIPK2 mRNA (Fig. 8.6A) and 
had no effect on RP105 expression (Fig. 8.6B). Our findings support previous studies 
concluding  that  IL-4  and  IL-10  activate  distinct  gene  profiles  in  monocytes  and 
macrophages (307, 316) and that the anti-inflammatory actions of IL-4 and IL-10 are 
mechanistically distinct (146, 148). The different actions of IL-4 and IL-10 can in part 
be explained by the fact that many of IL-4’s anti-inflammatory actions are mediated 
by STAT6 (136-138), while IL-10’s actions are largely dependent on STAT3 (317). 
 
 
IL-4 up-regulated LPS-induced RIPK2, a mediator of innate immunity required for 
optimal signalling through TLRs (318, 319) and NOD receptors (320). While RIPK2 
was previously up-regulated in a gene array on alternatively activated macrophages 
(308), the function of IL-4-induced RIPK2 is unknown. RIPK2 is recruited by insulin-
like growth factor-1 (IGF-1) receptor following IGF-1 binding (321), suggesting that 
RIPK2 may be recruited to the IL-4 receptor because like IGF-1, IL-4 activates the 
Ras/ MAPK pathway via insulin receptor substrate (IRS)-1 and IRS-2 (90). It was 
hypothesised IL-4-induced RIPK2 mediates the suppression of TNFα production by 
IL-4,  possibly  via  ubiquitinylation  or  proteosomal  degradation  of  LPS  signalling   181 
components.  For  instance,  NOD2-induced  RIPK2  ubiquitinylates  IKKγ,  a  key 
component of TLR signalling (322) and IL-4-induced ubiquitination and proteosomal 
degradation of  SHIP,  a  regulator of TLR signalling, occurs  via recruitment of  an 
unidentified  PP2-inhibitable  kinase,  possibly  RIPK2  (233).  However,  the  two 
inhibitors  of  RIPK2  kinase  activity,  SB203580  and  PP2,  did  not  prevent  the 
suppression  of  LPS-induced  TNFα  by  IL-4  (Fig.  8.8A  and  B).  Furthermore,  the 
proteasome inhibitor, MG-132 (10 µM), also had no effect on the suppression of LPS-
induced  TNFα  production  by  IL-4,  suggesting  the  actions  of  IL-4  are  mediated 
independently of proteosomal degradation (see Chapter 4, Fig. 4.8B).  
 
RIPK2 is required for secretion of IL-10 induced by Streptococcus pneumoniae in 
murine BMM  by  mediating cross-talk between  TLR2  and NOD2 receptors (323). 
Hence IL-4-induced RIPK2 may mediate the enhancement of IL-10 production by IL-
4 in LPS-treated monocytes. Exogenously added IL-10 (Fig. 8.6A) and LPS-induced 
IL-10 at 24 h (Fig. 8.7A) down-regulated RIPK2 expression in human monocytes, 
supporting a role for RIPK2 in the regulation of IL-10 production. However, RIPK2 
kinase inhibition did not prevent the enhancement of LPS-induced IL-10 by IL-4 at 3 
h (Fig. 6C). In conclusion, the anti-inflammatory actions of IL-4 in human monocytes 
do not require the kinase activity of RIPK2. However, because RIPK2 also functions 
independently of its kinase activity and serves as an adaptor molecule (322), the role 
of IL-4-induced RIPK2 in the regulation of LPS-induced TNFα and IL-10 production 
requires further investigation. 
 
Interestingly,  IL-4  failed  to  regulate  many  NF-κB  responsive  genes  in  the  array, 
including  IκB  and  RelA  (Table  8.1),  suggesting  that  IL-4  may  down-regulate 
inflammatory cytokine and chemokine expression independently of a block in NF-κB   182 
activation. Instead, the anti-inflammatory actions of IL-4 may be mediated by the 
induction of a transcriptional repressor or transcription factor. A possible candidate is 
the transcription factor, c-Maf, which was induced by IL-4 (Fig. 8.3C), and mediates 
the up-regulation of IL-10 (200). While IL-4-induced IL-10 did not regulate the anti-
inflammatory actions of IL-4 in monocytes, overexpression of c-Maf suppresses LPS-
induced IL-12 transcription (324), suggesting that c-Maf may directly regulate the 
transcription of inflammatory genes. In our studies the enhancement of c-Maf and IL-
10 by IL-4 was weaker in more differentiated monocytes (data not shown); in these 
more differentiated cells, IL-4 has an impaired ability to suppress LPS-induced TNFα 
production (see Chapter 3). However, the suppressive actions of c-Maf are reported to 
be relatively specific to IL-12 (324). It remains possible that IL-4-induced c-Maf is 
responsible for up-regulation by IL-4 of anti-inflammatory genes, other than IL-10. 
 
Further  investigations  into  the  role  of  IL-4-induced  c-Maf  were  restricted  by  an 
absence  of  c-Maf  inhibitors.  Similarly,  RIPK2  could  only  be  inhibited  with  non-
specific kinase inhibitors, while many of the functions of RIPK2 may be independent 
of its kinase activity. Therefore overexpression or knockdown studies are required to 
further delineate the function of IL-4-induced RIPK2 and c-Maf. Like the present 
investigations, these should be performed using primary human monocytes. However, 
adenoviral vectors encoding potential regulatory molecules activate  IFN-dependent 
pathways  and  complicate  studies  of  the  TLR  pathways  in  monocytes  and 
macrophages  (172).  Alternatively,  studies  could  be  conducted  on  transfected 
monocyte and macrophage cell lines, using siRNA to these genes, or on cells from 
gene knockout mice. It must be noted however, that fundamental differences in IL-4 
signalling exist between cell lines, murine cells and human cells (142-150).    183 
 
In conclusion, IL-4 caused an early up-regulation of IL-10, RIPK2 and c-Maf mRNA, 
however, the anti-inflammatory actions of IL-4 occurred independently of IL-10 and 
the  kinase  activity  of  RIPK2.  Additional  studies,  including  gene  arrays  on  c-Maf 
deficient monocytes, may delineate whether c-Maf mediates any of the changes in 
gene expression induced by  IL-4 in  LPS-treated monocytes. Our customised gene 
arrays focused on only  a small subset of  TLR-related signalling  genes. Therefore 
broader gene arrays may be required to identify additional candidate genes induced by 
IL-4.  Furthermore,  while  our  gene  arrays  failed  to  identify  any  effect  of  IL-4  on 
mRNA levels of TLR signalling components, the product of some of these genes may 
be altered by IL-4 at the protein level. For instance, the translation of TLR-related 
genes  may  be  altered  by  IL-4  through  modification  of  micro-RNA  (miRNA) 
expression (325, 326). Proteomic analysis, which allows a more detailed analysis of 
the protein profiles of monocytes (174) along with profiling of miRNA expression 
profiles induced by IL-4 in LPS-treated human monocytes, may identify new targets 
of IL-4 in the regulation of the TLR signalling cascade.  
   185 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Nine 
 
Role of RP105 in the Regulation of Monocyte 
Responses to LPS and IL-4 
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9.1  Introduction 
TLR  signalling  must  be  tightly  regulated  at  a  number  of  levels  to  prevent  an 
exaggerated response to pathogens and adverse effects on the host, inflammation of 
host tissue and septic shock (12). Such regulatory mechanisms include the induction 
of negative regulators, blockade of intracellular signalling events, the loss of surface 
expression components of the TLR signalling complex, namely TLR, CD14 and MD-
2, and up-regulation of anti-inflammatory cytokines, including IL-4 (327). A better 
understanding of these processes may lead to novel therapeutic approaches to control 
dysregulated inflammatory responses. 
 
In Chapter 8, profiling the expression of multiple TLR signalling genes found that the 
down-regulation of LPS-induced inflammatory genes by IL-4 correlated with an up-
regulation of RP105 mRNA. RP105 is a TLR-like molecule belonging specifically to 
the TLR4 subfamily (328-330). Like TLR4, which is associated with the secreted 
extracellular protein MD-2, RP105 requires the MD-2 homolog, MD-1, for its proper 
surface  expression  and  function  (331,  332).  RP105  is  an  important  biological 
modulator of TLR4 signalling. In B cells it facilitates TLR4 signalling, drives B cell 
proliferation and protects against apoptosis (333-335). However, in macrophages and 
dendritic  cells,  RP105  is  a  negative  regulator  of  TLR4-mediated  activation  and 
inhibits LPS-induced inflammatory cytokine production (330, 336).   
 
RP105  lacks  the  intracellular  Toll/  Interleukin-1  receptor  (TIR)  domain  that  is 
required for TLR signal transduction via adapters such as MyD88, and its effects are 
mediated  by  associating  with,  and  influencing,  signalling  of  other  receptors.  The 
inhibition of TLR4 signalling by RP105–MD-1 occurs by a direct interaction with   187 
TLR4–MD-2 complexes. Because the extracellular domain of RP105 is sufficient for 
suppression (330),
 it is likely that the interaction with the TLR4 signalling complex 
occurs at the cell surface. RP105 inhibits LPS binding to TLR4 without binding LPS 
directly (330, 337), suggesting the suppression may be in part mediated by inhibiting 
TLR4 binding to microbial ligand. The inhibitory actions of RP105 are specific to 
TLR4 as RP105 fails to suppress TLR9- and TLR2-driven cytokine production (330). 
Rather, the RP105/MD-1 complex facilitates TLR2 signalling and enhances TLR2-
driven  cytokine  production  in  Mycobacterium  tuberculosis-infected  macrophages. 
These findings identified RP105 as an accessory molecule for TLR2 and potentially 
other receptors (338).  
 
RP105-deficient  mice  produce  significantly  more  systemic  TNFα  and  exhibit 
substantial  acceleration  and  amplification  of  endotoxicity  in  response  to  LPS 
challenge (330). They also have accelerated onset and increased severity of collagen- 
and LPS-induced arthritis (339), suggesting that RP105 plays an important role in the 
regulation of in vivo LPS responses and inflammatory disease. It has been proposed 
that  RP105  also  down-regulates  responses  to  LPS  during  endotoxin  tolerance. 
However, RP105 expression has only been analysed at the mRNA level following 
LPS treatment in human and mouse DCs (330). Therefore, it is unclear whether the 
LPS-induced loss of CD14 and TLR4, which occurs during endotoxin tolerance, is 
also accompanied by a concurrent up-regulation of cell surface RP105.  Our study is 
the first to identify that IL-4 up-regulates RP105 mRNA, however the exact function 
of IL-4-induced RP105 is unknown. We hypothesised IL-4-induced RP105 may be 
responsible  for  regulating  the  anti-inflammatory  actions  of  IL-4  in  LPS-treated 
monocytes.    188 
To further determine the role of RP105 in regulating responses of monocytes to both 
LPS and IL-4, flow cytometry was used to characterise intracellular and cell surface 
expression of RP105 in  LPS-  and  IL-4-treated  human monocytes.  To  account  for 
changes in the expression of the TLR signalling complex that may be induced by 
LPS, the expression of RP105 was correlated with TLR4 and CD14 expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1:  Negative regulation of TLR4 signalling by RP105. RP105 is a cell 
surface  receptor,  homologous  in  structure  to  TLR4,  but  it  lacks  the  TIR  domain 
required for intracellular signalling. In macrophages and DCs, RP105-MD-1 directly 
interacts with TLR4-MD-2 complexes at the cell surface to inhibit LPS-signalling 
through  the  MyD88-dependent  pathways  of  TLR4  and  LPS-activation  of 
inflammatory genes. IL-4 up-regulates RP105 mRNA in LPS-treated monocytes, but 
it is unclear whether this up-regulation also occurs at the cell surface to mediate the 
anti-inflammatory action of IL-4 in these cells. Adapted from Divanovic et al. 2007 
(336). 
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9.2  Results 
9.2.1  Effect of LPS and IL-4 on mRNA levels of RP105, TLR4 and CD14 in Human 
Monocytes 
In Chapter 8, gene arrays were used to profile the expression of 84 genes related to 
TLR-mediated signal transduction in human monocytes treated with the TLR4 ligand, 
LPS (500 ng/ml), with or without IL-4 (10 ng/ml). In the first 3 h, IL-4 significantly 
increased  RP105  mRNA  levels  in  LPS-treated  monocytes.  When  comparing 
expression to untreated cells, LPS significantly down-regulated RP105 mRNA in the 
first 3 h and IL-4 reversed this down-regulation (Fig. 9.2A). LPS and IL-4 had no 
effect on the mRNA expression of MD-1, the co-expressed helper molecule of RP105 
(Fig. 9.2B). LPS and IL-4 also had no effect on mRNA levels of TLR4 (Fig. 9.2C) 
and its co-expressed protein MD-2 (Fig. 9.2D). However LPS caused a small but 
significant decrease in CD14 mRNA expression 3 h after treatment (Fig. 9.2E). 
 
The up-regulation of RP105 mRNA by IL-4 over a 24 h time course was confirmed 
using real-time PCRs with primers designed in house (Fig. 9.3). In concordance with 
the  array  data,  LPS  down-regulated  RP105  mRNA  and  this  down-regulation  was 
reversed  by  IL-4,  to  levels  seen  in  untreated  cells.  Culture  on  its  own  had  no 
significant  effect  on RP105 mRNA in the first 3  h, but  by 24  h caused a 6 fold 
increase from baseline levels. The effect of IL-4 was also examined in the absence of 
LPS,  IL-4  dramatically  enhanced  RP105  mRNA  levels  causing  up  to  an  18  fold 
increase compared to untreated monocytes 3 and 24 h after initiation of culture.  
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Figure 9.2:  Effect of LPS and IL-4 on mRNA levels of RP105/ MD-1, TLR4/ 
MD-2 and CD14 in human monocytes. The expression of 84 mRNAs in human 
monocytes treated with LPS and IL-4 was assessed using the Human TLR-signalling 
pathway RT2 Profiler PCR; results for five genes encoding for components of the 
TLR4 and RP105 signalling complexes are shown. Fold increases in mRNA for A. 
RP105, B. MD-1, C. TLR4, D. MD-2 and E. CD14 in the first 3 h after treatment with 
medium, LPS and LPS + IL-4 relative to mRNA levels in freshly isolated monocytes. 
Results were pooled from 3 separate donors (mean ± SEM). An asterisk indicates a 
significant (p<0.05) and more than 2 fold increase by IL-4. A significant decrease by 
LPS relative to untreated monocytes is indicated by a hash. 
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Figure 9.3:  Confirmation  of  RP105  expression  using  real-time  PCR.  RP105 
mRNA  expression  was  confirmed  using  real-time  PCRs  with  primers designed  in 
house.  Fold  increases  in  mRNA  for  RP105,  relative  to  mRNA  levels  in  freshly 
isolated monocytes, were measured after incubation for 24 h with medium, IL-4, LPS 
and LPS + IL-4. Shown are pooled results (mean ± SEM) from 3 separate donors. An 
asterisk indicates a significant increase by IL-4 in LPS treated cells. A significant 
decrease by LPS relative to untreated monocytes is indicated by a hash 
 
 
9.2.2  LPS Causes a Transient Loss of Cell Surface CD14 Expression in Human 
Monocytes which is Coupled with a Loss of RP105 and TLR4 Expression 
CD14  expression  was  measured  firstly  as  a  marker  for  cells  of  the  monocyte/ 
macrophage lineage, distinguishing these cells from lymphocytes and other PBMCs. 
CD14  expression  was  also  important  because  it  is  an  essential  part  of  the  TLR4 
signalling complex. Loss of surface CD14 in monocytes reduces responsiveness to 
LPS and is one of the factors mediating endotoxin tolerance (346, 347). Monocytes 
were defined by flow cytometric analysis as the larger cells as determined by forward- 
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and side-scatter (Fig. 9.4A). This was confirmed by CD14 expression, with (69% ± 
3%, mean ± SEM, n=3 donors) of the larger cells expressing CD14 (Fig. 9.4B), while 
the  smaller  cells  outside  of  the  gate,  proposed  to  be  mainly  lymphocytes,  were 
predominantly  CD14-negative  (data  not  shown).  Of  the  CD14-positive  monocytes 
almost  all  (95%  ±  4%)  expressed  TLR4  while  69%  ±  3%  expressed  RP105.  In 
contrast, CD14-negative cells in the monocytes gate did not express RP105 or TLR4 
(data not shown). 
 
No change in the percentage of monocytes expressing CD14 occurred with culture 
alone or in the presence of IL-4. LPS treatment resulted in a loss of CD14 expression 
from up to 40% of CD14-positive monocytes, reducing the proportion of monocytes 
expressing  CD14  to  42%  at  3  h  and  44%  at  5  h  (Fig.  9.4C).  Whenever  CD14 
expression was lost following LPS treatment, cells also lost cell surface TLR4 and 
RP105  expression  (Fig.  9.4D).  In  accordance  with  previous  studies  on  human 
monocytes (340, 341), the loss of CD14 expression by LPS was transient. By 24 h, 
the percentage of monocytes expressing CD14 following LPS treatment had returned 
to close to baseline levels (61% ± 7%, mean ± SEM, n=3 donors) (Fig. 9.4C) and LPS 
caused  a  significant  increase  in  mean  surface  CD14  expression  in  CD14-positive 
monocytes  (Fig. 9.4E).  While IL-4 had no significant  effect  on the percentage of 
monocytes  expressing  CD14  (Fig.  9.4C),  it  down-regulated  the  mean  surface 
expression of CD14 in CD14-positive monocytes at 24 h and counteracted the late 
increase in CD14 expression by LPS (Fig. 9.4E). 
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Figure 9.4:  Effect of LPS and IL-4 on cell surface CD14 expression by human 
monocytes. Cell surface expression of CD14 by human monocytes was examined 
using flow cytometry. A. Gating of monocytes in PBMC population. Monocytes were 
defined as larger cells by forward and side scatter. B. Representative histogram of 
freshly isolated cells showing percentage CD14 expression on cells in the monocyte 
gate. C. LPS causes a transient loss in the percentage of monocytes expressing CD14 
at 3 and 5 h (n=4 donors, mean ± SEM). D. Expression of RP105, TLR4 and CD14 
was analysed by flow cytometry on monocytes cultured with or without LPS for 5 h. 
Arrows indicate that when cells lose CD14 expression following LPS treatment they 
also become negative for expression of RP105 and TLR4.  Shown is a plot from one 
donor representative of experiments carried out on 4 separate donors. Similar results 
were seen after 3 h. E. After 24 h, LPS increases, and IL-4 decreases, mean surface 
expression  of  CD14  (assessed  as  Mean  Fluorescence  Intensity,  MFI)  in  CD14-
positive  monocytes  (n=4  donors,  mean  ±  SEM).  Significant  differences  in  CD14 
expression between groups are indicated with an asterisk.  
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9.2.3  LPS, but not IL-4, Alters Cell Surface TLR4 and RP105 Expression in Human 
Monocytes 
The  up-regulation  of  RP105  mRNA  by  IL-4  in  LPS-treated  human  monocytes 
identified RP105 as a potential mediator of the anti-inflammatory actions of IL-4. 
Because  the  inhibition  of  TLR4  signalling  by  RP105  involves  an  extracellular 
interaction,  we  used  flow  cytometry  to  ascertain  whether  IL-4  also  up-regulated 
RP105 at the cell surface of monocytes. However, in contrast to the mRNA results, 
IL-4 had no effect on RP105 surface expression, on its own or in the presence of LPS 
(Fig. 9.5). In the whole monocyte population (defined by size), LPS also had little 
effect on RP105 surface expression (Fig. 9.5A). However, the LPS-induced loss of 
CD14  expression  which  occurred  in  approximately  40%  cells  at  3  and  5  h,  was 
coupled with a complete loss of RP105 and TLR4 expression in the cells that became 
CD14-negative (Fig. 9.4). When we took into account this loss of CD14 expression, 
and only considered the monocytes that remained CD14-positive, LPS significantly 
increased RP105 expression at the cell surface 3, 5 and 24 h after treatment (Fig. 
9.5B).  
 
The up-regulation of surface RP105  by LPS correlated with a down-regulation of 
surface TLR4 which occurred as early as 1 h after treatment with LPS and remained 
suppressed over 24 h (Fig. 9.5A and B). Because of the loss of TLR4 expression that 
occurred when CD14 was lost, the LPS-induced down-regulation of TLR4 was more 
pronounced in the whole monocyte population defined by size (Fig. 9.5A) than that 
defined  by  CD14  expression  (Fig.  9.5B).  Fig.  9.5C  demonstrates  that  by  24  h  in 
CD14-positive human monocytes, LPS redefined the monocyte population to one that 
is much lower in expression of its own receptor (TLR4), but has increased expression   195 
of the negative regulator of TLR4, RP105. IL-4 had no effect on RP105 or TLR4 
expression  apart  from  causing  a  small  but  significant  reduction  in  mean  surface 
expression of TLR4 in LPS-treated monocytes at 24 h (Fig. 9.5C).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.5:  Effect of LPS and IL-4 on cell surface RP105 and TLR4 expression 
by  human  monocytes.  Cell  surface  expression  of  RP105  and  TLR4  by  human 
monocytes  was  examined  using  flow  cytometry  on  A.  all  monocytes  (defined  by 
forward- and side-scatter) and B. CD14-positive monocytes, treated with IL-4, LPS 
and LPS+IL-4 for up to 24 h. Shown are pooled results from 4 separate donors (mean 
± SEM). A significant increase or decrease in expression caused by LPS is designated 
with an asterisk. C. Representative FACS plot of CD14-positive monocytes from one 
donor  at  24  h,  comparing  TLR4  and  RP105  expression  following  each  of  the 
treatments.  Solid  arrows  show  significant  changes  in  expression  induced  by  LPS. 
Dotted arrows show significant changes induced by IL-4. 
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9.2.4  Intracellular Expression of RP105 in Human Monocytes 
Cell  surface  expression  of  RP105  in  human  monocytes  following  LPS  and  IL-4 
treatment (Fig. 9.5) did not match mRNA levels for RP105 (Fig. 9.3). One possible 
explanation for this is that only some of the translated product of RP105 localises to 
the cell surface. Therefore flow cytometry was used to determine intracellular RP105 
expression (Fig. 9.6A). Baseline levels of intracellular RP105 were more than double 
the expression of RP105 at the cell surface in freshly isolated monocytes. Like mRNA 
expression, intracellular RP105 accumulated with culture, with levels doubling by 5 h 
and tripling by 24 h (Fig. 9.6B and C). This was in contrast to cell surface RP105 
which stayed relatively stable with culture (Fig. 9.6C). The effects of LPS and IL-4 on 
intracellular RP105 were also more reflective of mRNA levels than of cell surface 
expression, although changes were not as strong (Fig. 9.7). LPS had no significant 
effect on intracellular RP105, but after 24 h, IL-4 stimulated a small and significant 
increase  in  intracellular  RP105.  However,  IL-4  had  no  significant  effect  on 
intracellular RP105 in the presence of LPS. 
 
9.2.5  IL-4 Suppresses both TLR4- and TLR2-driven TNFα Production 
The inhibitory actions of RP105 are TLR4 specific, and RP105 does not inhibit TLR2 
signalling  (330).  Instead,  overexpression  of  RP105  augments  TLR2  mediated 
cytokine production in HEK 293 cells (330), and RP105 is required for optimal TLR2 
driven cytokine release in macrophages (338). To further confirm whether the actions 
of IL-4 are RP105 dependent, the effect on IL-4 on TNFα production was compared 
between human monocytes treated for 24 h with the TLR4 ligand, LPS, and the TLR2 
ligand, Pam3Cys. There was inter-individual variation in responses, with Pam3Cys 
tending to induce less TNFα production. Therefore results have been calculated as a   197 
percentage of LPS- or Pam3Cys-induced levels. IL-4 caused a significant decrease in 
both  LPS-  and  Pam3Cys-induced  TNFα  production.  There  was  no  significant 
difference in the percentage suppression of TNFα production by IL-4 in monocytes 
treated with LPS (78% + 2%, mean + SEM, n=12 donors) or Pam3Cys (80% + 10%, 
mean + SEM, n=3 donors) (Fig. 9.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.6:  Intracellular  expression  of  RP105  in  untreated  monocytes. 
Intracellular RP105 expression in human monocytes (defined by forward- and side-
scatter) was examined using flow cytometry A. Representative plot from one donor. 
Arrows  show  significant  changes  in  intracellular  RP105  caused  by  culture.  B. 
Histogram from the same donor showing the accumulation of intracellular RP105 
expression with culture. Binding by the isotype antibody is unshaded. C. Comparison 
of the levels of expression of cell surface RP105 in monocytes to intracellular RP105 
during  24  h  in  culture.  Results  are  expressed  as  the  mean  fluorescence  intensity 
(MFI); (mean ± SEM), n=3 donors. 
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Figure 9.7:  Effect  of  LPS  and  IL-4  on  intracellular  RP105  expression  in 
human  monocytes.  Intracellular  RP105  expression  was  determined  by  flow 
cytometry in  monocytes cultured for 5 and 24 h with  IL-4 alone or  LPS ±  IL-4. 
Results are expressed as the mean-fluorescence intensity (MFI); mean + SEM, n=3 
donors. An asterisk indicates a significant increase relative to untreated cells (p<0.05).  
 
 
 
 
 
 
 
 
Figure 9.8:   Suppression of LPS- and Pam3Cys-induced TNFα production by 
IL-4 in human monocytes. TNFα protein in supernatants was assayed 24 h after 
incubation with LPS (500 ng/ml) or Pam3Cys (500 ng/ml) ± IL-4 (10 ng/ml). TNFα 
levels have been calculated as the percentage of the LPS- or Pam3Cys-induced levels 
(Mean + SEM), LPS, n= 12 donors, Pam3Cys, n=3 donors. An asterisk indicates a 
significant suppression of TNFα production by IL-4 (p<0.05). 
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9.2.6  Summary of RP105, TLR4 and CD14 Expression in LPS- and IL-4-treated 
Human Monocytes 
In  human  monocytes  IL-4  up-regulated  RP105  mRNA  and  reversed  the  down-
regulation  of  RP105  mRNA  by  LPS.  In  the  absence  of  LPS,  IL-4  increased 
intracellular RP105 expression. However, IL-4 failed to increase expression of RP105 
at the cell surface of monocytes. IL-4 down-regulated the mean surface expression of 
CD14 at 24 h and in the presence of LPS, it counteracted the late increase in CD14 
expression  and  further  enhanced  the  LPS-induced  down-regulation  of  TLR4. 
However, changes in the expression of these receptors induced by IL-4 were only 
evident at 24 h and not at earlier time-points. LPS had dual effects on RP105, TLR4 
and CD14 surface expression. In approximately 40% of monocytes, LPS caused a 
transient loss of CD14 expression, which was followed by a significant increase in 
mean surface CD14 expression in CD14-positive monocytes at 24 h. Cells that lost 
expression of CD14 also lost surface expression of RP105 and TLR4. In cells that 
remained CD14-positive LPS up-regulated surface RP105, while at the same time 
down-regulating TLR4 surface expression.  
 
Table 9.1:   Summary  of  the  effect  of  LPS  and  IL-4  on  RP105,  TLR4  and 
CD14 expression in human monocytes.  
  IL-4  LPS  LPS+IL-4 
 
CD14 
 
 (24 h) 
 (3 h, 5 h) 
 (24 h) 
 
 (24 h) 
RP105 mRNA       
Intracellular RP105    No effect  No effect 
 
Cell Surface RP105 
 
No effect 
 in CD14-negative 
 in CD14-positive 
 
No effect 
TLR4  No effect     
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9.3  Discussion 
In  human  monocytes  IL-4  reversed  the  LPS-induced  down-regulation  of  RP105 
mRNA (Figs. 9.2 and 9.3). We hypothesised that if IL-4 also up-regulated cell surface 
RP105 expression in LPS-treated monocytes this could be part of the mechanism by 
which IL-4 suppressed LPS-induced TNFα production. However, IL-4 had no effect 
on  cell  surface  RP105,  either  on  its  own  or  in  the  presence  of  LPS  (Fig.  9.5). 
Therefore the anti-inflammatory actions of IL-4 are likely to occur independently of 
RP105. While LPS down-regulated RP105 mRNA expression, dual mechanisms for 
RP105, TLR4 and CD14 in the regulation of inflammatory responses to LPS were 
identified.  The  first  was  a  coordinated  down-regulation  of  TLR4  with  an  up-
regulation of RP105 in CD14-positive monocytes. In a second group of monocytes 
LPS caused a transient loss of surface CD14 and in these cells TLR4 and RP105 
expression was also lost.  
 
The suppressive actions of RP105 are TLR4-specific; RP105 has opposite effects on 
TLR2 signalling, enhancing TLR2-driven cytokine production in transfected HEK-
293 cells (330) and Mycobacterium tuberculosis-infected macrophages (338). IL-4 
caused a similar suppression of TLR2- and TLR4-induced TNFα production (Fig. 
9.8),  further  supporting  that  the  anti-inflammatory  actions  of  IL-4  occur 
independently of RP105. IL-4 did not alter surface expression of components of the 
TLR  signalling  complex  until  24  h,  when  it  significantly  reduced  TLR4  surface 
expression (Fig. 9.5C) and counteracted the late increase in CD14 by LPS (Fig. 9.4E). 
Because these changes  did  not  occur until  24 h, they are  unlikely to  mediate the 
suppression of LPS-induced TNFα production by IL-4, which occurred in the first 3 h 
(Chapter 3).    201 
 
LPS caused a transient loss of CD14 from approximately 40% monocytes. This loss 
directly correlated with a loss of both RP105 and TLR4 from the cell surface (Fig. 
9.4).  LPS  may  reduce  CD14  expression  in  monocytes  by  shedding  (344), 
transcriptional regulation
 (340) or internalisation (345).
 Loss of surface CD14 renders 
monocytes  hypo-responsive  to  LPS
  (346,  347)  and  mediates  other  regulatory 
mechanisms including TLR4 internalisation and LPS uptake (345), and competition 
of soluble CD14 with membrane CD14 for binding to LPS (348).
 Our array data 
demonstrated CD14 mRNA was down-regulated 3 h after LPS treatment (Fig. 9.2E) 
indicating transcriptional control. However, soluble and intracellular CD14 were not 
measured to determine if shedding or internalisation of CD14 was also involved. The 
concurrent  loss  of  RP105,  TLR4  and  CD14  from  the  cell  surface  following  LPS 
treatment suggests that these receptors are associated, and may be shed or internalised 
together  as  a  complex.  Thus,  RP105  surface  expression  in  LPS-treated  human 
monocytes is, in part, regulated by CD14. 
 
LPS down-regulated RP105 mRNA in  human monocytes, within 1 h of exposure 
(Figs. 9.2 and 9.3). This was similar to a report in human DCs (330), which proposed 
that because the down-regulation of RP105 mRNA by LPS occurred with a down-
regulation of TLR4 mRNA, RP105 may not be involved in endotoxin tolerance (330). 
However, our study has revealed that the down-regulation of RP105 mRNA by LPS 
does not correlate with cell surface RP105 expression on human monocytes defined 
by CD14 positivity. When we excluded those cells that became CD14-negative upon 
LPS treatment (Fig. 9.3), LPS significantly increased RP105 expression at the cell 
surface on the monocytes that remained CD14-positive from 3 h after exposure (Fig.   202 
9.5).  This  up-regulation  of  RP105  by  LPS  correlated  with  a  down-regulation  of 
surface  TLR4,  one  of  the  mechanisms  involved  in  endotoxin  tolerance  (342). 
Coordinated up-regulation of the TLR4 inhibitor, RP105, by LPS, is therefore likely 
to be an additional mechanism involved in endotoxin tolerance and the regulation of 
inflammation. This finding is supported by a study on monocytes from patients with 
primary biliary cirrhosis which are hypersensitive to LPS and have reduced RP105 
and increased TLR4 surface expression relative to controls 1 h after LPS treatment 
(343). Further supporting this are in vivo studies showing that RP105 plays a key role 
in regulating septic shock
 (330) and inflammatory diseases such as arthritis (339). 
 
Analysis of intracellular RP105 found that, like mRNA levels of RP105, it did not 
match cell surface expression of RP105. Firstly, intracellular RP105 expression was 
higher than extracellular expression, suggesting that not all RP105 localises to the cell 
surface of monocytes. Secondly, both RP105 mRNA and intracellular RP105, but not 
cell surface RP105, increased with culture, suggesting RP105 may be accumulating 
inside  the  cells  (Fig.  9.6).  In  accordance  with  the  mRNA  data,  IL-4  on  its  own 
increased intracellular RP105 accumulation at 24 h, though it had no effect in the 
presence of LPS (Fig. 9.7). The magnitude of the increase in intracellular RP105 by 
IL-4 (36%) did not match the 18-fold increase in RP105 mRNA seen at 24 h. This 
indicates that not all of the mRNA is translated or that RP105 protein is rapidly turned 
over  if  it  doesn’t  reach  the  cell  surface.  These  differences  between  mRNA, 
intracellular  and  cell  surface  expression  of  RP105  support  that  there  are  multiple 
mechanisms controlling whether RP105 localises  to the cell surface of monocytes 
following exposure to LPS and IL-4. 
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RP105 inhibition of TLR4 signalling occurs at the cell surface (330). However, the 
possibility  that  RP105  interacts  with  TLRs  internally  has  not  been  ruled  out.  For 
example, RP105 enhances signalling from the intracellular receptor TLR9 in B cells 
(349). While TLR4 first induces TIRAP-MyD88 signalling at the plasma membrane, 
it is also expressed intracellularly following transport from the plasma membrane to 
lysosomes, where it is degraded as part of a mechanism terminating LPS responses 
(350).  Once  internalised,  TLR4  activates  TRAM-TRIF  signalling  from  early 
endosomes  (351).  If  intracellular  RP105  also  localises  to  the  endosomes  it  may 
interact directly with endosomal TLR4 to inhibit TRIF-mediated signalling. However, 
this is unlikely to be the mechanism by which IL-4 suppresses LPS-induced TNFα 
production because the suppression by IL-4 occurs within the first 3 h of treatment 
suggesting it is TRIF independent (Chapter 3). It remains a possible mechanism for 
the late suppression of LPS-induced, TRIF-dependent cytokines by IL-4, such as IL-
10. 
 
The accumulation of RP105 mRNA and intracellular RP105 following IL-4 treatment, 
suggests that IL-4-induced RP105 may need an additional trigger to reach the cell 
surface. Interestingly, both LPS and IL-4 had no effect on the expression of MD-1 
(Fig. 9.2), a molecule that is essential for cell surface expression of RP105 (331, 332). 
Perhaps MD-1 expression also needs to be up-regulated in order for IL-4-induced 
RP105 to reach the cell surface. It would be interesting to investigate the effects of IL-
4 on RP105 expression in the presence of other mediators, including GM-CSF, which 
significantly  increases  RP105  mRNA  and  cell  surface  expression  in  alveolar 
macrophages  (352).  The  role  of  IL-4-induced  RP105  in  regulating  inflammatory 
responses should be considered in other disease contexts where IL-4 expression is up-  204 
regulated, such as in asthma and allergy. Der p-2, the main dust-mite allergen, has 
structural  homology  to  MD-2  and  directly  interacts  with  TLR4,  potentiating  LPS 
signalling in the absence of MD-2 (353). Therefore, IL-4 induced RP105–MD-1 may 
directly interact with TLR4–Der p-2 complexes and regulate TLR4-signalling during 
allergic inflammation.  
 
Ideally, the role of IL-4- and LPS-induced RP105 in monocytes could be confirmed 
further using neutralising antibodies or overexpression and knockdown studies. The 
surface  expression  of  RP105  in  murine  cells  can  be  inhibited  with  anti-MD-1 
antibodies  (332,  338).  However,  inhibitory  antibodies  to  human  MD-1  are  not 
commercially available. In B cells, a monoclonal anti-RP105 antibody transmits an 
activation signal  through the RP105 receptor  and induces  B cell activation (333).  
However, in our studies, treatment with the same RP105 antibody did not activate 
human  monocytes  and  had  no  effect  on  LPS-induced  inflammatory  cytokine 
production (results not  shown). Another possibility is to transfect monocytes with 
RP105  or  a  siRNA  to  RP105.  However,  while  adenoviral  vectors  achieve  higher 
transfection  efficiencies  (>50%),  they  complicate  studies  of  the  TLR  pathways  in 
monocytes  and  macrophages  due  to  activation  of  IFN-dependent  pathways. 
Alternatively studies could be conducted on monocyte and macrophage cell lines or 
gene  knockout  mice,  though  it  must  be  noted  fundamental  differences  in  IL-4 
signalling exist between murine cells, cell lines and human primary cells (145-150).  
 
In  conclusion,  RP105  is  unlikely  to  mediate  the  inhibition  of  LPS-induced 
inflammatory  cytokine  production  by  IL-4  in  human  monocytes.  However,  dual 
mechanisms for RP105, TLR4 and CD14 in the regulation of responses to LPS were   205 
identified,  supporting  that  RP105  is  involved  in  the  control  of  inflammatory 
responses  and  endotoxin  tolerance.  We  found  that  mRNA  expression  and 
intracellular RP105 did not match cell surface expression suggesting the need for 
further  characterisation  of  how  RP105  reaches  the  cell  surface,  in  particular  the 
involvement of MD-1 and CD14. Further studies of the subcellular localisation of 
intracellular RP105 following LPS and IL-4 treatment is required to determine if 
there are any interactions with TLR4 and CD14 within the endosomes.  
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Chapter Ten 
General Discussion and Conclusions 
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10.1  Aims of this Thesis and Summary of Findings 
This thesis aimed to identify the mechanisms by which IL-4 suppresses inflammatory 
cytokine production by LPS-activated human monocytes, with the broader goal of 
understanding how monocyte/macrophage function can be modulated in inflammatory 
disease. Firstly, the mechanisms by which IL-4 suppresses LPS-induced inflammatory 
cytokine production were defined in both freshly isolated monocytes and monocytes 
cultured  overnight  in  M-CSF.  Secondly,  the  TLR  signalling  components  that  are 
targeted by IL-4 were identified. Finally, new proteins induced by IL-4 and their role 
in mediating the anti-inflammatory actions of IL-4 were investigated. Findings from 
these  studies  may  lead  to  improved  and  more  targeted  treatments  for  chronic 
inflammatory disease. 
 
10.1.1  Aim 1: To Compare the Mechanisms by which IL-4 Suppresses Inflammatory 
Cytokine Production by Freshly Isolated Monocytes and Monocytes After Overnight 
Culture. 
Several differences in IL-4 signalling occur between murine and human cells, cell 
lines, and monocytes as they differentiate into macrophages (142-153). Further, the 
mechanisms  by  which  IL-4  suppresses  LPS-induced  pro-inflammatory  cytokine 
production  by  human  monocytes  remain  poorly  understood.  An  advantage  of  our 
study  was  that  responses  to  IL-4  in  human  primary  cells  were  examined  in  two 
different  differentiation  states,  namely  freshly  isolated  monocytes  and  monocytes 
cultured overnight in M-CSF. 
 
In freshly isolated monocytes, IL-4 suppressed LPS-induced TNFα production at the 
level of transcription. The suppression of LPS-induced inflammatory cytokine and   209 
chemokine production by  IL-4 occurred within  the first  3 h, suggesting that  IL-4 
targets the early MyD88-dependent pathway of TLR signalling (Chapter 3). While IL-
4 enhanced early LPS-induced IL-10 production, it strongly suppressed LPS-induced 
IL-10 production at 24 h in freshly isolated monocytes, but not in monocytes cultured 
overnight in M-CSF or in murine macrophages  (Chapter 8). This suggests that in 
freshly isolated monocytes, IL-4 may also target the later acting MyD88-independent, 
TRIF-dependent  pathway,  which  is  crucial  for  mediating  LPS-induced  IL-10 
production (315). 
 
In monocytes cultured overnight in M-CSF, IL-4 not only suppressed LPS-induced 
TNFα production more weakly than in freshly isolated monocytes, but IL-4 also had 
no effect on LPS-induced TNFα mRNA. This suggested that the suppression of LPS-
induced  TNFα  production  by  IL-4  in  these  cells  occurs  by  another  mechanism, 
possibly translational. In addition, the ability of IL-4 to suppress LPS-induced TNFα 
and  IL-10,  but  not  IL-1β,  production  was  impaired  in  monocytes  after  overnight 
culture.  Many  other  responses  to  LPS  and  IL-4  and  the  cellular  morphology  of 
monocytes cultured overnight resembled that of monocytes differentiated for seven 
days in M-CSF (MdMacs) (see Table 10.1). This suggests that monocytes cultured 
overnight  in  M-CSF have already begun to  differentiate and acquire  many of the 
morphological and functional changes associated with macrophages.  
 
In MdMacs, the reduced ability of IL-4 to suppress LPS-induced TNFα and IL-10 
production  correlates  with  reduced  expression  of  the  γc  chain,  more  rapid  and 
transient phosphorylation of the IL-4Rα chain and reduced phosphorylation of STAT6 
in  response  to  IL-4  (152,  153).  Hence  it  was  proposed  that  altered  IL-4  receptor   210 
conformation  and  signalling  may  also  explain  the  impaired  responses  to  IL-4  in 
monocytes  cultured  overnight  in  M-CSF.  However,  unlike  MdMacs,  the 
phosphorylation and activation of STAT6 by IL-4 in monocytes cultured overnight 
did not differ to that in freshly isolated monocytes. 
 
 
Table 10.1:  Differences  in  responses  to  IL-4  by  freshly  isolated  human 
monocytes  (Fresh),  monocytes  cultured  overnight  (Overnight)  and  MdMacs. 
Major differences in morphology and responses to LPS and IL-4 by freshly isolated 
monocytes are are highlighted. 
 
   
Fresh 
 
Overnight 
 
MdMacs
a 
 
Morphology 
 
Large cells, 
uniform in 
size, kidney 
shaped nuclei  
 
Larger, more 
granular cells 
with rounder 
nuclei 
 
Large 
granular cells 
with rounded 
nuclei 
 
LPS-induced cytokine secretion 
 
Less TNFα, 
More IL-1β 
 
More TNFα 
Less  IL-1β 
 
More TNFα 
Less  IL-1β 
 
Suppression of cytokine 
production by IL-4 
LPS-induced TNFα  
Proposed Mechanism 
LPS-induced IL-10 
LPS-induced IL-1β 
 
 
 
 
Transcription 
 
 
 
 
 
 
Translation 
 
 
 
 
 
None 
nd
b 
 
 
 
IL-4 activation of STAT6  
 
 
 
 
 
 
Effect of IL-4 on TLR signalling 
IκB/NF-κB 
p38 MAPK 
ERK MAPK 
JNK MAPK  
 
None 
None 
Enhanced 
None 
 
None 
None 
Enhanced 
None 
 
 
nd 
nd 
nd 
nd 
IL-4 induction of genes 
TREM-2  
PPARγ 
c-Maf  
 
Not expressed 
 
 
 
 
 
 
 
nd 
nd 
nd 
asee Bonder et al. 1998 (152), 
bnd, not done   211 
It remains possible that IL-4 differentially activates STAT6-independent pathways, 
such as those initiated through the insulin IL-4 receptor (I4R) motif, in monocytes 
differentiated in  vitro.  We and others  have shown the regulation  of inflammatory 
cytokine  production  by  IL-4  is  not  dependent  on  the  MAPK  (Chapter  4)  or  PI-3 
kinase  pathways  (Unpublished  data,  C.  Bonder,  PhD  thesis,  2001).  However, 
activation  of  several  other  STAT6-independent  signalling  components  by  IL-4, 
including  IRS-1/2  and  Akt,  may  differ  between  freshly  isolated  monocytes  and 
monocytes cultured overnight. Functional crosstalk exists between IL-4-induced JAK-
STAT  signalling  and  STAT6-independent  pathways  and  may  contribute  to  the 
regulation of IL-4 transcription (354). This may result in the differential induction of 
genes  encoding  for  proteins  that  mediate  the  anti-inflammatory  actions  of  IL-4 
between freshly isolated monocytes and monocytes after overnight culture, despite the 
similarities in STAT6 activation. 
 
Unstimulated  freshly  isolated  blood  monocytes  expressed  low  levels  of  PPARγ 
mRNA and did not express TREM-2, suggesting they are representative of naive ‘M0’ 
monocytes.  The  elevated  levels  of  PPARγ  and  TREM-2  mRNA  observed  in 
monocytes after overnight culture in M-CSF closely resembled the expression profiles 
of PPARγ and TREM-2 in IL-4-polarised (M2) monocytes, suggesting that culture in 
M-CSF may result in a default shift to an M2 phenotype (Chapter 7). Transcriptional 
profiling has revealed that culture in M-CSF leads to the expression of a substantial 
part of the M2 transcriptome and these cells are consequently relatively insensitive to 
IL-4-induced alterations in gene expression (305). Hence the acquisition of an M2 
phenotype  following  culture  in  M-CSF  could,  in  part,  explain  the  impaired 
suppression of LPS-induced TNFα production by IL-4 observed in these cells.   212 
 
While responses to IL-4 by MdMacs are representative of tissue macrophages (151, 
152), monocytes cultured overnight in M-CSF may be representative of monocytes 
newly infiltrated into tissues. This is supported by the finding that after overnight 
culture in M-CSF, monocytes have increased expression of integrin receptors (160). 
They  also  expressed  mRNA  for  TREM-2,  a  marker  of  newly  differentiated 
macrophages  that  is  up-regulated  in  macrophages  infiltrating  tissues  from  the 
circulation  (Chapter  7).  The  upregulation  of  PPARγ  mRNA  we  observed  in 
monocytes  after  overnight  culture,  was  similar  to  observations  in  synovial  fluid 
macrophages  (Chapter  7)  and  monocytes  newly  infiltrating  atherosclerotic  lesions 
(303, 304). Thus, monocytes cultured overnight in M-CSF may be more relevant than 
blood monocytes for the study of many in vivo disease situations, such as rheumatoid 
arthritis, which involve recruitment of monocytes into the tissues. 
 
Previous  studies  on  the  anti-inflammatory  actions  of  IL-4  have  used  murine  and 
human cells in a range of differentiation states. The inconsistent findings reported 
between human and murine studies (142-150) may be explained by our finding that 
the responses of monocytes to IL-4 differ dramatically even after overnight culture 
(Table  10.1).  In  contrast  to  human  studies  which  often  use  blood  monocytes  and 
PBMCs, many mouse studies use bone marrow-derived macrophages (BMM), which 
are  differentiated  from  bone  marrow  cells  cultured  for  several  days  in  M-CSF. 
Interestingly, the responses of murine BMM to IL-4 in our studies (Chapter 8) were 
identical to those of monocytes cultured overnight in M-CSF (Chapter 3), namely that 
IL-4 caused only a weak suppression of LPS-induced TNFα production, and enhanced 
LPS-induced IL-10 production at 24 h. Hence, the differences in methods used to   213 
isolate  and  culture  mouse  and  human  cells,  may  account  for  the  differences  in 
response to IL-4 previously attributed to species differences. Inconsistencies in the 
actions of IL-4 reported by human studies (Table 1.4) may also be due to variations in 
whether the cells were used immediately after isolation or cultured first in M-CSF. 
The different responses to IL-4 by cell lines could be explained the fact that these 
cells are often originated from tissue macrophages, treated with immortilising agents 
and grown for long periods in culture, often with M-CSF. These variations in IL-4 
signalling  depending  on  their  stage  of  differentiation  highlight  the  importance  of 
studying responses to IL-4 by primary human monocytes. 
 
In conclusion, the anti-inflammatory actions of IL-4 are strongest in blood monocytes. 
However, these effects are partially lost upon monocyte migration into the tissues and 
further  weaken  once  monocytes  differentiate  into  tissue  macrophages.  IL-4  is  not 
considered to circulate at significant levels in the blood but is detected at relatively 
high concentrations (>1 ng/ml) in the tissues (355, 356). Therefore, these changes in 
responses  to  IL-4  that  occur  in  monocytes  as  they  differentiate  into  tissue 
macrophages  are  important  when  considering  the  role  of  IL-4  as  a  regulator  of 
inflammation  and  its  potential  in  therapy.  I  propose  that  the  differences  in  IL-4 
signalling by freshly isolated monocytes and monocytes cultured overnight in M-CSF 
may  be  used  as  a  tool  to  further  clarify  the  mechanisms  by  which  IL-4  is  anti-
inflammatory.  For  instance,  genes  encoding  for  proteins  that  mediate  the  anti-
inflammatory  actions  of  IL-4  may  be  expressed  at  lower  levels  in  monocytes 
differentiated in M-CSF. Likewise, the LPS signalling components targeted by IL-4 in 
freshly isolated monocytes may not be affected in  more differentiated monocytes. 
Secondly, identifying the mechanisms by which IL-4 is anti-inflammatory in freshly   214 
isolated human monocytes and understanding why these mechanisms are lost after in 
vitro differentiation in M-CSF, could allow these mechanisms to be targeted in tissue 
macrophages.  Targeting  monocyte-specific  IL-4  signalling  intermediates  may  be 
more effective than treatment with IL-4 itself for chronic inflammatory diseases such 
as RA, where monocytes that have infiltrated the tissues play an important role (64, 
65). It would also avoid many of side effects associated with systemic administration 
of  IL-4, which  result from  the pleiotropic  effects  of  IL-4 on other immune cells, 
including lymphocytes (123-125). 
 
10.1.2  Aim 2: To Identify the TLR-signalling Components that are Targeted by IL-4 
In freshly isolated monocytes, IL-4 suppressed LPS-induced TNFα production at the 
level of transcription. IL-4 down-regulated LPS-induced expression of inflammatory 
cytokines and chemokines within the first 3 h, suggesting that IL-4 targets the early 
MyD88-dependent  components  of  TLR-signalling  (Chapter  3  and  8).  However, 
Western blotting (Chapter 4) and gene array analysis (Chapter 8) failed to detect an 
inhibition of TLR signalling components by IL-4 at the mRNA and protein level. 
Furthermore, IL-4 had no effect on LPS-activation of NF-κB as measured by EMSA 
and  IL-4  maintained  the  ability  to  suppress  TNFα  production  in  the  presence  of 
specific MAPK inhibitors. Therefore the suppression of pro-inflammatory cytokine 
production by IL-4 is mediated independently of an inhibition of LPS-induced IKK-
NF-κB signalling and MAPK activation.   
 
IL-4 activated p38 and ERK MAPK in the absence of LPS, most likely by activation 
of  the  Ras/MAPK  signalling  pathway.  Further,  IL-4  enhanced  LPS-induced  ERK 
phosphorylation  in  human  monocytes,  suggesting  that  the  Ras/MAPK  pathway   215 
activated  by  IL-4  may  directly  interact  with  and  potentiate  LPS-induced  MAPK-
activation (Chapter 4). While this activation of MAPK signalling by IL-4 was not 
responsible for the suppression of LPS-induced TNFα production by IL-4, it may be 
involved in the potentiation of LPS-induced inflammatory cytokine production that 
occurs with IL-4 priming (93, 159). This may explain the potential ‘inflammatory 
actions’ of IL-4 and exacerbation of inflammatory disease by IL-4 outlined in Section 
1.11.2 (116-120). Therefore the timing of IL-4 addition relative to disease onset is a 
critical factor determining IL-4’s potential effectiveness as a therapy, and highlights 
the importance of further determining the exact mechanisms of actions of IL-4.  
 
Reports have conflicted as to whether IL-4 targets NF-κB or another transcription 
factor involved in inflammatory gene expression (145-149). In our study, not only did 
IL-4 fail to alter LPS-activation of the IKK/NF-κB pathway (Chapter 4), IL-4 also 
failed to regulate many NF-κB responsive genes, including IκB and RelA (Chapter 8). 
Therefore it is  likely that in  human monocytes  IL-4 down-regulates  inflammatory 
cytokine and chemokine expression independently of a block in NF-κB activation.  
Rather  than  specifically  targeting  LPS  signalling  components  and  activation  of 
transcription factors, IL-4 may target gene transcription more broadly, for example by 
modifying chromatin states of genes. Histone acetylation plays an important role in 
mediating  immune  function  and  inflammation  by  selectively  silencing  active 
inflammatory  genes  and  enhancing  others  (175-177).  In  Chapter  5,  I  found  that 
histone acetylation was important for regulating LPS-induced cytokine production by 
human monocytes. Class I HDACs deacetylated promoters and specifically mediated 
transcriptional  repression  of  the  TNFα  and  COX-2  genes,  while  Class  II  HDACs 
enhanced IL-10 production and late TNFα production, most likely by targeting of   216 
transcription factors regulating these genes. It is possible HDACs are required for 
deacetylation and activation of c-Maf, a transcription factor required for both LPS-
induced IL-10 transcription and the enhancement of LPS-induced IL-10 production by 
IL-4 (200). However, the transcriptional repression of the inflammatory genes, TNFα 
and COX-2, by IL-4 was mediated independently of histone acetylation. It remains 
possible that IL-4 modifies chromatin structure by other histone modifications, such 
as methylation.  
 
Human peripheral blood monocytes are a heterogenous population consisting of three 
distinct subsets; CD14
+CD16
-, CD14
+CD16
+ and CD14
dimCD16
+ (5). It is possible 
that IL-4 is anti-inflammatory by altering the proportions of monocytes belonging to 
these subsets. For instance IL-4, in the presence of LPS, may reduce the percentage of 
inflammatory  CD14
+CD16
+  monocytes,  which  are  the  major  producers  of  TNFα 
following LPS-stimulation. While IL-4 did not reduce cell surface CD14 expression 
in monocytes until 24 h (see Chapter 9), further analysis is required to determine 
whether  IL-4 alters the  expression of  other  markers associated with  inflammatory 
monocyte subsets, including CD16, CX3CR1, CCR2 and LY6 (5). 
 
Alternatively, the actions of IL-4 may be mediated by the induction of a transcription 
factor or transcriptional repressor. A potential candidate is c-Maf because in addition 
to mediating the enhancement of IL-10 production by IL-4 in monocytes, it has also 
been implicated in the suppression of LPS-induced IL-12 production (324). IL-4 may 
also compete for, or sequester, cofactors required for inflammatory gene transcription 
(139). Therefore ChIP assays would be useful to specifically characterise both histone 
modifications and the binding of transcription factors and cofactors to the promoters   217 
of inflammatory genes following LPS and IL-4 exposure. In addition, a proteomics 
approach would allow more detailed examination of the protein profiles of monocytes 
following LPS and IL-4 treatment (174), and may identify changes in expression of 
TLR  signalling  components  induced  by  IL-4  that  were  not  detected  by  Western 
blotting. 
 
10.1.3  Aim  3:  To  Identify  IL-4-induced  Proteins  that  may  Mediate  the  Anti-
inflammatory Actions of IL-4 
The suppression of LPS-induced pro-inflammatory cytokine production by IL-4 in 
human monocytes requires new protein synthesis (143-145). However, the protein/s 
involved have not been identified. In Chapter 6, SOCS proteins were investigated as 
potential candidates because of their ability to not only regulate IL-4 signalling, but 
also inflammatory cytokine signalling and TLR responses. IL-4 rapidly induced CIS 
mRNA, and SOCS1 mRNA and protein, in human monocytes. While the induction of 
SOCS1 by IL-4 immediately preceded the induction of SOCS1 mRNA and protein by 
LPS  and  IFNγ,  SOCS1  did  not  mediate  the  anti-inflammatory  actions  of  IL-4  in 
human monocytes. CIS, a negative regulator of STAT5 signalling (219, 220), is also 
unlikely to be involved in the regulation of responses to LPS because LPS does not 
directly signal through STAT5. However, it remains possible that IL-4-induced CIS 
contributes to the modulation of certain inflammatory responses by IL-4 by regulating 
the signalling of cytokines which signal through STAT5, such as GM-CSF and M-
CSF. While LPS and IL-4 did not induce PIAS, SHP, SHIP mRNAs in monocytes 
(Chapter  6),  Western  blotting  is  required  to  determine  whether  IL-4  alters  the 
expression of these regulators at the protein level. Co-IP studies may be useful to   218 
characterise PIAS, SHP, SHIP, SOCS4 and SOCS5 interactions with the IL-4 and 
LPS receptors. 
 
IL-4 induced two markers of alternative activation, PPARγ and TREM-2; both have 
also been implicated in the suppression inflammatory cytokine production (258, 259). 
However, IL-4 failed to induce TREM-2 mRNA in freshly isolated monocytes. Hence 
while TREM-2 may down-modulate inflammatory responses following subsequent 
exposure to microbial stimuli in alternatively activated macrophages, the suppression 
of LPS-induced inflammatory cytokines by IL-4 when added concomitantly with LPS 
is not mediated by TREM-2. Similarly, PPARγ may be important for regulating the 
expression of phenotypic markers and metabolic programming of macrophages during 
alternative activation, but not the suppression of LPS-induced TNFα production by 
IL-4. PPAR remains a potential candidate which could be investigated with PPAR 
antagonists.  
 
Our  gene  array  profiling  identified  several  additional  candidates,  including  IL-10, 
RP105, RIPK2 and c-Maf, which were up-regulated by IL-4 in a timeframe consistent 
with  the  effects  of  IL-4  on  reducing  LPS-induced  TNFαproduction  (Chapter  8). 
However, the mRNA and intracellular expression of RP105 did not match cell surface 
expression  (Chapter  9).  CD14  was  identified  as  a  novel  regulator  of  RP105 
localisation  to  the  cell  surface  in  LPS-treated  monocytes.  In  monocytes  that  lost 
CD14, RP105 expression was also lost. In monocytes that remained CD14 positive, 
LPS caused a concurrent up-regulation of surface RP105 and a down-regulation of 
TLR4, supporting that RP105 is involved in the regulation of inflammatory responses 
to LPS and endotoxin tolerance.  However, IL-4 had no effect on cell surface RP105,   219 
either on its own or in the presence of LPS, suggesting that the anti-inflammatory 
actions  of  IL-4  are  likely  to  occur  independently  of  RP105.  Further  studies  are 
required  to  determine  whether  intracellular  RP105,  which  was  increased  by  IL-4 
treatment, interacts with TLR4 and CD14 within the endosomes.  IL-4 may increase 
surface RP105 in the presence of inflammatory stimuli other than LPS. Hence, the 
function  of  IL-4-induced  RP105  should  also  be  investigated  in  different  disease 
contexts, particularly asthma and allergy. Here IL-4-induced RP105 has the potential 
to interact with the main dust-mite allergen, Der p-2, which can act as a substitute for 
the TLR4 accessory molecule, MD-2 (353).  
 
While IL-4 up-regulated mRNA for the signalling kinase, RIPK2, in LPS-activated 
monocytes,  the  anti-inflammatory  actions  of  IL-4  were  independent  of  the  kinase 
activity of RIPK2. However, RIPK2 can also function as an adaptor molecule and 
mediate insulin-like growth factor-I (IGF-I) signalling (321, 322). As IL-4 activates 
(IRS)-1 and IRS-2 signalling pathways via its I4R motif, it would be interesting to 
further  investigate  what  role  RIPK2  protein  plays  in  IL-4  signalling.  If  RIPK2 
associates with the IL-4 receptor, it could potentially mediate pathways involved in 
both  the  suppression  of  LPS-induced  inflammatory  cytokine  production  and 
enhancement of IL-10 production by IL-4.  
 
IL-4  rapidly  and  transiently  enhanced  LPS-induced  IL-10  production  with  similar 
kinetics to the suppression of LPS-induced TNFα production. However, I found the 
suppression of LPS-induced TNFα production by IL-4 was independent of this early 
enhancement of IL-10 production (Chapter 8). Furthermore, the up-regulation of anti-
inflammatory genes by IL-4 was also independent of IL-10. Instead, the actions of IL-  220 
4 could be mediated by c-Maf, the transcription factor that mediates the up-regulation 
of  IL-10  production  by  IL-4  (200).  c-Maf  may  up-regulate  IL-4-induced  anti-
inflammatory  genes other than  IL-10,  and also has  the potential to  down-regulate 
inflammatory genes, including IL-12 (324). Furthermore, the induction of c-Maf by 
IL-4 was reduced in monocytes after overnight culture in M-CSF, where IL-4 has an 
impaired ability to suppress LPS-induced inflammatory cytokine production.  
 
Our customised gene arrays focused on only a small subset of TLR-related signalling 
genes. Broader gene arrays may identify additional candidate genes induced by IL-4. 
For example, a gene array on B cells identified B cell lymphoma 6 (BCL-6), as an IL-
4-inducible, STAT6-dependent gene (217). BCL-6 is a transcriptional repressor which 
attenuates  macrophage  activation  and  pro-inflammatory  cytokine  production  in 
murine cardiomyopathy (357). Hence, it is possible that BCL-6 regulates the anti-
inflammatory actions of IL-4 in monocytes. Gene arrays on c-Maf or BCL-6 deficient 
and over-expressing cells, would be interesting to delineate whether any changes in 
gene expression induced by IL-4 in LPS-activated monocytes are mediated by c-Maf 
or BCL-6. 
 
10.2  Significance of Findings and Future Directions 
 
This thesis did not definitively identify the molecules involved in the regulation of 
LPS-induced TNFα production by IL-4. However, it improved the understanding of 
how  LPS  and  IL-4  signal  in  human  monocytes  and  identified  several  potential 
candidates that may mediate IL-4’s anti-inflammatory actions (see Fig. 10.1). Our 
findings  indicate  that  IL-4  may  suppress  LPS-induced  inflammatory  gene 
transcription, via chromatin modifications or induction of transcriptional regulators,   221 
rather than directly targeting LPS-activation of transcription factors, such as NF-κB. 
This  transcriptional  suppression  by  IL-4  is  partially  lost  during  monocyte 
differentiation  in  vitro  and  in  tissue  macrophages,  highlighting  the  importance  of 
clarifying the differences in IL-4 signalling between these cells.  
 
The transcription factor, c-Maf, may mediate the anti-inflammatory actions of IL-4 in 
human monocytes. Alternatively, a transcriptional repressor, such as BCL-6, may be 
involved.  Broader  gene  arrays  on  LPS-  and  IL-4-treated  human  monocytes  may 
identify  additional  candidates.  While  histone  acetylation  does  not  mediate  the 
suppression of inflammatory cytokine transcription by IL-4, other covalent histone 
modifications such as methylation may be responsible. ChIP assays would be useful 
to  more  specifically  characterise  histone  modifications  and  the  binding  of 
transcription  factors,  transcriptional  repressors  and  cofactors  to  the  promoters  of 
inflammatory genes following LPS and IL-4 treatment. 
 
While the kinase activity of RIPK2 did not mediate the anti-inflammatory actions of 
IL-4,  the  role  of  RIPK2  in  IL-4  signalling  was  not  conclusively  determined.  As 
RIPK2  may  also  function  as  an  adaptor  molecule,  it  would  be  interesting  to 
investigate whether RIPK2 is recruited to the IL-4 receptor. Further understanding of 
the importance of c-Maf, RIPK2 and other candidate genes, in mediating the anti-
inflammatory  actions  of  IL-4  in  monocytes,  could  be  gained  by  conducting  gene 
arrays on macrophages from knockout or transgenic mice, and in human monocytes 
or cells lines overexpressing, or underexpressing these genes. It must be noted that 
adenoviral  vectors  activate  IFN-dependent  pathways  complicating  studies  of  TLR   222 
signalling  in  human  monocytes  (172)  and  that  fundamental  differences  in  IL-4 
signalling exist between cell lines and murine and human cells (142-150). 
 
Gene arrays failed to identify any effect of IL-4 on mRNA levels of TLR signalling 
components. However, it remains possible that expression of some of these genes may 
be  altered by  IL-4 at  the protein level.  Proteomics would be useful  to  define the 
protein profiles of LPS- and IL-4-treated monocytes in more detail and may identify 
LPS signalling components whose expression is altered at the protein, but not mRNA, 
level by IL-4.  While the actions of IL-4 are likely to be independent of proteosomal 
degradation of TLR-signalling components (see Chapter 4), another possible mode of 
regulation of translation of TLR-related genes by IL-4 is micro-RNAs (miRs). Several 
miRNAs  influence  the  translation  of  LPS-induced  mRNAs,  for  example  miR-155 
reduces  protein  levels  of  TLR  signalling  components,  including  TGF-β  Activated 
kinase 1 Binding protein 2 (TAB2) (325, 358). In the lungs of IL-4 transgenic mice, 
miR-21 is up-regulated and represses IL-12, indicating miRNAs are a possible mode 
of regulation of inflammatory genes by IL-4 (326). An analysis of miRNA expression 
using  miRNA  PCR  arrays  would  be  useful  to  determine  which  miRNAs  are  up-
regulated by IL-4 in LPS-treated monocytes. This may identify potential IL-4 targets 
of the TLR signalling cascade, not previously identified using Western blotting.  
 
10.3  Concluding Remarks 
Biological therapies are playing an increasing role in the management of immune and 
inflammatory disorders. Further clarification of the pathways involved in macrophage 
activation, in particular those that down-modulate inflammatory responses, may lead 
to  improved  therapeutic  approaches  for  targeting  tissue  inflammation.  IL-4  is  a   223 
pleiotropic cytokine, which in monocytes and macrophages inhibits the production of 
pro-inflammatory  cytokines  while  enhancing  secretion  of  anti-inflammatory 
mediators.  During  chronic  inflammation,  IL-4-activated  macrophages  counteract 
classical inflammatory reactions induced by LPS- and IFNγ-stimulated macrophages, 
while promoting tissue repair and wound healing and protecting against cartilage and 
bone erosion.   
  
Therefore therapeutic administration of IL-4, drugs that induce IL-4 or targeting of 
IL-4  signalling  intermediates,  are  potential  strategies  for  the  treatment  of 
inflammatory diseases, including rheumatoid arthritis. IL-4 has pleiotropic effects on 
the immune system, and monocytes isolated from the blood respond differently to IL-
4 than monocytes and macrophages at inflammatory sites. Hence, while targeting of 
IL-4 to the affected joints and tissues can successfully treat inflammation in a number 
of animal models, systemic treatment with IL-4 has only limited therapeutic effects in 
human  patients.  Continuing  research  is  therefore  required  to  further  clarify  the 
mechanisms by which IL-4 exerts its anti-inflammatory actions in human monocytes 
and macrophages. A more complete understanding of the TLR signalling components 
inhibited by IL-4 and the proteins induced by IL-4 that mediate the suppression of 
inflammatory genes may allow these pathways to be targeted in human monocytes 
and  macrophages.  The  interacting  pathways  of  cell  activation  and  suppression  of 
inflammatory  cytokine  production  by  IL-4  are  likely  to  be  monocyte-  and 
macrophage-specific. Therefore targeting these pathways would avoid the side-effects 
associated  with  systemic  IL-4  treatment,  resulting  in  more  effective  and  targeted 
therapies for chronic inflammation 
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Figure 10.1:  Summary  of  the  mechanisms  by  which  IL-4  exerts  its  anti-
inflammatory actions in human monocytes identified in this thesis. Pathways not 
responsible are indicated by a cross, while potential  candidates  are highlighted in 
green.  IL-4  suppressed  LPS-induced  inflammatory  gene  transcription  primarily  by 
targeting early MyD88-dependent components of TLR4 signalling. However, IL-4 did 
not alter LPS-activation of ERK, JNK and p38 MAPK or the IκB/NFκB pathway. IL-
4 induced a number of genes encoding for molecules with potential anti-inflammatory 
properties. However, many of these, including PPARγ, TREM-2, SOCS1, CIS and 
IL-10, were not responsible for the suppression of inflammatory genes by IL-4. IL-4 
also induced RP105 mRNA; however, IL-4-induced RP105 did not reach the cell 
surface and therefore is unlikely to mediate inhibition of TLR responses by IL-4. 
While  histone  acetylation  did  not  mediate  the  actions  of  IL-4,  other  histone 
modifications such as methylation, may be involved. The kinase activity of RIPK2 
was not required for IL-4’s anti-inflammatory actions; however, IL-4-induced RIPK2 
may associate with the IL-4 receptor to mediate signalling pathways required for the 
anti-inflammatory  actions  of  IL-4.  Alternatively,  the  repression  of  LPS-induced 
inflammatory genes by IL-4 may also be mediated by up-regulation of transcriptional 
regulator such as c-Maf, which mediates the enhancement of IL-10 production by IL-
4.  
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